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Abstract 
Hedgehog signaling is a pathway essential in embryonic development, adult stem cell 
maintenance, and is implicated in the formation and progression of cancer. Signaling in this 
pathway is triggered when the secreted protein Hedgehog binds to its membrane receptor, 
Patched. Patched normally inhibits the seven-spanner transmembrane protein Smoothened 
(Smo). Binding of Hedgehog inhibits Patched resulting in Smo derepression. Active Smo then 
triggers the activation of the cytoplasmic steps of the signaling pathway. The regulation of Smo 
is poorly understood mechanistically. 
Oxysterols bind Smo and potently activate vertebrate Hedgehog signaling. However, it is 
unknown if oxysterols are important for normal Hedgehog signaling, and whether antagonizing 
oxysterols can inhibit the Hedgehog pathway. I developed azasterols that block Hedgehog 
signaling by inhibiting the oxysterol-binding site of Smo. I show that the binding site for 
oxysterols maps to the extracellular, cysteine-rich domain of Smoothened, which is distinct from 
the site bound by other small molecule Smo modulators. Smo mutants that abolish oxysterol 
binding no longer respond to oxysterols and cannot be maximally activated by the Hedgehog 
ligand. My results show that oxysterol binding to vertebrate Smoothened is required for high 
level Hedgehog signaling. Importantly, I found that targeting the oxysterol binding site is an 
effective strategy to block Smoothened activity. 
Signal transduction in the vertebrate Hedgehog pathway is spatially restricted to the 
primary cilium. I explored the mechanism of ciliary localization of Smo, and identified two 
degenerate ciliary localization sequences within its cytosolic tail. I further identified a cytosolic 
 iii 
domain of Smo, which is essential but not sufficient for activation of downstream components. 
Finally, I show that while the ciliary localization aspect is unique to vertebrates, signaling to 
downstream components is conserved across phyla. 
My findings indicate that Smo is a modular protein, wherein each module serves a 
specific role and reflects a distinct mechanism of regulation. This suggests a model wherein Smo 
is at the confluence of several distinct regulatory inputs: an oxysterol regulated module, a second 
small-molecule regulated module, and a ciliary localization module, as well as a module for 
downstream signalling – which all converge for maximal activation.  
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 General Introduction Chapter 1:
  
 2 
1.1 Signaling in Embryonic development 
The development of complex structures such as individual organs or limbs requires a 
crosstalk between adjacent cell populations in order to establish different cell fates and spatial 
organization. This section will review the principal signalling pathways involved in embryonic 
development. 
Morphogenesis of the Drosophila embryo begins with specification of the anterior-
posterior (A/P) and dorsal-ventral (D/V) axes before the egg is laid. These processes rely on 
maternal mRNAs deposited in the oocyte as it matures in the developing follicle; bicoid and 
oskar mRNAs localize at opposite ends of the oocyte and form opposite gradients along the A/P 
axis. Upon fertilization, translation of the bicoid and oskar maternal mRNAs forms opposite 
gradients of the morphogens across the dividing cells to maintain the A/P axis throughout the 
early stages of embryonic development (Jones et al., 2011). Subsequently, the embryo is divided 
along the A-P axis into a series of 14 segments (Gehring, 2012). 
In a series of classic genetic experiments, Nusslein-Volhard and Wieschaus identified 
three classes of mutants which caused early lethality during embryonic development in 
Drosophila. These three classes of mutant phenotypes correspond to multiple genes involved in 
embryonic patterning, and highlight three levels of spatial and temporal organization. First, gap 
genes specify broad region of the embryo encompassing the multiple segments. Pair-rule genes 
then subdivide the embryo in similar regions in every other segment. Finally, segment polarity 
genes (such as patched, wingless and hedgehog) are turned on in all segments to control portions 
within each segment; mutations in segment polarity genes cause similar deletions across all 
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segments, with the remaining part of the segment duplicated in a mirror-like fashion. Taken 
together, these three classes of mutants suggest a hierarchical organization of segmentation genes 
to specify the final body plan. The segment polarity genes stand out because the mutants affect 
components of only two signaling pathways – wingless and hedgehog.  
Wingless (wg) is a secreted protein homologous to the vertebrate Wnt, and is involved in 
maintenance of engrailed; wg binds to its receptor Frizzled (Fz), a seven transmembrane domain 
protein with homology to G-protein coupled receptors, and turns on downstream transcription 
via the nuclear effector Pan (Brunner et al., 1997). Hedgehog (Hh) codes for a secreted 
morphogen and is transcribed upon Engrailed activation. Early in embryonic development, wg 
and hh function to specify the parasegment boundary (Bokor and DiNardo, 1996) while later 
they are involved in patterning of the nervous system and the imaginal discs. In Drosophila, 
imaginal discs are precursors of the adult appendages; during embryogenesis, the discs are 
patterned to reflect their specific fate, and upon metamorphosis to the adult fly, they build the 
adult exoskeleton. During the third larval instar, wg is responsible for patterning the region 
around the margins of wing imaginal discs (Couso et al., 1994). engrailed activity leads to 
production of hedgehog in the posterior compartment of imaginal discs, which establishes a 
gradient along the A-P axis. Hedgehog signaling from the posterior compartment turns on 
Decapentaplegic (Dpp) in the anterior compartment, which in turn maintains Wg production.  
The Hedgehog (Hh) signaling pathway in vertebrates is also responsible for correct 
patterning and differentiation during embryonic development of most tissues and organs; the Hh 
pathway has also been implicated in postembryonic tissue homeostasis by regulating 
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proliferation and differentiation of adult stem cells (Beachy et al., 2004; Trowbridge et al., 
2006). In the vertebrate embryo, the hedgehog ligand is initially expressed in the notochord and 
guides specification of all ventral cell types such as motor neurons in the developing neural tube, 
which will later on become the spinal cord (Jessell, 2000). Later in development, hedgehog 
signaling is required for limb formation and specification of digit identity in the developing limb 
bud (reviewed by (Johnson et al., 1994)).  
While vertebrates lack segments as seen in arthropods like Drosophila, the formation of 
somites is an analogous process of division along the anterior-posterior axis that specifies a 
segmented body plan. The somites are structures along the anterior-posterior axis of the embryo 
that will eventually become vertebrae, skeletal muscle and skin. In somites, Shh secreted from 
the adjacent neural tube regulates the differentiation of the ventral sclerotome (Fan and Tessier-
Lavigne, 1994; Marigo and Tabin, 1996). Mutations of Shh manifest themselves at this stage as 
defects of the spine and ribs (Chiang et al., 1996). 
Mysregulation of Hh signaling leads to birth defects and a number of sporadic cancers in 
humans (Beachy et al., 2004; Hooper and Scott, 2005; Ingham and McMahon, 2001; Rubin and 
de Sauvage, 2006). The Hedgehog pathway regulates both differentiation and proliferation in the 
cardiovascular system; in early embryonic development, it plays a crucial role during 
morphogenesis of the heart by determining left/right asymmetry, and directing the correct 
looping of the heart tube (Cooper et al., 2005). Hedgehog signaling is implicated in maintenance 
and repair of adult cardiovascular tissues and regulates angiogenesis. Hh signaling induces 
angiopoietins and VEGF, leading to coronary neovascularization in the adult heart; treatment 
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with recombinant Shh induces neovascularization and confers protection against ischemic injury 
in a surgically induced mouse hind-limb ischemia model (Pola et al., 2001). Furthermore, 
transient intra-myocardial gene transfer of Shh induces recovery from myocardial ischemia in 
adult mice and pigs (Kusano et al., 2005). Aberrant activation of Hedgehog signaling leads to 
neovascularization of tumors and is a central step in tumor growth in a variety of cancers. In the 
absence of a steady blood supply, tumors are severely restricted in growth; many tumors secrete 
Shh to signal the surrounding stroma and attract blood vessel formation, allowing progressive 
growth in both tumor size and metastatic potential (Folkman, 2002; Yamazaki et al., 2008).  
 
1.2 Hedgehog pathway overview 
The Hh pathway structure remains mainly conserved from Drosophila to humans, 
although some differences exist (Varjosalo et al., 2006). This section will examine the individual 
components of the Hh pathway and their regulation in arthropods and in vertebrates. 
The secreted protein Hedgehog (Hh in Drosophila, or one of three vertebrate orthologs, 
primarily Sonic hedgehog, Shh) is synthesized as a precursor protein which undergoes a 
cholesterol-catalyzed self-cleavage and palmitoylation. The processed N-terminal fragment is 
then secreted in a process that depends on the 12-spanner Dispatched and is further assisted by 
Scube (Tukachinsky et al., 2012). On the receiving end (Figure 1.1), signaling is triggered when 
the secreted Hh ligand binds to its membrane receptor, the 12-spanner protein Patched 
(Ptc)(Stone et al., 1996). Ptc normally inhibits the 7-pass transmembrane protein Smoothened  
 6 
 
Figure 1.1 Overview of the Hedgehog pathway components in the receiving cell 
(Smo). When bound by Hh, Patched is inhibited resulting in Smo activation. Active Smo then 
triggers the activators of the cytoplasmic steps of the signaling pathway, and ultimately induces 
transcription of the Hh target genes which include Gli1 and Ptc (Rohatgi and Scott, 2007).  
Regulation of Smo is critical for Hh signaling; however, the way Smo is activated and 
inhibited is poorly understood mechanistically. Ptc does not directly bind Smo (Denef et al., 
2000), and acts catalytically to inhibit it (Taipale et al., 2002). The non-stoichiometric inhibition 
of oncogenic Smo suggests that Ptc regulates Smo indirectly, by affecting the concentration of an 
intermediate modulator (Chen et al., 2002a), and several lines of evidence point to a small-
molecule mediator (Chen et al., 2002b; Taipale et al., 2002) whose identity remains unknown. 
Furthermore, in a cellular context, Smo is constitutively active in the absence of Ptc (Rohatgi et 
al., 2007); however, it is not known whether Smo is intrinsically in the active conformation, or is 
kept active by a ubiquitous activator molecule – and Ptc may act indirectly on Smo by interfering 
In the absence of stimulation Ptc prevents Smo from entering the primary cilium; upon 
stimulation by Sonic hedgehog ligand, the inhibition is relieved and Smo can enter the cilium 
where it signals downstream effectors (adapted from (Huangfu and Anderson, 2005)) 
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with this activator. Ptc may regulate the abundance of a Smo modulator; nevertheless, in the 
absence of direct biochemical evidence, the mechanism of Smo inhibition remains an open 
question.  
While Hedgehog, Patched and Smoothened as well as the Ci/Gli transcription factors are 
conserved from Drosophila to vertebrates, the pathway components downstream of Smo have 
diverged significantly. Moreover, despite sequence conservation of Smo throughout species, the 
presence of additional regulatory sequences in the cytoplasmic tail of Drosophila Smo suggests a 
divergent, specialized mechanism of downstream signaling (Varjosalo et al., 2006). In 
Drosophila and in the absence of signaling, the zinc-finger transcription factor Cubitus 
interruptus (Ci) forms two separate complexes, one containing the kinesin-like protein Costal2 
(Cos2) and the serine/threonine kinase Fused (Fu), and a small fraction exists in a separate 
complex containing the Suppresor of Fused, Su(Fu); the complexed Ci is then proteolytically 
cleaved to a repressor form. Cos2 is anchored to microtubules in the cytosol and thus sequesters 
Ci in the cytosol. Cos2 inhibits the vast majority of available Ci while Sufu only plays a minor 
role (Varjosalo 2006). Pathway activation leads to accumulation of Smo, which binds Cos2 
directly; this in turn destabilizes the Ci-Cos2 complex , releases Ci and inhibits the proteolytic 
cleavage of Ci. The full-length Ci-activator form translocates to the nucleus where it transcribes 
the hedgehog target genes. Smo binds Cos2 through its C-terminal domain, while the vertebrate 
Smo does not interact with Cos2; interestingly, the Drosophila C-terminal domain renders 
vertebrate Smo sensitive to Cos2 in a chimeric protein (Varjosalo et al., 2006). 
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In vertebrates, the Glioma-associated family of transcription factors (Gli1, 2 and 3) are 
the homologs of Ci. Gli forms a complex with Suppresor of Fused (SuFu) in the cytosol, and is 
proteolyzed to a short repressor form. Pathway activation leads to destabilization of the Gli-SuFu 
complex, which inhibits the proteolytic cleavage of Gli and frees the active Gli-A form to 
translocate to the nucleus and transcribe the Hedgehog target genes (Tukachinsky et al., 2010). 
Of the three Gli proteins present in vertebrates, Gli3 is processed robustly to the repressor form 
in the absence of signaling (Wang et al., 2000), while pathway activation stabilizes the full-
length Gli3 activator form which translocates to the cilium along with SuFu (Tukachinsky et al., 
2010). Gli1 only exists in the activator form and is not processed to a repressor (Dai et al., 1999; 
Kaesler et al., 2000; Park et al., 2000), while Gli2 is primarily in the active form but is kept 
repressed by binding to SuFu in the cytosol (Pan et al., 2006; Tukachinsky et al., 2010). The 
primary mediator of transcriptional activation is Gli2, while the primary mediator of 
transcriptional repression is Gli3 (Bai et al., 2002; Persson et al., 2002; Wang et al., 2000); as a 
direct target of Hh signaling, Gli1 is not essential for Hedgehog signaling but forms a positive 
feedback loop to amplify the transcriptional output of the pathway (Park et al., 2000). Early on in 
embryonic development, mouse knockouts of the positive regulators Shh, Smo or Gli2 show 
severe defects in specifying left-right asymmetry, in establishing midline structures such as the 
notochord or floor plate; later in embryonic development, gross morphological defects include 
holoprosencephaly, cyclopia, absence of motor neurons in the ventral neural tube, and defects in 
limb development (Chiang et al., 1996; Ding et al., 1998; Kim et al., 2001; Tsukui et al., 1999; 
Zhang et al., 2001).  
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Strikingly, mouse knockouts of the Fu kinase homolog (Stk36) are viable and have 
normal Hh signaling (Wilson et al., 2009). The closest vertebrate homologs of Cos2 are Kif27 
and Kif7. The mouse Fu homolog interacts directly with Kif27, and together are essential for 
assembly of the central pair of microtubule dublets in motile cilia, but have no role in Hedgehog 
signaling (Wilson et al., 2009). Separately, Kif7 is a ciliary protein which acts downstream of 
Smo and does not bind Smo directly (Varjosalo et al., 2006). In the absence of signaling, Kif7 
localizes at the base of the primary cilium; activation of the hedgehog pathway triggers a 
redistribution of Kif7 along the entire length of the cilium, and it accumulates at the distal tip of 
the cilium. Furthermore, mutations in the motor domain of Kif7 disable this movement, impair 
the formation of the Gli3 repressor form, and result in ectopic Hh pathway activation; this is 
similar to the effect of a complete loss of Kif7, which also recapitulates the Gli3-null phenotype 
(Endoh-Yamagami et al., 2009; Liem et al., 2009). 
 
1.3 Ptc and the Sterol Sensing Domain 
Several proteins involved in cholesterol biosynthesis or homeostasis contain a conserved 
sterol sensing domain (SSD), a region of five transmembrane domains which appears conserved 
across a variety of proteins involved in cholesterol biosynthesis, homeostasis or trafficking – but 
despite the conservation, the SSD has no known function. This section will review cholesterol 
biosynthesis and the role of the SSDs in cholesterol homeostasis in cells, before returning to 
Patched and examining what role the SSD might play in its function. 
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Cholesterol in cells is synthesized starting from acetate. The rate-limiting step of the 
cholesterol biosynthetic pathway involves the production of mevalonate in the ER through the 
catalytic action of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA 
reductase); statins potently inhibit this step and are highly successful in the clinic to control 
cholesterol levels in circulation and thus prevent cardiovascular disease. Mevalonate is 
subsequently transformed through a number of steps into squalene which undergoes cyclization 
to lanosterol, the first compound to bear the four ring structure of sterols. Lanosterol is then 
transformed into cholesterol in 19 steps catalyzed by 9 different enzymes (Fakheri and Javitt, 
2011). 
Two enzymes in the cholesterol biosynthetic pathway contain SSDs. HMG-CoA 
reductase contains an SSD that is not required for its catalytic function but appears essential for 
the accelerated proteasomal degradation of HMG-CoA induced by sterols (Gil et al., 1985; Sever 
et al., 2003). The ER protein Insig-1 binds to the SSD of HMG-CoA reductase, and binding of 
sterols to Insig-1 greatly enhances this interaction and accelerates the degradation of HMG-CoA. 
This provides feedback inhibition in the sterol biosynthetic pathway. Separately, 7-
dehydrocholesterol reductase (DHCR7) is an SSD-containing enzyme which catalyzes the 
transformation of 7-dehydrocholesterol into cholesterol, the last step in the biosynthesis of 
cholesterol; DHCR7 also catalyzes the transformation of cholesta-5,7,34-trienol into 
desmosterol.  
Cholesterol levels in cells of vertebrates are tightly regulated. The majority of cholesterol 
in vertebrates comes from the diet and is derived from lipoprotein particles that transport 
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cholesterol and cholesterol esters from the gut throughout the organism. Thus, in the presence of 
cholesterol, cells must keep the endogenous production of cholesterol off; this occurs by turning 
off the transcription of HMG-CoA reductase and of cholesterol uptake receptors. Sterols 
facilitate the binding of Insig to the HMG-CoA reductase SSD and induce its accelerated 
proteolysis to further shunt the cholesterol biosynthesis (Sever et al., 2003). The promoter region 
of the HMG-CoA gene contains a sterol regulatory element, a region of DNA to which the sterol 
regulatory element binding protein (SREBP) binds. The N-terminal end of SREBP is a 
transcription factor, while its C-terminal end interacts with the SREBP cleavage-activating 
protein (SCAP) in the ER. SCAP contains an SSD, and in the presence of sterols SCAP binds 
Insig, which causes the SCAP-SREBP complex to be retained in the ER. In the absence of 
sterols, the interaction of SCAP with Insig is abolished, and the SCAP-SREBP complex 
translocates to the Golgi where the Golgi-resident zinc metalloproteases S1P and S2P cleave 
SREBP into its transcriptionally active form. The cytosolic N-terminal fragment of SREBP then 
enters the nucleus where it activates transcription of sterol regulatory element-containing genes 
(Rawson, 2003).  
Interestingly, sterol binding correlates with the presence of an SSD in a protein but is not 
restricted to SSD-containing proteins: while cholesterol binds to SCAP and causes it to bind 
Insigs, the more soluble oxysterols bind directly to Insigs and cause them to bind SCAP in return 
(Radhakrishnan et al., 2007). A search for proteins that bind oxysterols, including 25-
hydroxycholesterol, has identified the Niemann-Pick type C1 (NPC1) protein as an unexpected 
mediator of intracellular sterol transport. Cholesterol is transported through circulation in 
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complexes with lipoproteins and enters cells via receptor-mediated endocytosis in vesicles that 
fuse with the lysosomes. NPC1 is a transmembrane protein that functions in lysosomes where it 
binds cholesterol and dissociates it from lipoproteins; NPC1 also binds certain oxysterols bearing 
an –OH group at the 24, 25 or 26 positions, but not oxysterols with –OH groups at the 7, 19 or 20 
position. It then transports the sterols from lysosomes to the endoplasmic reticulum. Patients 
deficient in NPC1 accumulate large amounts of cholesterol in the endosomal-lysosomal system 
(Infante et al., 2008a). NPC1 has a low specificity for substrates as long as they are lipophilic or 
at least amphiphilic; in a remarkable assay, NPC1 expressed in outer membrane of E. coli 
bacteria transports acriflavine and oleic acid from the periplasmic space across the plasma 
membrane into the cytosol (Davies et al., 2000). NPC1 has 13 transmembrane helices and 
contains a sterol-sensing domain embedded within helices 3-7 that resembles the SSD of SCAP. 
However, both SCAP and NPC1 bind sterols through a soluble, luminal loop near the N-terminal 
end, and thus the role of the SSD remains unclear (Infante et al., 2008b; Motamed et al., 2011). 
Separately, NPC2 is a soluble glycoprotein which lacks an SSD altogether. NPC2 fails to bind 
oxysterols but binds cholesterol and facilitates its transport between membrane compartments 
(Cheruku et al., 2006; Infante et al., 2008b); defects in NPC2 account for 5% of Niemann-Pick 
Type C disease cases (Wilson et al., 2009). NPC1 and NPC2 act together in a sequential 
mechanism wherein NPC2 captures cholesterol released from LDL particles and transfers it to 
NPC1; NPC1 then transports cholesterol out of lysosomes and to the various cellular membrane 
compartments by incorporating it in the membrane of outbound vesicles (Infante et al., 2008c). 
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Two homologs of Patched exist in vertebrates, Patched 1 and Patched 2; however, only 
Ptc1 is the primary receptor for hedgehog ligands in vertebrates (and from here on will be 
referred to as Ptc), while Ptc2 plays only a minor role as Ptc2-null mice are born alive without 
the gross abnormalities or cancer susceptibility associated with Ptc1 defects (Lee et al., 2006). 
Mutations in Patched that result in constitutive activation of Shh signaling are linked to Gorlin 
Syndrome. Nevoid Basal Cell Carcinoma Syndrome (NBCCS), also known as Gorlin Syndrome 
or Gorlin-Goltz Syndrome, is a familial cancer syndrome characterized by an abundance of basal 
nevoid cell carcinomas. These Ptc mutations show autosomal dominant inheritance, and trigger 
tumor formation through loss of heterozygosity in individual cells – this results in extremely 
variable expressivity of symptoms throughout the entire lifespan of individuals affected. Age of 
onset varies greatly between 2 and 65 years of age, and symptoms include skeletal as well as 
numerous basal cell carcinomas occurring at a young age, jaw cysts, palmar and plantar pits, and 
occasionally cognitive impairment (Jones et al., 2011). 
Ptc associates with accessory membrane proteins such as the transmembrane proteins 
Cdo or Boc, or the GPI-anchored Gas1 to bind the Hedgehog ligand. These proteins have 
overlapping roles in soaking up the Hedgehog ligand, and thus limiting its range, but also form 
co-receptors with Ptc and together appear essential for proper Hedgehog signal transduction 
(Allen et al., 2011; Izzi et al., 2011; Zheng et al., 2010). Ptc is highly conserved from Drosophila 
to humans and shares homology with NPC1. Both Ptc and NPC1 contain an SSD, and are 
distantly related to the bacterial proton-driven small molecule transporters of the Resistance-
Nucleation-cell Division (RND) superfamily (Davies et al., 2000; Rohatgi and Scott, 2007; 
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Tseng et al., 1999). Several members of this family actively translocate lipophilic small 
molecules across the cell membrane with broad specificity. In bacteria, several RND permeases 
are efflux pumps that account for multidrug resistance, as is the case with MexD in P. 
aeruginosa;. Furthermore, RND permeases function as homotrimers, and biochemical evidence 
suggests that Ptc forms trimers under physiological conditions through its C-terminal domain (Lu 
et al., 2006).  
The SSD of Ptc is critical for its function, and this function is independent of binding of 
the Hedgehog ligand. Several mutations, including some mutations observed in patients with 
Gorlin Syndrome, map to conserved residues within the SSD that are essential for the activity of 
functional RND transporters (Taipale et al., 2002), of SCAP, or of NPC1 (Martin et al., 2001; 
Strutt et al., 2001). These mutations abolish the ability of Ptc to repress Smo and result in 
constitutive hedgehog pathway activity, but do not affect the binding of the Hedgehog ligand to 
Ptc. Taken together, the data suggest that Ptc may function as a small molecule transporter; 
nevertheless, no such activity of Ptc has yet been demonstrated and no known binding substrates 
exist (Rohatgi and Scott, 2007; Taipale et al., 2002). 
 
1.4 Smo and G-Protein Coupled Receptors 
One class of receptors involved in mediating cellular signalling and transducing the 
extracellular signal to the inside of the cell are seven-pass transmembrane-domain G-protein 
Coupled Receptors (GPCRs). This section will first review GPCRs, and then will examine the 
similarities and differences between GPCRs and Smo. 
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Canonical GPCRs exist in a conformational equilibrium between two distinct states – a 
ground, “inactive” form and an “activated” one. Binding the ligand triggers the switch between 
the two states. Despite significant diversity in their sequences, GPCRs share structural 
homology: the seven transmembrane helices form a bundle, a barrel-like cavity where ligands 
bind; the three extracellular loops as well as the N-terminal region are stabilized by a series of 
disulfide bridges and function to modulate ligand access to the transmembrane core, while the 
intracellular loops and the C-terminal tail relay the signal to the associated G protein. The 
extracellular disulfide bridges are structurally essential, as reducing agents or mutagenesis 
impairs the receptor (Gill et al., 2008). 
The most numerous family of GPCRs is by far the Class A rhodopsin/β-adrenergic 
receptor family; in these receptors the extracellular loop 2 is often the longest extracellular loop 
(although exceptions exist) and ligands bind inside the transmembrane domain barrel. Class B 
GPCRs share a common N-terminal fold which interacts with ligands directly but it is not clear 
whether transmembrane domains contribute to the creation ligand binding pocket (Javitt, 2002b). 
Class C GPCRs contain a “venus flytrap module” in the N-terminal domain which binds ligands 
directly; the signal is relayed from the ligand-bound extracellular N-terminus to the 
transmembrane core through allosteric coupling. Finally, the Frizzled (Fz) class GPCRs are 
characterized by the presence of a Cysteine-Rich Domain in the N-terminal, which in the case of 
Frizzled binds the canonical ligand Wnt (Janda et al., 2012). 
Smo resembles GPCRs and shares significant homology with Fz. The Fz family of 
receptors contains a conserved large extracellular Cysteine-Rich Domain (CRD) at the N-
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terminal end. Fzs bind their cognate ligand through the CRD and signal to downstream 
components through their cytoplasmic tails (Bhanot et al., 1996; Janda et al., 2012); however, the 
CRD of Smo serves no known function (Chen et al., 2002b; Hooper, 2003; Rohatgi and Scott, 
2007). Furthermore, Fzs form coreceptors with a Low-Density Lipoprotein Receptor-related 
protein in order to signal, while no such complex is known to exist for Smo.  
GPCRs bind ligands on the extracellular side of the transmembrane barrel; this leads 
initially to a small conformational change within the transmembrane region, which in turn results 
in more significant structural rearrangements on the cytosolic side. A common mechanism for 
GPCR activation conserved across many class A receptors involves the relocation of 
transmembrane domains 3 and 7 upon agonist binding, which leads to a reconfiguration of the 
TM3-TM5 and TM5-TM6 interfaces; together, these coordinated movements bring together the 
extracellular ends of the TM helices while moving the cytosolic ends further apart (Javitt, 
2002b). This creates a cleft-like pocket where the Gα subunit of the heterotrimeric G protein can 
bind and downstream signaling is activated ((Venkatakrishnan et al., 2013) provide a 
comprehensive review of the structural changes accompanying agonist binding). 
Signaling downstream of canonical GPCRs occurs primarily through associated 
heterotrimeric GTP-binding regulatory proteins (G proteins). Heterotrimeric G proteins are 
activated by the conformational switch of the GPCR induced by ligand binding. This in turn 
triggers the dissociation of the inhibitory Gβγ subunits dimer from Gα; in mammals there are 
four families of Gα proteins (i.e. Gs, Gq/11, Gi/o, and G12/13), as well as 5 Gβ and 12Gγ 
isoforms, leading to over 1000 heterotrimeric combinations of subunit isoforms possible, and the 
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exact combination of the heterotrimer determines the specificity of its interactions with GPCRs 
(Dingus et al., 2002; Javitt, 2002a). Interestingly, more than one active state conformation may 
exist for a given receptor, as different ligands can modulate different conformational changes in 
GPCRs, biasing the receptor to preferentially bind one or more G proteins, or in turn to couple 
the receptor to other cytosolic effectors such as scaffold proteins like the β-arrestins – thus 
altering their signaling output or altogether shifting the response of the receptor to a parallel 
downstream cascade (Bjorkhem, 2007; Gill et al., 2008). More recently, the subunits Gβγ 
themselves have been implicated as direct messengers that relay the signal downstream of 
GPCRs directly, rather than the signal proceeding through the Gα subunit (reviewed by (Smrcka, 
2008)). In the end, a two-step desensitization process limits the duration of activated GPCR 
signaling: extensive phosphorylation by G-protein coupled receptor kinases (GRKs) stops the 
interaction with G proteins, and β-arrestins trigger internalization and recycling of 
phosphorylated receptors from the cell surface (Chen et al., 2004).  
Smo is reminiscent of functional GPCRs and is likely triggered by an unknown 
endogenous ligand. Smo is highly druggable, and a number of small molecule modulators of 
Smo activity exist: both agonists such as the synthetic small molecules SAG (Chen et al., 2002b) 
or purmorphamine (Wu et al., 2004), as well as antagonists such as the plant alkaloid 
cyclopamine (Taipale et al., 2000) or the synthetic compounds SANT-1 (Chen et al., 2002b) and 
Vismodegib (Robarge et al., 2009). While the canonical Wnt signal transduction occurs through 
a protein cascade that involves β-catenin and is independent of G protein coupling, several 
Frizzled receptors couple to heterotrimeric G protein subunits Gαo (Katanaev et al., 2005) and 
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GαS (Nichols et al., 2013) to trigger non-canonical effects such as the regulation of the actin 
cytoskeleton through activation of Rho and Rac small GTPases (Angers and Moon, 2009). 
Evidence for G protein activation by Smo is scarce, but co-expression of G protein subunits 
along with Smoothened in baculovirus-infected insect cells indicates that Smo specifically 
activates several members of the Gi family, which inhibit the production of cAMP (Riobo et al., 
2006; Varjosalo et al., 2006); human Smo also appears to activate Gαi-mediated pigment 
aggregation in Xenopus melanophores, although whether this interaction is direct remains 
unknown (DeCamp et al., 2000). Further evidence for a potential involvement of G proteins 
comes from the functional similarities Smo shares with other GPCRs: activated Smo can be 
phosphorylated in a G-protein-coupled receptor kinase 2 (GRK2) dependent manner, and leads 
to accumulation and binding of β-Arrestin (Chen et al., 2004). Interestingly, a Smo mutant 
lacking the cytosolic tail which is unable to signal through Gli can nevertheless interact with 
Gαi; this suggests that the interaction of Smo and Gαi is mediated through the cytosolic loops of 
Smo, and further suggests that this activity is independent of the canonical hedgehog signaling 
pathway (Polizio et al., 2011). Finally, Smo promotes fibroblast migration through activation of 
GαI in a Gli-independent mechanism, suggesting the possibility that the GPCR-like function of 
Smo is involved in a function outside of canonical Hh signaling. 
A conformational change of Smo upon stimulation of the Hh pathway has been suggested 
(Zhao et al., 2007). The fact that Smo is susceptible to small molecule modulation points to a 
possible mechanism of regulation through an endogenous small molecule. Cyclopamine binds 
directly to the seven transmembrane domain region and stabilizes the inactive 
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conformation(Chen et al., 2002a). Furthermore, oncogenic mutations (such as the SmoM2 
mutant which corresponds to a tryptophane to a leucine point mutation towards the cytosolic end 
of the seventh transmembrane domain (Xie et al., 1998)) that render Smo insensitive to both 
Patched and cyclopamine, and which result in constitutive downstream signaling, could act 
simply by sterically impairing the ground state conformation and instead favouring a less 
ordered, intermediate conformation as evidenced by an increased retention in the endoplasmic 
reticulum (Chen et al., 2002a). SAG binding stabilizes oncogenic Smo and rescue it from ER 
retention, while overexpression of Ptc or addition of a more potent cyclopamine derivative revert 
such activated Smo mutants to the stable, inactive conformation (Chen et al., 2002a; Taipale et 
al., 2000; Zhao et al., 2007). The data point to a common mechanism of Smo inhibition by 
regulation of its conformational equilibrium. Furthermore, cyclopamine affinity for oncogenic 
Smo increases with Ptc overexpression, suggesting that Ptc shifts Smo to an inactive-state 
conformation similar to that recognized and stabilized by cyclopamine; the non-stoichiometric 
inhibition of oncogenic Smo suggests that Ptc regulates Smo indirectly, by affecting the 
concentration of an intermediate modulator (Chen et al., 2002a). 
 
1.5 Sterols and the Hedgehog pathway 
Hh signal transduction in vertebrates depends on proper sterol metabolism, as defects in 
sterol biosynthesis phenocopy Hh signal transduction defects. This section will review the 
evidence implicating sterols as regulators of the Hedgehog pathway. 
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Smith-Lemli-Opitz (SLOS), lathosterolosis and desmosterolosis are three human 
disorders that result in defects in the last stages of cholesterol biosynthesis. In mouse models of 
SLOS and lathosterolosis, which lack the enzymes 7-dehydrocholesterol reductase or lathosterol 
5-desaturase respectively, the formation of Shh cholesterol-modified ligand is unaffected, but the 
response of cells to the secreted Shh ligand is impaired. Furthermore, non-specific depletion of 
sterols from cell membranes blocks Shh transduction at the level of Smo (Cooper et al., 2003). 
The SmoM2 mutation disrupts the ligand binding pocket of Smo and significantly decreases the 
affinity of Smo for ligands, as the inhibitors Cyclopamine, SANT-1 and Vismodegib show 
markedly higher IC50 values towards the M2 mutant than towards wildtype Smo (Chen et al., 
2002b; Taipale et al., 2000; Yauch et al., 2009). However, the constitutive, ligand-independent 
SmoM2 (also called SmoA1 in the human protein) is not affected by sterol depletion (Cooper et 
al., 2003). Inhibition of the sterol biosynthetic pathway at various steps suggests that a 
cholesterol derivative, but not a steroid, is critical for Hh signaling (Corcoran and Scott, 2006). 
Two endogenous oxysterols, 20α-hydroxycholesterol (20-OHC, Figure 1.2) and 25-
hydroxycholesterol (25-OHC, Figure 1.2), strongly activate the Hh pathway at the level of Smo 
and rescue the sterol-depletion defects (Corcoran and Scott, 2006; Dwyer et al., 2007; 
Nachtergaele et al., 2012; Rohatgi et al., 2007). 20-OHC and 25-OHC are so far the only 
endogenous molecules known to modulate Smo activity; 20-OHC acts directly on Smo as an 
allosteric agonist (Nachtergaele et al., 2012), yet whether it is the endogenous modulator of Smo 
is unclear. Together, this evidence suggests that endogenous regulation of Smo may involve a 
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hydrophobic small molecule such as a cholesterol derivative – however, the identity of such 
modulator remains unknown.  
 
Figure 1.2 Structures of cholesterol and oxysterols 
 
Several enzymes are known that catalyze the transformation of cholesterol into particular 
oxysterols (the structures of which are shown in Figure 1.2); these are generally cytochrome 
P450 hydroxylases. For instance, CYP3A4 forms 4β-hydroxycholesterol (Gill et al., 2008); 
CYP7A1 is responsible for the synthesis of 7α-hydroxycholesterol, the precursor to all bile acids 
(however, a separate, non-enzymatic path also exists to generate this particular oxysterol as an 
autoxidation product of cholesterol); CYP46 synthesizes 24(S)-hydroxycholesterol in neurons 
and is 100-fold enriched in the brain over other tissues, while CYP27A1 in mitochondria 
catalyzes the production of 26-hydroxycholesterol which is the major circulating oxysterol in 
humans and also an intermediate of the bile acid biosynthesis (Bjorkhem, 2007; Gill et al., 2008; 
Javitt, 2002a). The only known exception is the cholesterol 25 hydroxylase which forms 25-
OHC from cholesterol; it belongs to a larger family of transmembrane enzymes that catalyze 
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oxidations using a di-iron cofactor in the catalytic site instead of a heme iron center (Lund et al., 
1998). 
Importantly, 20(S) and 22(R)-hydroxycholesterol form a special case as no single 
hydroxylase produces either of them as the stable end product. Instead, they are produced for a 
brief period as intermediates in the conversion of cholesterol to pregnenolone through the action 
of the cytochrome P450SCC sidechain cleavage enzyme (also known as CYP11A1 in humans) in 
the adrenal glands (reviewed in (Gill et al., 2008) and (Javitt, 2002b). Naturally occurring 20(S)-
hydroxycholesterol was found in the brain and placenta, but its origin remains unclear (Lin et al., 
2003). Several specific inhibitors of the P450SCC have been identified: the synthetic derivative 
22-azacholesterol (Counsell et al., 1971) and 22-thiacholesterol (Miao et al., 1995) are both 
potent competitive inhibitors of P450Scc and block the formation of pregnenolone.  
Since the majority of mutations associated with Hedgehog pathway defects in humans 
map to Ptc and result in constitutive derepression of Smo, and because Smo is easily druggable, 
there is significant interest in developing Smo-specific pharmacological inhibitors for therapeutic 
use ((Mas and Ruiz i Altaba, 2010) provide a comprehensive review of the inhibitors currently in 
clinical trials). One such compound, Vismodegib (formerly known as GDC-0449) has received 
approval from the U.S. Food and Drug Administration in 2012 as a treatment for basal cell 
carcinoma (Dubey et al., 2013). Vismodegib is the first Hh pathway inhibitor to receive 
authorization, and is in further clinical trials for a number of other cancers and metastatic solid 
tumors including medulloblastoma, recurrent glioblastoma multiforme, advanced stomach 
cancer, gastroesophageal junction cancer, pancreatic cancer, metastatic colorectal cancer, small 
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cell lung cancer, basal-cell nevus syndrome, multiple myeloma, chondrosarcoma, ovarian and 
prostate cancers (Mas and Ruiz i Altaba, 2010; Sandhiya et al., 2013). Vismodegib binds the 
same site as cyclopamine on Smo and displaces cyclopamine in competitive experiments 
(Rominger et al., 2009). A crystal structure of Smo with an inhibitor bound at the cyclopamine 
site shows the ligand binding pocket buried deep within the transmembrane domain, with a cap 
formed by the extracellular loops 2 and 3. Interestingly, a mutation in the extracellular loop of 
Smo renders it insensitive to inhibition by Vismodegib while keeping its signaling function 
intact. The D473H mutation was isolated from a medulloblastoma patient treated with 
Vismodegib (Yauch et al., 2009); residue D473 maps to the interface between the 
transmembrane helix 6 and the extracellular loop 3, and the mutation likely disturbs a hydrogen-
bonding network within the ligand binding pocket (Wang et al., 2013). 
Separately, two classes of glucocorticoid compounds were identified in a recent screen 
for small molecules that affect the ciliary localization of Smo (Wang et al., 2012). One class of 
compounds which contains fluocinolone acetonide (a common over-the-counter glucocorticoid 
medication used routinely as an anti-inflammatory topical treatment in dermatology (Scholtz, 
1961)) behaves similar to cyclopamine in that they push Smo to the cilium in the inactive 
conformation and the compounds compete with a fluorescent cyclopamine derivative for binding 
Smo (Wang et al., 2012). A second class of compounds inhibited Smo translocation to the 
cilium, synergized with Vismodegib to block Hedgehog signaling at the level of Smo, and 
inhibited both wildtype as well as Smo mutants refractory to inhibition by Vismodegib (Wang et 
al., 2012). This second class of compounds do not directly compete with cyclopamine, indicating 
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that they may act elsewhere on Smo, or act indirectly on Smo. In this regard, the compounds 
behave closer to the protein kinase A (PKA) activator forskolin, and most likely act on Smo like 
forskolin through an indirect mechanism (see Section 1.8 for more effects of forskolin on the Hh 
pathway). An example of this class of compounds is budesonide (Wang et al., 2012). It is worth 
mentioning that glucocorticoids elicit their anti-inflammatory action by binding to and activating 
the glucocorticoid receptor, a member of the nuclear receptor family of transcription factors 
(Vandevyver et al., 2013). Whether budesonide acts directly on Smo, or indirectly through a 
separate mechanism is not known. 
 
1.6 The primary cilium 
The primary cilium is a unique organelle comprising a hair-like membrane projection 
surrounding a bundle of microtubules, which forms the axoneme. The primary cilium is a highly 
conserved structure, which exists in most eukaryotic cells and serves as an anchoring point to a 
variety of receptors including some GPCRs to increase their local concentration; the cilium thus 
serves as a cellular antenna for sensing the presence of nutrients or growth factors. Structurally, 
the cilium consists of three distinct regions - the axoneme forms the majority of the cilium and is 
attached to the basal body through the transition zone. The basal body is a complex of proteins 
formed around one of the two centrioles in the cell and functions to assemble and elongate the 
cilium. In addition to the primary cilium, some organisms also contain a separate flagellum 
which is a specialized, beating cilium; primary cilia contain 9 pairs of microtubules in a barrel-
like arrangement across the axoneme, while motile cilia contain two additional central pairs of 
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microtubules attached to a flagellar motor complex. The primary cilium lacks the central pairs of 
microtubules and is therefore a rigid structure. No protein synthesis takes place at the primary 
cilium, thus any protein found at the cilium must be transported there; this includes the tubulin 
building blocks required for elongation of the cilium.  
Microtubules are a major component of the cellular cytoskeleton and are involved in a 
variety of cellular processes, such as vesicular transport, cytokinesis and in particular cell 
division. The precursor of microtubules, tubulin is a globular protein, and its two most common 
isoforms (α and β) form heterodimers that are used as assembly blocks in the formation of 
microtubules. The microtubules are polarized, with the α-Tubulin subunit of the heterodimers 
exposed at the – end, and the β-Tubulin subunit exposed at the + end. Polymerization of tubulin 
dimers occurs at the + end of microtubules, when a new heterodimer attaches in its GTP-bound 
form to pre-existing tubulin polymers and subsequently hydrolyzes GTP to GDP. Microtubules 
are highly dynamic structures, and their length and stability is controlled by the balance between 
assembly and disassembly at both the + and the – ends; the net result of these processes at the – 
end is a shortening of the microtubule, while a net lengthening can be observed at the + end. 
Furthermore, microtubules suffer a variety of modifications, with acetylation being a hallmark of 
stable microtubules such as those in the primary cilium. Two families of ATP-dependent 
molecular motors provide bi-directional transport of cargo along microtubules: kinesins walk on 
microtubules towards the + end in a stepwise manner, while dyneins transport cargo along 
microtubules in the opposite direction. Ciliary microtubules are anchored with the – end to the 
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basal body, and the + end extends into the tip of the cilium; this translates to microtubule 
assembly occurring primarily at the tip of the cilium. 
Genetic screens have identified two protein assemblies involved in ciliary transport – the 
intraflagellar transport IFT-A and IFT-B complexes (Ou et al., 2005). Defects in IFT-A 
components lead to accumulation of proteins along the cilium and at the ciliary tip, causing a 
bulging at the tip. In contrast, defects in IFT-B components lead to short or nonexistent cilia. 
One possible explanation is that IFT-B is involved in anterograde transport which would be 
required for extension of the cilium, while IFT-A along with cytoplasmic dynein mediates 
retrograde transport; a core component of IFT-B is the plus-directed motor kinesin II which 
brings cargo. Older evidence however suggests that IFT-A and IFT-B complexes function 
together in both anterograde and retrograde transport, as they associate with each other prior to 
movement along the cilium. The key player in ciliary transport and ciliary assembly is the 
BBSome, a complex of proteins essential for ciliary formation which catalyzes the assembly of 
IFT complexes at the base of the cilium. The IFT-A/IFT-B complexes transport both cargo and 
the BBSome to the distal end of the cilium where the complex dissociates and the cargo is 
unloaded. The BBSome at the ciliary tip then facilitates the reassociation of the IFT-A and IFT-
B, which in turn recycles both components as well as cargo (which includes the BBSome) back 
to the base of the cilium. While IFT-A appears critical for retrograde transport, a defect in BBS-1 
which renders the BBSome unable to associate with IFT-A/IFT-B and thus unable to reach the 
ciliary tip, leads to the accumulation of IFT-B complexes at the ciliary tip. This suggests that the 
BBSome functions to associate IFT-A to IFT-B in both the basal body and at the ciliary tip, and 
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that the association between IFT-A and IFT-B is maintained throughout both anterograde and 
retrograde transport (Wei et al., 2012). 
 
1.7 Mechanisms of ciliary translocation 
No protein synthesis takes place at the primary cilium, thus any protein found at the 
cilium must be transported there. This section will review the mechanism of ciliary translocation 
and the structural requirements for ciliary localization 
The ciliary membrane has a unique lipid composition that is different from that of the 
plasma membrane (Tyler et al., 2009). Notably, sterols are enriched at (and distributed uniformly 
throughout) the ciliary shaft membrane, but are absent from the base of the cilium (Montesano, 
1979). The highly curved membrane at the base of the cilium consists of a condensed lipid zone 
and may itself act as a diffusion barrier for integral membrane proteins or lipid-anchored proteins 
and lipids to restrict their movement into the ciliary membrane through lateral diffusion (Rohatgi 
and Snell, 2010). Furthermore, a ring in the transition zone consisting of Septin2 along with the 
B9 complex and the products several other ciliopathy genes forms a diffusion barrier at the base 
of the cilium that restricts access of membrane proteins into the ciliary membrane; this resembles 
the diffusion barrier found in the nuclear pore that restricts entry of soluble cytosolic proteins 
into the nucleus (Chih et al., 2012; Hu et al., 2010). The B9 complex is essential for both the 
ciliary translocation as well as for the sequestration of transmembrane proteins in the ciliary 
membrane (Chih et al., 2012). The septin diffusion barrier blocks the diffusion of a GPI-linked 
membrane-anchored fluorescent protein but does not restrict access of ciliary transport proteins 
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such as IFT88 into the ciliary membrane; these are instead inserted by IFT proteins and by the 
BBSome into the ciliary membrane directly above the septin diffusion barrier (Nachury et al., 
2010).  
At present, trafficking of proteins to the primary cilium is poorly understood 
mechanistically. One possibility is that ciliary entry is limited through a diffusion barrier at the 
base of the cilium, similar to how a size-selective diffusion barrier at the nuclear pore restricts 
entry into the nucleus. The size exclusion limit is around 30-40 kDa for both nuclear and ciliary 
entry by diffusion; proteins below the limit float in freely, while proteins above the limit are 
restricted from entering the cilium by diffusion alone, and instead require active transport (Kee et 
al., 2012). Members of the importin and Ran-GTPase families are required for ciliary entry and 
transport, as they are for nuclear import (Dishinger et al., 2010). In nuclear entry, importins 
recognize and bind the basic residues of the NLS, and move the cargo proteins through the 
nuclear pore complex; the importins then release the cargo upon binding to Ran-GTP, which is 
highly enriched in the nucleus, and are shuttled back to the cytosol where hydrolysis of the Ran-
GTP to Ran-GDP restarts the process (Macara, 2001; Stewart, 2007). At the base of the primary 
cilium, importins and Ran along with the BBSome load cargo onto IFT-A/IFT-B complexes for 
transport to the distal end of the cilium (Fan and Margolis, 2011). Furthermore, nucleoporins 
localize to the base of the cilium as they do in the nuclear pore, and nucleoporin-blocking agents 
such as a truncated importin-β1 block entry of the kinesin-2 Kif17 motors into the ciliary 
compartment (Kee et al., 2012). However, it must be noted that the exact nature of the ciliary 
pore (and whether it actually exists) remains unknown. 
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While the simple diffusion barrier model above explains the ciliary import of soluble 
proteins, a different mechanism must account for the entry of membrane or lipid-anchored 
proteins into the primary cilium. Trafficking of membrane proteins between cellular 
compartments occurs through vesicles coated with the cage proteins COPI, COPII or clathrin 
(Faini et al., 2013). It is unlikely that whole vesicles would enter the ciliary lumen directly since 
the size of the smallest vesicles is larger than the 60nm spacing available between the transition 
fibers that anchor the transition zone of the primary cilium to the ciliary membrane (Anderson, 
1972; Nachury et al., 2010). Instead, vesicles containing membrane proteins originating from the 
trans-Golgi fuse either to the membrane compartment at the base of the cilium and deliver their 
cargo there; or to the plasma membrane, and the cilium-directed cargo then moves into the 
ciliary membrane through lateral diffusion (Nachury et al., 2010). It must be noted that the 
directed vesicular trafficking mechanism from the Golgi to the base of the cilium is currently the 
preferred model for selective sorting of protein and lipids to the primary cilium (Rohatgi and 
Snell, 2010). A single component of the IFT-B complex, IFT20, also has a function independent 
of the IFT B complex and couples vesicular traffic from the Golgi to the canonical IFT 
components at the primary cilium. IFT20 is the only IFT protein in the Golgi; it localizes 
primarily to the trans-Golgi network as well as to post-Golgi vesicles that fuse with the base of 
the cilium (Follit et al., 2006), and moves dynamically between the Golgi and the primary cilium 
along with ciliary-targeted cargo (Keady et al., 2011). The light-detecting outer segments of 
vertebrate photoreceptors are highly specialized structures derived from the primary cilium and 
function as anchoring points for the light-sensitive GPCRs of the opsin family. In rod cells of the 
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retina, IFT20 binds the photopigment rhodopsin directly, both as part of the IFT particle as well 
as outside of it, and loss of IFT20 leads to accumulation of opsins in the Golgi network of the 
cell body (Keady et al., 2011). In the Hh pathway, however, Smo translocates to the primary 
cilium primarily through lateral movement from the plasma membrane, a mechanism that is 
distinct from the common vesicular trafficking to the ciliary base (Milenkovic et al., 2009). 
One mechanism for regulation of proteins at the primary cilium is through regulation of 
their transport to and from the primary cilium. Ciliary access is tightly regulated as ciliary 
proteins must contain a ciliary localization sequence (CLS); interestingly, functional CLS 
resemble nuclear localization sequences and are stretches of basic residues (Dishinger et al., 
2010) or a motif of adjacent hydrophobic and basic residues immediately C-terminal to the 
seventh transmembrane domain of olfactory GPCRs (Dwyer et al., 2001). Ciliary transport also 
resembles nuclear entry; members of the importin and Ran-GTPase families are required for 
ciliary entry, as they are for nuclear import (Dishinger et al., 2010). In nuclear import, importins 
recognize and bind the NLS of the cargo proteins, and move them through the nuclear pore 
complex in a Ran-GTPase dependent manner. At the cilium, importins and Ran along with the 
BBSome load cargo at the base of the cilium onto IFT-A/IFT-B complexes for transport to the 
distal end of the cilium (Fan and Margolis, 2011). Membrane proteins enter the base of the 
cilium through both vesicular trafficking as well as through lateral diffusion from the cell 
membrane. A septin ring in the transition zone forms a diffusion barrier at the base of the cilium 
that restricts access into the ciliary membrane; this is similar to the diffusion barrier found in the 
nuclear pore (Hu et al., 2010). However, it must be noted that other CLS exist, such as the 
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conserved AX[S/A]XQ motif found in the third intracellular loop of many ciliary-targeted 
GPCRs; this sequence is bound directly by the BBSome rather than by importins, and facilitates 
ciliary entry through a parallel mechanism (Berbari et al., 2008; Jin et al., 2010). 
Lipid modifications of soluble proteins or protein domains result in attachment to the 
plasma membrane and affect sorting into the various cellular compartments. The addition of 
either a C15 (farnesyl) or a C20 (geranylgeranyl) fatty acid linker through S-prenylation of C-
terminal cysteines in a conserved CAAX motif results in attachment to the inner leaflet of the 
plasma membrane (Fu and Casey, 1999); similarly, N-terminal myristoylation attaches a C14 
fatty acid sidechain to N-terminal glycine residues and leads to incorporation in lipid rafts 
(Gordon et al., 1991). Separately, glycophosphatidylinositol (GPI) anchors can tether the C-
terminus end of proteins to the plasma membrane (Low, 1989). Finally, S-palmitoylation of 
cysteine residues anchors soluble proteins to the plasma membrane via a C16 fatty acid sidechain 
(Munday and Lopez, 2007). Of these lipid modifications, palmitoylation and myristoylation are 
often encountered among ciliary proteins, and myristoylation motifs are enriched in ciliary 
proteins of Chlamydomonas (Pazour et al., 2005). Palmitoylation and myristoylation move 
proteins into lipid rafts, which are detergent-insoluble, cholesterol-rich microdomains of the 
plasma membrane; at the same time, prenylation prevents proteins from entering lipid rafts due 
to the branched bulky structure of the prenyl groups which disfavours the liquid-ordered phase 
domains of lipid rafts (Melkonian et al., 1999). Interestingly, the ciliary membrane is enriched in 
sterols, sphingolipids and glycolipids which are constituents of lipid rafts, and contains a high 
degree of liquid order indicative of lipid raft microdomains (Tyler et al., 2009).  
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Despite the fact that the CLSs identified to date do not share significant sequence 
homology to each other, a majority of them incorporate in lipid rafts via palmitoyl and/or 
myristoyl modifications (for instance fibrocystin, cystin, and calflagin) (Follit et al., 2010; 
Godsel and Engman, 1999; Tao et al., 2009). Myristoylation addresses proteins without 
transmembrane domains to the plasma membrane (as in the case of the flagellar calcium-binding 
protein calflagin in African trypanosomes, (Emmer et al., 2009)) or to the ciliary membrane as in 
the case of the ciliopathy protein nephrocystin-3 (NPHP3) (Godsel and Engman, 1999; Wright et 
al., 2011). Several proteins involved in myristoylated protein trafficking localize to the cilium: 
Unc119 binds myristoylated proteins, while the small GTPase Arf-like 3 (ARL3) along with the 
Retinitis pigmentosa 2 protein, which acts as the Arl3 GTPase-activating protein (GAP), release 
myristoylated cargo proteins from Unc119; all three proteins are enriched at the transition zone 
(Wright et al., 2011). Separately, cysteine residues next to blocks of basic amino acids are targets 
of palmitoylation (Bijlmakers and Marsh, 2003), and in the case of calflagin, palmitoylation 
provides a secondary signal that relocates the myristoylated calflagin from the plasma membrane 
to the ciliary membrane (Emmer et al., 2009). Furthermore, palmitoylation of an 18-aminoacid 
stretch which was recently identified as the CLS of fibrocystin is essential for correct ciliary 
targeting (Follit et al., 2010). Mutations that abolish the palmitoylation of certain CLSs also 
prevent targeting to the primary cilium (Emmer et al., 2009; Follit et al., 2010), and defects in the 
calflagin palmitoyltransferase TbPAT7 which acylates the CLS of calflagin recapitulate the 
behaviour of the lipidation-defective mutants (Emmer et al., 2009). This suggests that despite 
their similarity, the stretches of basic residues of the NLS and those of certain CLSs probably 
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serve completely different functions – in the case of the NLS they bind importins and facilitate 
movement through the nuclear pore, whereas in the case of the CLS they serve as palmitoylation 
signals to link the CLS to lipid membranes. It is conceivable that ciliary targeting depends on 
partitioning into membrane microdomains or lipid rafts with a unique lipid composition; a 
precedent along these lines exists – targeting of proteins to the apical membrane in epithelial 
cells requires the association of cargo targeted to the apical membrane with lipid rafts (Simons 
and Toomre, 2000). 
While myristoylation is a static modification that is generally applied to proteins through 
a co-translational process, palmitoylation is a reversible modification and palmitoylation–
depalmitoylation dynamics can coordinate protein sorting as evidenced by the cycling of the Ras 
oncogene between the Golgi and the plasma membrane: the cytosolic Ras is palmitoylated at the 
Golgi membrane and then shuttles on vesicles to the plasma membrane where it is 
depalmitoylated and recycled to the cytosol through a non-vesicular pathway for another round 
of palmitoylation; this process ensures a constant supply of Ras at the plasma membrane, while 
at the same time maintains a high turnover rate of Ras at the plasma membrane that prevents it 
from accidentally entering other membrane compartments in the cell (Goodwin et al., 2005). 
Regulated trafficking to the cilium may involve a similar dynamic mechanism.  
 
1.8 Hedgehog signaling at the primary cilium 
The spatial localization of the Hedgehog pathway components in vertebrates provides an 
additional layer of regulation, as primary cilia are essential for transduction of the Hedgehog 
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signal across the membrane (Huangfu and Anderson, 2005). This section will review the Hh 
signaling in vertebrates in the context of the primary cilium, and will highlight the key 
differences between the regulation of the Hh pathway in flies and in vertebrates. 
In the absence of signal, Smo appears primarily in intracellular vesicles, while Ptc 
localizes to the base of the primary cilium. Upon activation by Shh, Ptc is internalized which 
allows Smo to accumulate at the primary cilium where the intracellular components of the Hh 
signaling pathway reside, to physically associate with the ciliary protein Evc2, and to activate 
downstream signaling; Smo also localizes to the cilium when overexpressed (Dorn et al., 2012; 
Rohatgi et al., 2007; Singla and Reiter, 2006). Smo translocates to the primary cilium primarily 
through lateral movement from the plasma membrane (Milenkovic et al., 2009). However, the 
ciliary localization sequences of Ptc or Smo are not known. 
In vertebrates, the major negative hedgehog pathway regulator SuFu inhibits Gli proteins 
in the cytosol by forming a complex with them. Upon pathway activation at the level of Ptc or 
Smo, the SuFu-Gli complexes travel to the primary cilium, where the activated Smo triggers 
their rapid dissociation; the liberated full-length Gli (the unproteolysed activator form, Gli-A) 
then enters the nucleus and starts transcribing the Hh target genes. Pharmacologic activation of 
protein kinase A (PKA) by forskolin uncouples Smo activation from the SuFu-Gli complex 
dissociation, inhibits ciliary entry of the SuFu-Gli complex and prohibits the derepression of Gli. 
Furthermore, the loss of SuFu triggers maximal pathway response, and these cells do not require 
cilia for signaling, providing further evidence that the net result of the ciliary steps of the 
Hedgehog pathway is the liberation of full-length Gli (Svard et al., 2006; Tukachinsky et al., 
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2010). In contrast, Drosophila cells lack a primary cilium, which explains the divergent signaling 
mechanism downstream of Smo through Costal2 in the cytosol, and the relatively minor role of 
Su(fu) as a negative regulator in flies (Svard et al., 2006). 
Knockout of the negative regulators Ptc and Sufu leads to constitutive pathway activity, 
which results in ventralization of the neural tube, polydactyly and inverted cardiac looping in the 
embryo. Ectopic activation of the Hedgehog pathway directly causes a number of tumors in 
humans including sporadic medulloblastoma, a common but devastating childhood brain tumor; 
mouse knockout models recapitulate these tumors (Goodrich et al., 1997; Svard et al., 2006). 
Furthermore, reactivation of the Hh pathway is observed in a variety of cancers as they 
metastasize and enhances their metastatic potential (Yoo et al., 2011).  
Several IFT proteins have been implicated in Hedgehog signaling. IFT172 and IFT88 are 
present in the same IFT-B complex and are essential for ciliogenesis; both proteins are required 
for normal activation of the Hh pathway and for establishing correct left-right asymmetry in the 
developing embryo. Mice lacking IFT172 or IFT88 have an open neural tube that lacks the 
groove normally observed on the ventral midline, as well as random looping of the heart tube, 
and die in utero at E10.5-13.5; this phenotype is characteristic for defects in Hh signaling, and 
loss of IFT172 prevents processing of Gli3 to the repressor form which results in a higher basal 
transcriptional level of Hh target genes (Huangfu and Anderson, 2005; Huangfu et al., 2003). 
The mouse Kif3a is an essential subunit of the kinesin-II anterograde IFT motor, while Dnchc2 is 
an essential subunit of the retrograde IFT motor complex. Defects in Kif3a result in a failure of 
ciliary assembly and blocks hedgehog signaling (Ko et al., 2009). Loss of either Kif3a or Dnchc2 
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results in lack of ventral neural types, which is similar to the loss of IFT172 and IFT88 (Huangfu 
and Anderson, 2005; Huangfu et al., 2003). Interestingly, the loss of IFT88 or Kif3a homologs in 
Drosophila does not impair Hh signaling; this is in line with the divergent signal transduction 
mechanism downstream of Smo in Drosophila, which does not involve the primary cilium (Han 
et al., 2003; Ray et al., 1999).  
A different set of IFT-B proteins, IFT25 and IFT27 form a binary complex that is 
conserved throughout vertebrates but is missing in Drosophila. The IFT25-IFT27 complex is not 
required for ciliogenesis, but appears essential for transduction of the Hh signal in vertebrates; 
the loss of IFT25 leads to mislocalization of Ptc, Smo and Gli2 at the cilium and disrupts the Hh 
pathway response upon stimulation. In these animals, Gli2 does not accumulate at the cilium in 
response to signaling, while Patched and Smo are constitutively localized at the cilium regardless 
of the presence or absence of the Hh ligand. Interestingly, the cilia of these animals appear 
morphologically normal, and also show normal localization as well as normal amounts of other 
IFT proteins such as IFT88; the animals survive to birth but show severe abnormalities indicative 
of Hh signaling defects: cleft palate, incorrect alignment of the sternal vertebrae, and polydactyly 
(Keady et al., 2012). Thus, rather than facilitating transport to the primary cilium, the IFT25-
IFT27 complex enables the dynamic redistribution of Hh pathway components in response to 
signaling. Furthermore, this dynamic is critical to establishing the correct enrichment of pathway 
components in the cilium versus the rest of the cell in both the OFF state (Ptc at cilium, Smo and 
Gli2 outside the cilium) and the ON state (Ptc outside the cilium, Smo at the cilium and Gli2 
accumulated at the tip of the cilium and in the nucleus) of the Hh pathway. 
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Any ciliary-bound protein must cross through the ciliary transition zone in order to reach 
the axoneme. Multiple ciliopathy proteins reside at the transition zone and are involved in ciliary 
assembly and trafficking; this includes proteins whose defects result in human ciliopathies such 
as Meckel syndrome (MKS), Joubert syndrome and Nephronophthisis (NPHP) (Garcia-Gonzalo 
et al., 2011). Interestingly, while the disease phenotypes are different, the molecular aetiologies 
of the different ciliopathies overlap. For instance, the defining features of MKS are occipital 
encephalocele, kidney cysts and polydactyly, while JBTS patients show primarily brainstem and 
cerebellar malformations; however, mutations in a subset of six genes originally identified in 
MKS such as CEP290 can cause JBTS or a related ciliopathy, COACH (short for cerebellar 
vermis hypoplasia, oligophrenia, ataxia, coloboma and hepatic fibrosis) (Garcia-Gonzalo et al., 
2011). Of particular relevance is the JBTS protein Tectonic (Tctn1), as it is a modulator of Hh 
signaling and acts at a level downstream of Smo (Reiter and Skarnes, 2006). Tctn1 is required 
for ciliogenesis in a tissue-specific manner and forms a transition zone complex with other MKS 
and JBTS proteins that includes membrane components as well as the two other vertebrate 
homologs of Tctn1 – Tctn2 and Tctn3 (Garcia-Gonzalo et al., 2011). Tctn1-/- mice die in-utero at 
E13.5-E16.5, and show morphological defects such as holoprosencephaly which are indicative of 
impaired Hedgehog signaling in the neural floorplate (Reiter and Skarnes, 2006). Loss of Tctn1 
blocks the transition zone localization of the proteins Mks1 and Tmem67, but does not affect the 
localization of Septin2 or of the IFT-A, IFT-B or BBSome complexes. This suggests that the 
action of Tctn1 is required at the transition zone. Intriguingly, Tctn1 acts as both a positive as 
well as a negative regulator on the Hedgehog pathway. This can be explained by the role of cilia 
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in the partial proteolytic processing of Gli to the Gli-R repressor form, as well as by the role of 
cilia in the dissociation of the SuFu-Gli complex and the release of the full-length Gli-A 
activator form from the inhibitory effect of SuFu. In the absence of Tctn1, neither of these 
processes occurs; the net effect is a combination of the reduced function of both Gli-A and Gli-
R. What the role of Tctn1 is in the context of the ciliary transition zone, and whether the Tctn1-
containing complex interacts with the SuFu-Gli complex is not clear. 
 
1.9 Aims of this dissertation 
Over the last three decades, genetics studies in model organisms such as flies, fish, mice 
and chick have made great progress in identifying the Hedgehog pathway components. However, 
a mechanistic understanding of various key aspects remains lacking. In this dissertation I 
describe experiments both in-vitro and in the tissue culture system that were used to answer 
several mechanistic questions. 
In Chapter 2 I show that oxysterols which potently activate Hedgehog signaling bind 
Smo at a site in the extracellular, cysteine-rich domain which is distinct from the site bound by 
cyclopamine and the other small molecule Smo modulators. I describe azasterols that block 
Hedgehog signaling by inhibiting the oxysterol-binding site of Smo. My results show that 
oxysterol binding to vertebrate Smoothened is required for high-level Hedgehog signaling, and 
that targeting the oxysterol binding site is an effective strategy to block Smoothened activity. 
In Chapter 3 I explore the mechanism of ciliary localization of Smo. I map the ciliary 
localization domain to the cytosolic tail of Smo and identify two degenerate ciliary localization 
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sequences within its cytosolic tail. I further identify a cytosolic domain of Smo, which is 
essential but not sufficient for activation of downstream components. Finally, I show that while 
the ciliary localization aspect is unique to vertebrates, signaling to downstream components is 
conserved across phyla. 
In Chapter 4 I discuss the significance of my findings and suggest future experiments to 
address the open questions raised by my work. My findings indicate that Smo is a modular 
protein, wherein each module serves a specific role and reflects a distinct mechanism of 
regulation. This suggests a model wherein Smo is at the confluence of several distinct regulatory 
inputs: an oxysterol regulated module, a second small-molecule regulated module, and a ciliary 
localization module, as well as a module for downstream signalling – which all converge for 
maximal activation.  
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2.1 Author contributions 
I performed cellular and biochemical experiments. J.L., C.J. and A.S. designed and 
synthesized all reported compounds. J.L. performed the purification and characterization of the 
reported compounds. Y.X. and I developed the automated image analysis software, and I 
analyzed all the imaging data.  
2.2 Abstract 
Oxysterols bind the seven-spanner transmembrane protein Smoothened and potently 
activate vertebrate Hedgehog signaling, a pathway essential in embryonic development, adult 
stem cell maintenance and cancer. It is unknown, however, if oxysterols are important for normal 
Hedgehog signaling, and whether antagonizing oxysterols can inhibit the Hedgehog pathway. 
We developed azasterols that block Hedgehog signaling by binding to the oxysterol-binding site 
of Smoothened. We show that the binding site for oxysterols and azasterols maps to the 
extracellular, cysteine-rich domain of Smoothened, and is completely separable from the site 
bound by other small molecule modulators, located within the heptahelical bundle of 
Smoothened. Smoothened mutants that abolish oxysterol binding no longer respond to 
oxysterols, and cannot be maximally activated by the Hedgehog ligand. Our results show that 
oxysterol binding to vertebrate Smoothened is required for high level Hedgehog signaling, and 
that targeting the oxysterol binding site is an effective strategy to block Smoothened activity.  
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2.3 Introduction 
Cell-cell signaling via the Hedgehog (Hh) pathway is critical for numerous aspects of 
metazoan embryonic development and regeneration, while excessive Hh signaling is involved in 
many cancers (Ingham and McMahon, 2001; Lum and Beachy, 2004). Among the poorly 
understood aspects of Hh signal transduction is the mechanism by which Hh signals are relayed 
across the plasma membrane, via the functional interaction between the multi-spanning 
membrane protein Patched (Ptc), which functions as the Hh receptor, and the seven-spanner 
Smoothened (Smo), a member of the Frizzled family of membrane proteins. In the absence of the 
Hh ligand, Ptc inhibits Smo through an unknown mechanism, ensuring that Hh signals are not 
relayed to the cytoplasm. Hh signaling is initiated by binding of the Hh ligand to Ptc, which 
leads to Smo activation and the consequent initiation of a specific transcriptional program driven 
by the Gli transcription factors. 
A major unanswered question in Hh signaling is the mechanism by which the activity of 
Smo is regulated. By analogy with other seven-spanners, it is thought that Smo equilibrates 
between active and inactive conformations, and that this equilibrium is controlled by a ligand 
(Taipale et al., 2002), whose identity has remained elusive. Consistent with this hypothesis, 
vertebrate Smo harbors within its heptahelical bundle a binding site (Chen et al., 2002a) (hereby 
referred to as “Site A”) reminiscent of the ligand-binding site of G protein-coupled receptors 
(GPCRs). Site A is targeted by a large number of small molecules, including Smo inhibitors 
(such as the plant alkaloid cyclopamine (Chen et al., 2002a), SANT1 (Frank-Kamenetsky et al., 
2002), or the FDA-approved Smo inhibitor GDC0449 (Robarge et al., 2009)) as well as Smo 
activators (such as SAG (Chen et al., 2002b; Frank-Kamenetsky et al., 2002) and 
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purmorphamine (Sinha and Chen, 2006)). In spite of the relative ease in finding synthetic 
modulators of vertebrate Smo, no endogenous small molecule that regulates Smo via binding to 
Site A has been identified so far. 
The only naturally occurring molecules that activate the Hh pathway at the level of Smo 
are oxysterols, a class of oxidized cholesterol derivatives known for their potent effects on many 
cellular processes, including signaling and metabolism. Specifically, vertebrate Hh signaling is 
stimulated by oxysterols carrying hydroxyl groups on the isooctyl side chain of the molecule 
(Corcoran and Scott, 2006; Dwyer et al., 2007), the most potent such oxysterol being 20(S)-
hydroxycholesterol (20-OHC, figure 1A) (Nachtergaele et al., 2012). Oxysterols activate Smo by 
direct binding, and do not compete with compounds that bind to Site A, suggesting that they 
activate Smo by an allosteric mechanism involving a second, distinct binding site (Nachtergaele 
et al., 2012) (hereby referred to as “Site B”). Several important mechanistic questions about the 
role of oxysterols in Hh signaling are currently open. First, it is unknown where Site B is located 
in Smo, and whether Site B is separable from Site A. Second, while Site A is targeted by both 
Smo activators and inhibitors, so far we only know of oxysterol activators that bind Site B, 
raising the question of whether Site B can also be targeted by inhibitors. Finally, although 
oxysterols are potent activators of Smo, it is unknown if binding of oxysterols to Smo is required 
for Smo activation during normal Hh signaling in vertebrates. 
We have developed azasterols that block Hh signaling triggered by the Hh ligand and by 
20-OHC. These compounds compete with 20-OHC for binding to Smo, indicating that they bind 
to Site B; in contrast, azasterols do not compete with small molecule activators or inhibitors that 
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bind Site A. We used azasterol and oxysterol affinity probes to map Site B to the extracellular, 
cysteine-rich domain (CRD) of vertebrate Smo; furthermore, we show that Site A and B are 
completely separable. When Site B is mutated, 20-OHC binding to Smo is abolished and 20-
OHC can no longer activate Smo, thus validating functionally the surprising identification of Site 
B within the CRD of Smo. These oxysterol-insensitive Smo mutants have greatly decreased 
responsiveness to the Hh ligand compared to wild-type Smo, indicating that binding of 
endogenous oxysterols to Smo is necessary for high level vertebrate Hh signaling. 
2.4 Results  
2.4.1 An azasterol inhibitor of vertebrate Hedgehog signaling that mimics the effects of 
sterol depletion 
Vertebrate Hh signaling is strongly activated by 20-OHC (Nachtergaele et al., 2012); 
however, the consequences for Hh signaling of blocking 20-OHC are not known. To obtain a 
potential inhibitor of 20-OHC, we synthesized 22- azacholesterol (22-NHC, Figure 2.1a). When 
tested in Hh-responsive NIH-3T3 cells, 22-NHC inhibited Hh pathway activation by the Sonic 
Hedgehog (Shh) ligand in a dose-dependent manner, with an IC50 of about 3 µM (Figure 2.1b). 
Synthesis of 22-NHC generates a chiral center at C20, resulting in 2 possible diastereomers, 
22(S)-NHC and 22(R)-NHC. The diastereomeric mix from our synthesis consisted mostly of 
22(S)-NHC, and pure 22(S)-NHC recapitulated the inhibitory activity of the mix. 22-NHC did 
not affect the EC50 of the Shh ligand (Figure 2.1b) but it decreased the maximum stimulation 
level (Figure 2.1c), a profile indicative of non-competitive inhibition. 
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We first sought to determine what step in the Hh signal transduction pathway is blocked 
by 22-NHC. In vertebrate cells, binding of Shh to Patched (Ptc) causes the removal of Ptc from 
the primary cilium (Rohatgi et al., 2007), which, in turn, triggers Hh pathway activation. 22-
NHC had no effect on the disappearance of Ptc from the cilium in response to Shh 
(Supplementary Figure S1a), suggesting that 22-NHC inhibits the Hh pathway downstream of  
 
Figure 2.1 22-azacholesterol (22-NHC), an azasterol inhibitor of vertebrate Hh signaling 
(a) Structures of the azasterol, 22-azacholesterol (22-NHC, shown as the S diastereomer), and of 
the Hh- activating oxysterol, 20(S)-hydroxycholesterol (20(S)-OHC). 
(b) Shh Light II cells were treated with various concentrations of Shh, in the presence of 
increasing amounts of 22-NHC, and Hh pathway activation was measured by luciferase assay. 
All experiments were performed in quadruplicate and error bars represent the standard deviation  
b c 
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Figure 2.1 (continued) 22-azacholesterol (22-NHC), an azasterol inhibitor of vertebrate Hh 
signaling 
of the mean. 22-NHC inhibits Hh pathway activation by Shh but does not significantly change 
the EC50 of Shh. 
(c) The data in (b) was plotted to show that 22-NHC decreases the maximal stimulation of the 
Hh pathway by Shh. 
(d) As in (b) but Hh signaling was activated by various concentrations of the 20-OHC analog, 
20-OHC- Pent. 22-NHC inhibits Hh pathway activation by 20-OHC-Pent, without significantly 
changing the EC50. 
(e) The data in (d) was plotted to show that 22-NHC decreases the maximal stimulation of the 
Hh pathway by 20-OHC-Pent. 
(f) As in (b) but Hh signaling was activated by various concentrations of SAG. 22-NHC does not 
inhibit Hh pathway activation by SAG but decreases the EC50 for SAG. 
 (g) Smo-/- MEFs were rescued by stable expression of mSmo or the constitutively active mutant 
mSmoM2. Transcription of the Hh target gene, Gli1, was measured by Q-PCR in the absence or 
presence of 22-NHC (20 µM) or SANT1 (2 µM). All experiments were performed in triplicate, 
and error bars indicate the standard deviation of the mean. 22-NHC does not inhibit SmoM2. 
(h) Shh Light II cells were stimulated with Shh, in the presence of increasing amounts of 22-
NHC, with the addition of the indicated concentrations of cylopamine and cyclopamine-KAAD. 
Hh pathway activity was assayed as in (b) 
(i) As in (h) but with addition of the indicated concentrations of SANT1, GDC0449 and 
itraconazole. 
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Ptc. We next asked if 22-NHC inhibits two activators of the Hh pathway that function at the level 
of Smoothened (Smo), 20-OHC and the synthetic activator, SAG. 22- NHC inhibited 20-OHC in 
a dose-dependent manner and non-competitively: 22-NHC did not significantly change the EC50 
of 20-OHC (Figure 2.1d) but decreased the level of maximal stimulation (Figure 2.1e). In 
contrast, 22-NHC did not inhibit Hh pathway stimulation by SAG (Figure 2.1f); in fact, 22-NHC 
caused an increase in the responsiveness of cells to SAG (note the decrease in EC50 for SAG in 
the presence of 22-NHC, in Figure 2.1f). While we do not understand the basis for the synergy 
with SAG, one possibility is that it is caused by 22-NHC promoting Smo translocation to cilia 
(see below). Additionally, 22-NHC did not block signaling by mSmoM2 (Figure 2.1g), an 
oncogenic mouse Smo mutant locked in the active conformation (Taipale et al., 2000), or the 
constitutive Hh signaling in SuFu-/- MEFs (Svard et al., 2006)
 
(Supplementary Figure S1b), in 
which the Hh pathway is activated downstream from Smo. Together, these results indicate that 
22-NHC targets either Smo or an unknown component between Ptc and Smo. Importantly, the 
inhibition profile of 22-NHC mirrors the effect of sterol depletion, which blocks activation of the 
vertebrate Hh pathway by Shh but not by SAG, mSmoM2 or by loss of SuFu (Cooper et al., 
2003). 
Finally, we asked if 22-NHC synergizes with known Hh pathway inhibitors that target 
Smo. As shown in Figure 2.1h and Figure 2.1i, 22-NHC did not synergize with cyclopamine 
(Cyc), cyclopamine-KAAD, SANT1, GDC0449 and itraconazole to inhibit Hh pathway 
activation by Shh; conversely, these inhibitors did not significantly affect the IC50 of 22-NHC. 
Thus 22-NHC does not interact with other Smo inhibitors, suggesting a potentially different 
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mechanism. In summary, 22-NHC is an inhibitor that recapitulates the effect of sterol depletion 
on vertebrate Hh signaling, and epistatic analysis suggests Smo as a candidate target of 22-NHC. 
 
2.4.2 22-NHC binds Smoothened at a site distinct from the cyclopamine-binding site 
We next tested the effect of 22-NHC on the accumulation of Smo in primary cilia, an early 
response to vertebrate Hh stimulation (Corbit et al., 2005). As shown in Figure 2.2a, 22-NHC by 
itself caused Smo to accumulate in cilia, a behaviour reminiscent of Cyc (Rohatgi et al., 2009; 
Wang et al., 2009), an Hh pathway inhibitor that binds Smo at Site A. To test if 22-NHC also 
binds to Site A of Smo, we performed binding assays in cells with the fluorescent derivative, 
BODIPY-cyclopamine (Chen et al., 2002a)
 
(BODIPY-Cyc). 22-NHC did not compete binding of 
BODIPY-Cyc to mouse Smo (mSmo), similar to 20-OHC (Supplementary Figure S2c); as 
expected, the Site A-binding small molecule SANT1 abolished BODIPY-Cyc binding. We also 
synthesized a fluorescent derivative of SANT1, BODIPY-SANT1 (Supplementary Figure S2d), 
which retains the inhibitory activity of SANT1 (Supplementary Figure S2e). 22-NHC did not 
compete binding of BODIPY-SANT1 to mSmo, while unmodified SANT1 did (Supplementary 
Figure S2c). Together, these results indicate that 22-NHC does not bind to Site A of mSmo, in 
contrast to Cyc. 
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Figure 2.2 22-NHC binds Smo at a different site from cyclopamine 
(a) 22-NHC causes Smo accumulation at primary cilia. NIH-3T3 cells were treated with 22(S)-
NHC (10 µM) and localization of endogenous Smo was determined by immunofluorescence 
microscopy. The left panel shows representative micrographs of cilia. The graph in the middle 
shows the percentage of Smo- positive cilia. The box plot on the right shows the fluorescence 
intensity of Smo at cilia; the lower and 
upper bounds of each box represent the 25th and 75th percentile of the intensity distribution, 
while the horizontal line represents the median intensity of the entire population of cilia. 
(b) Schematic of the 22-NHC affinity matrix. Top: 22-NHC is covalently attached to agarose 
beads via a polyethylene glycol linker, to generate 22-NHC beads. Bottom: control beads. 
(c) 22-NHC beads were incubated with detergent extracts of 293T cells expressing mSmo-
Cherry, in the presence of the indicated concentrations of competitor compounds. The beads 
were washed and bound protein was eluted, separated by SDS-PAGE and immunoblotted with 
anti-Cherry antibodies. A portion of the extract was analyzed in parallel, to show input. MSmo 
binds specifically to 22-NHC beads. 
(d) As in (c) but with detergent extracts of 293T cells expressing Cherry-tagged mSmo, DrSmo 
or mFz7. Incubation with 22-NHC beads was done in the absence or presence of free 22-NHC 
(100 µM). DrSmo and mFz7 do not bind 22-NHC beads. 
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To test if 22-NHC binds mSmo at a different site, we developed a ligand affinity assay. 
We focused on the alkyl side chain of 22-NHC as potential site for covalent attachment to beads, 
and asked if analogs with shorter side chains inhibit Hh signaling. Analogs of 22-NHC bearing 
N-propyl and N-ethyl groups (Supplementary Figure S2f) retain the inhibitory activity of 22-
NHC, albeit they are slightly less potent (Supplementary Figure S2g). Interestingly, the 
stereochemistry of C20 does not matter in these 20-NHC analogs: both S and R diastereomers 
inhibit Hh signaling, in contrast to the strict C20 stereochemistry required for Hh pathway 
activation by oxysterols (Nachtergaele et al., 2012)
 
(see also below). 
Based on the structure-function analysis above, we synthesized 22-NHC-PEG-NH2, a 
derivative of 22- NHC with a polyethylene glycol (PEG) linker, which was covalently attached 
to amine-reactive beads, to generate 22-NHC beads (Figure 2.2b). As source of mSmo protein, 
we used detergent extracts of 293T cells stably expressing mSmo tagged with mCherry; this 
fusion protein is active, as demonstrated by rescue of Hh signaling in Smo-/- mouse embryonic 
fibroblasts (MEFs) (see below). As shown in figure 2C, 22-NHC beads efficiently captured 
mSmo, preferentially the glycosylated species with low electrophoretic mobility, representing 
post-Golgi mSmo molecules; this suggests that fully mature mSmo is the predominant species 
that binds 22-NHC. Binding of mSmo to 22-NHC beads was competed in a dose-dependent 
manner by free 22-NHC added to the detergent extract (Figure 2.2c), suggesting that it was 
specific. SAG, SANT1 and GDC0449 had no effect on mSmo binding to 22-NHC beads (Figure 
2.2c), consistent with 22-NHC not binding Site A. Itraconazole, a mSmo inhibitor that does not 
bind Site A (Kim et al., 2010)
 
also had no effect on binding of mSmo to 22-NHC beads (Figure 
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2.2c). As negative control, we used beads derivatized with the PEG linker incorporated into 22-
NHC-PEG-NH2 (Figure 2.2b); these beads captured negligible amounts of mSmo (Figure 2.2c). 
As further proof of specificity, 22-NHC beads did not bind another seven-spanner related to 
Smo, mouse Frizzled-7 (mFz7) (Figure 2.2d). Finally, binding was specific for vertebrate Smo 
proteins: 22-NHC beads did not bind Drosophila Smo (DrSmo, Figure 2.2d) but bound Xenopus 
Smo (xSmo, see Figure 2.3b below). Together, these results demonstrate that 22-NHC binds 
vertebrate Smo proteins at a different site from Site A and from the hypothetical site targeted by 
itraconazole. 
 
2.4.3 22-NHC binds the oxysterol-binding site of Smoothened 
Oxysterols are allosteric activators of vertebrate Smo that bind to Site B, which is distinct 
from Site A and from the itraconazole site (Nachtergaele et al., 2012). We asked if 22-NHC 
binds Smo at Site B by performing competition experiments with oxysterols. Binding of mSmo 
to 22-NHC beads was competed in a dose-dependent manner by two active oxysterols, 20-OHC 
and the analog 20-OHC-Pent (see below), while the inactive 7-hydroxycholesterol (7-OHC) had 
no effect (Figure 2.3a). Similarly, binding of xSmo to 22-NHC beads was competed by free 20-
OHC and 22-NHC, but not by 7-OHC (Figure 2.3b). Thus 22-NHC and oxysterols that activate 
the Hh pathway compete for binding to vertebrate Smo. 
Binding of 20-OHC is strictly stereospecific: 20(S)-OHC binds Smo while 20(R)-OHC 
does not (Nachtergaele et al., 2012). If 22-NHC binds Site B of Smo, it would be expected that 
oxysterol competition be also stereospecific. To test this prediction, we prepared the pure 
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diastereomers of 20-OHC-Pent (Figure 2.3c). Only the active diastereomer 20(S)-OHC-Pent (see 
below) competed mSmo binding to 22-NHC beads, while the inactive diastereomer 20(R)-OHC-
Pent had no effect (Figure 2.3d). Thus oxysterol stereochemistry at C20 is critical for competing 
with binding of 22-NHC to Smo. 
 
Figure 2.3 22-NHC binds Smo at the oxysterol-binding site 
(a) Detergent extracts of cells expressing mSmo-Cherry were incubated with 22-NHC beads, in 
the presence of the indicated concentrations of the inactive oxysterol 7-OHC or the active 
oxysterols, 20- OHC and 20-OHC-Pent. Bound mSmo-Cherry was analyzed by SDS-PAGE and 
immunoblotting. Binding of mSmo to 22-NHC beads is competed in a dose-dependent manner 
by 20-OHC and 20-OHC- Pent, but not by 7-OHC. 
(b) As in (a) but with eGFP-tagged xSmo. Binding of xSmo to 22-NHC beads is competed by 
free 22- NHC and 20-OHC but not by 7-OHC. All competitors were used at 100 µM. 
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Figure 2.3 (continued) 22-NHC binds Smo at the oxysterol-binding site  
(c) Structures of the two diastereomers of the active oxysterol 20-OHC-Pent. 
(d) As in (a) but with the addition of 20(S)-OHC-Pent and 20(R)-OHC-Pent. Binding of mSmo 
to 22- NHC beads is competed by the active S diastereomer but not by the inactive R 
diastereomer. 
(e) Schematic of the 20-OHC beads. 
(f) Detergent extracts of cells expressing mSmo-Cherry were incubated with 20-OHC beads, in 
the presence of the indicated concentrations of free 22-NHC or 20-OHC. Bound mSmo was  
analyzed as in (a). Binding of mSmo to 20-OHC beads is competed in a dose-dependent manner 
by free 22-NHC and 20-OHC.  
(g) As in (f) but with Cherry-tagged mSmo, DrSmo or mFz7. DrSmo and mFz7 do not bind 20-
OHC beads, in contrast to mSmo. Binding of mSmo was competed by free 20-OHC (100 µM). 
(h) As in (f) but with eGFP-tagged xSmo. The protein bound to beads was detected by 
immunoblotting with anti-GFP antibodies. XSmo binds to 20-OHC beads and is competed by 
free 20-OHC (100 µM) but not 7-OHC (100 µM). 
To perform reciprocal binding experiments, we generated 20-OHC beads (Figure 2.3e) 
by covalent attachment of an amine derivative of 20-OHC that incorporates the same PEG linker 
that we used for 22-NHC beads. These beads bound mSmo (Figure 2.3f), as previously described 
for a similar 20-OHC affinity matrix (Nachtergaele et al., 2012). Importantly, 22-NHC inhibited 
binding of mSmo to 20-OHC beads in a dose- dependent manner (Figure 2.3f). Like 22-NHC 
beads, 20-OHC beads did not bind DrSmo (Figure 2.3g), but bound xSmo (Figure 2.3h), 
consistent with the fact that oxysterols are activators of the vertebrate but not of the Drosophila 
Hh pathway. Furthermore, in a variety of Smo binding experiments (see below) 22-NHC and 20-
OHC beads behaved virtually identically. Together, these results indicate that 22-NHC and 20- 
OHC bind to the same site on mSmo (Site B), and suggest that 22-NHC inhibits Hh signaling by 
competing with binding of 20-OHC to mSmo. 
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2.4.4 Oxysterols and 22-NHC bind to the extracellular domain of Smoothened 
The location of Site B on mSmo has not been determined, and is unknown if Site B and 
Site A are physically separable, particularly in view of their allosteric interaction. We used 
mSmo deletion analysis (Figure 2.4a) and 22-NHC and 20-OHC ligand affinity to map the 
location of Site B. MSmo lacking the extracellular, cysteine-rich domain (mSmoΔCRD) did not 
bind to 22-NHC beads (Figure 2.4b) or to 20-OHC beads (Figure 2.4c), in contrast to full-length 
mSmo (Figure 2.4b and Figure 2.4c) and to mSmo lacking the intracellular C-terminal domain 
(mSmoΔICD) (Figure 2.4d). Importantly, mSmoΔCRD bound BODIPY-Cyc (Supplementary Figure 
S3a) and was functional in Hh signaling in Smo-/- MEFs (see below), indicating that it was 
properly folded. These results indicate that the CRD of mSmo is required for binding to 20-OHC 
and 22-NHC. 
We next asked if the CRD of mSmo (mSmoCRD), produced in cultured mammalian cells 
as a soluble, secreted protein, is sufficient to bind 22-NHC and 20-OHC. Secreted mSmoCRD 
bound to 22-NHC beads and was competed in a dose-dependent manner by free 22-NHC, similar 
to full-length mSmo (Figure 2.4e). As an additional control, we showed that secreted 
DrSmoCRD did not bind 22-NHC beads (Figure 2.4f), as expected from the lack of binding of 
full-length DrSmo. 
Binding of mSmoCRD to 22-NHC beads was competed by 20-OHC and 20-OHC-Pent, 
but not by 7- OHC (Figure 2.4g), suggesting that, like full-length mSmo, mSmoCRD binds 
specifically oxysterols that activate the Hh pathway. Furthermore, the stereochemistry of 
oxysterol competition was identical to the one observed for full-length mSmo: the active 
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diastereomer 20(S)-OHC-Pent but not inactive 20(R)-OHC-Pent competed mSmoCRD binding 
to 22-NHC beads in a dose-dependent manner (Figure 2.4h). We obtained identical results using 
20-OHC beads: mSmoCRD bound 20-OHC beads with an affinity similar to that displayed by 
full-length mSmo (Figure 2.4). Importantly, binding of mSmoCRD to 20-OHC beads was 
competed by 20(S)-OHC-Pent but not by 20(R)-OHC-Pent (Figure 2.4i). In addition, binding of 
mSmo and mSmoCRD to 20-OHC beads was competed by the active oxysterol 25-OHC but not 
by the inactive 7-ketocholesterol (Dwyer et al., 2007) (Supplementary Figure S3). Together, 
these results demonstrate that the oxysterol-binding site (Site B) resides in the CRD of Smo and 
is completely separable from Site A. Notably, it was proposed that SmoCRD might bind sterols, 
based on the structural similarity between the sterol-binding protein NPC2 and the CRD domain 
of Frizzled family proteins (Bazan and de Sauvage, 2009); our findings thus confirm this 
prediction. 
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Figure 2.4 Oxysterols and 22-NHC bind the extracellular cysteine-rich domain (CRD) of 
vertebrate Smo  
(a) Schematic of mSmo and of the mSmo deletion mutants used to map the oxysterol-binding 
site.  
(b) Binding of Cherry-tagged mSmo or mSmoΔCRD to 22-NHC beads was tested in the 
presence of 100 µM of the indicated compounds. The CRD of mSmo is required for binding to 
22-NHC beads. 
(c) As in (b) but with 20-OHC beads. The CRD of mSmo is required for binding to 20-OHC 
beads.  
(d) As in (b) but with mSmoΔICD-Cherry. The ICD of mSmo is not required for binding to 22-
NHC beads. 
(e) Secreted HA-tagged mSmoCRD and detergent extracts of mSmo-Cherry were tested for 
binding to 22-NHC beads, in the presence of the indicated concentrations of free 22-NHC. 
mSmoCRD binds 22- NHC beads, similar to mSmo. 
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Figure 2.4 (continued) Oxysterols and 22-NHC bind the extracellular cysteine-rich domain 
(CRD) of vertebrate Smo  
 (f) As in (b) but with secreted HA-tagged mSmoCRD and DrSmoCRD. DrSmoCRD does not 
bind 22-NHC beads in contrast to mSmoCRD. 
(g) mSmoCRD binding to 22-NHC beads was assayed as in (b), in the presence of the indicated 
concentrations of 7-OHC, 20-OHC and 20-OHC-Pent. Only the active sterols 20-OHC and 20-
OHC- Pent compete mSmo binding to 22-NHC beads, while the inactive 7-OHC does not. 
(h) As in (g) but with the indicated concentrations of the diastereomers 20(S)-OHC-Pent and 
20(R)-OHC-Pent. Only the active S diastereomer competes mSmoCRD binding to 22-NHC 
beads. 
(i) mSmoCRD and mSmo binding to 20-OHC beads was assayed as in (h). mSmoCRD binds 20-
OHC beads and is competed by 20(S)-OHC-Pent. The binding affinities of mSmoCRD and 
mSmo to 20-OHC beads are similar. 
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2.4.5 Structural requirements for oxysterols in Hedgehog signaling 
To gain a better understanding of the effect of oxysterols on Hh signaling, we asked what 
structural aspects of 20-OHC are important for mSmo activation and ciliary recruitment. We first 
focused on the isooctyl tail, and synthesized a series of 20-OHC analogs with progressively 
shorter tails (Figure 2.5a). Shortening the iso-octyl tail of 20-OHC by 1 or 2 carbons (20-OHC-
Pent and 20-OHC-Bu) preserved Hh stimulatory activity. As for 20-OHC (Nachtergaele et al., 
2012), the diastereomers 20(S)-OHC-Pent and 20(S)-OHC-Bu were active (Figure 2.5b) while 
20(R)-OHC-Pent and 20(R)-OHC-Bu were inactive (Supplementary Figure S4a); this correlated 
with their ability to recruit mSmo to cilia (Figure 2.5c and Figure 2.5d). Analogs of 20-OHC 
with shorter side chains (20-OHC-Pr, 20-OHC-Et and 20-OHC-Me) did not stimulate Hh 
signaling (Supplementary Figure S4a), indicating that a tail of 6 carbon atoms is the minimum 
required for mSmo activation. These shorter side chain analogs also did not inhibit Hh pathway 
activation by Shh (Supplementary Figure S4b). Interestingly, 20(S)-OHC-Pr caused 
accumulation of mSmo at cilia, while 20-OHC-Me, 20-OHC-Et (R and S) and 20(R)-OHC-Pr 
had no effect (Figure 2.5c). Thus 20(S)-OHC-Pr is sufficient to localize mSmo to cilia but cannot 
activate it, suggesting that it induces a conformation of mSmo distinct from the active one 
induced by 20(S) analogs with longer side chains. 
Finally, we asked if the Δ5 double bond and the 3β-OH group are important for the 
function of 20-OHC. The saturated analog, 20-OHC-PentSat (Figure 2.5a), activated Hh 
signaling as the S diastereomer (Figure 2.5b), while the R diastereomer was inactive 
(Supplementary Figure S4a); thus the Δ5 double bond is not required for activity. A 3β methyl 
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ether analog of 20-OHC-Pent (20-OHC-Pent-3β−OMe, Figure 2.5a) did not activate or inhibit 
Hh signaling (Supplementary Figure S4c), and had no effect on mSmo binding to 22-NHC beads 
(Supplementary Figure S4d). These results indicate that a free 3β-OH group is absolutely 
required for the activity of 20-OHC.  
 
Figure 2.5 Structural requirements for oxysterol activation of Smo 
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Figure 2.5 (continued) Structural requirements for oxysterol activation of Smo 
 (a) Structures of 20-OHC analogs used in this study. All analogs except 20-OHC-Me have a 
chiral C20 center, and pure S and R diastereomers were isolated and assayed separately. 
(b) Shh Light II cells were treated with varying concentrations of the oxysterols 20(S)-OHC, 
20(S)- OHC-Pent, 20(S)-OHC-PentSat and 20(S)-OHC-Bu, followed by measuring Hh pathway 
activity by luciferase assay. The inactive oxysterol, 7-OHC, was used as negative control. All 
experiments were performed in quadruplicate, and error bars represent the standard deviation of 
the mean.  
(c) NIH-3T3 cells were incubated overnight with the indicated oxysterols (10 µM). Cells were 
then fixed and processed for immunofluorescence with rabbit anti-Smo antibodies (to detect 
endogenous Smo) and mouse anti-acetylated tubulin antibodies (to visualize primary cilia). SAG 
(1 µM) and 7-OHC (10 µM) were used as positive and negative control, respectively. The graph 
shows the percentage of Smo-positive cilia. 
(d) As in (c), but with box plots showing the fluorescence intensity of endogenous Smo at cilia. 
For each condition, the Smo signal was normalized to the intensity of the 20(S)-OHC treatment. 
The lower and upper bounds of each box represent the 25th and 75th percentile of the 
distribution of Smo intensity at cilia, while the horizontal line represents the median intensity 
across the entire population of cilia. 
 
2.4.6 The role of oxysterols in vertebrate Hedgehog signalling 
Although oxysterols are potent activators of vertebrate Smo, it is not known what role their 
interaction with Smo plays in normal Hh signaling. To generate mSmo mutants that do not bind 
oxysterols, we relied on the homology between the CRDs of Smo and Frizzled (Fz) proteins. It 
was proposed that SmoCRD binds sterols similar to how FzCRD binds the palmityl residue 
attached to Wnt proteins (Bazan and de Sauvage, 2009). Based on the crystal structure of 
mFz8CRD bound to palmitylated Xwnt8 (Janda et al., 2012), we focused on a stretch of 8 amino 
acids in mSmo, whereby the corresponding sequence in mFz8 includes 5 amino acids that form 
close contacts with the palmityl residue (a and (Janda et al., 2012)). This stretch is highly 
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conserved among vertebrate Smo orthologs but not in DrSmo, which does not bind oxysterols. 
To test if this stretch is important for oxysterol binding, we swapped amino acids 112-119 of 
mSmo for the corresponding amino acids of DrSmo. The resulting mSmo mutant 
(mSmoDrSmoCRDmut) did not bind 22-NHC beads, (Supplementary Figure S5a), while the secreted 
mSmoCRDDrSmoCRDmut
 
did not bind 20-OHC beads (Supplementary Figure S5b). Importantly, 
mSmoDrSmoCRDmut
 
bound BODIPY-Cyc (Supplementary Figure S5c), indicating the protein is 
properly folded and harbors an intact Site A.  
 
Figure 2.6 Oxysterol binding to Smo is required for high level Hh signaling 
(a) Sequence alignment of a portion of the CRDs of mouse Smo (mSmo), chicken Smo (gSmo), 
Xenopus Smo (xSmo), zebrafish Smo (zfSmo), Drosophila Smo (DrSmo) and mouse Fz8 
(mFz8). The 8-amino acid stretch indicated with red lines contains 5 residues that, in mFz8, form 
contacts with the palmityl moiety of Xwnt8 (Q71, F72, P74, L75 and I78). 
(b) Cherry-tagged mSmo, mSmoL112D, mSmoW113Y or mSmoS114Y were tested for binding 
to 22- NHC and 20-OHC beads, in the presence or absence of 20-OHC (100 µM). MSmoL112D 
and mSmoW113Y do not bind 22-NHC and 20-OHC beads, in contrast to mSmo and 
mSmoS114Y. 
(c) Smo-/- MEFs rescued with mSmo, mSmoL112D, mSmoW113Y or mSmoS114Y were 
incubated overnight with DMSO control, SAG (1 µM), 20-OHC (10 µM) or Shh. The cells were 
processed for immunofluorescence, to measure ciliary localization of Smo. The graph shows the 
percentage of Smo- positive cilia. MSmoL112D and mSmoW113Y have a defective response to 
20-OHC and Shh. 
(d) As in (c), but with box plots showing Smo fluorescence intensity at cilia. For each condition, 
the Smo signal was normalized to the intensity of the SAG treatment for the respective cell line. 
(e) As in (c), but cells were processed for Q-PCR, to measure mRNA levels of the Hh target 
gene, Gli1. For each treatment, Gli1 levels were normalized to the level induced by SAG in the 
respective cell line. Each experiment was performed in triplicate, and the error bars show the 
standard deviation of the mean. MSmoL112D and mSmoW113Y do not respond to 20-OHC and 
have a reduced responsiveness to Shh. 
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Figure 2.6 (continued) Oxysterol binding to Smo is required for high level Hh signaling 
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To determine if mSmoDrSmoCRDmut
 
and mSmoΔCRD respond to oxysterols, we generated 
Smo-/- MEFs that stably express the proteins at low levels, and assayed their activation by SAG 
and 20-OHC, both by immunofluorescence (to measure ciliary recruitment of mSmo, 
Supplementary Figure S5d and S5e) and by Q-PCR (to measure the transcriptional output of the 
Hh pathway, Supplementary Figure S5f). Both mSmoDrSmoCRDmut
 
and mSmoΔCRD rescued the 
response of Smo-/- MEFs to SAG, indicating that they are fully functional in activating the 
downstream steps of the Hh pathway; however, mSmoDrSmoCRDmut
 
and mSmoΔCRD did not 
respond to 20-OHC, in contrast to wild-type mSmo. These results validate functionally our 
mapping of the oxysterol-binding site within mSmoCRD. 
We identified two mSmo point mutants defective in oxysterol binding by individually 
mutating residues in the LWS sequence (amino acids 112-114) to the corresponding DYY 
sequence of DrSmo. As shown in b, mSmoL112D and mSmoW113Y no longer bound 22-NHC 
and 20-OHC beads, in contrast to mSmoS114Y and wild-type mSmo. Importantly, mSmoL112D 
and mSmoW113Y showed a prominent post-Golgi band on SDS-PAGE (b) and bound BODIPY-
Cyc (Supplementary Figure S5g), indicating proper folding. 
To test the function of oxysterol binding to mSmo, we compared Hh signaling in Smo-/- 
MEFs stably expressing mSmo, mSmoL112D, mSmoW113Y or mSmoS114Y (see c and d for 
ciliary recruitment, and e for transcriptional activation). As expected, all 4 proteins rescued the 
response to SAG. Consistent with loss of oxysterol binding, mSmoL112D and mSmoW113Y did 
not respond to 20-OHC, in contrast to wild-type mSmo and mSmoS114Y. Interestingly, 
mSmoL112D and mSmoW113Y still responded to Shh, but the response was much reduced 
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compared to wild-type mSmo and mSmoS114Y. Similarly, a significantly lower response to Shh 
was observed in the case of mSmoΔCRD (Supplementary Figure S5h) or the double mutant 
mSmoL112D/W113Y (Supplementary Figure S5i). In conclusion, binding of oxysterols to the 
CRD is required for high-level mSmo activation by Shh; in contrast, low-level mSmo activation 
by Shh still occurs in the absence of oxysterol binding. This suggests that Hh signaling controls 
mSmo activity via Site A, or possibly via both Site A and Site B (see Discussion). 
2.5 Discussion 
Our findings suggest a mechanism for how the vertebrate Hh pathway is modulated by 
oxysterols. During Hh signaling, Shh relieves the inhibition exerted by Ptc on Smo, and a major 
open question is how Smo activity is regulated. Smo adopts active and inactive conformations, 
and it has long been hypothesized that endogenous small molecules control the equilibrium 
between the two conformations (Taipale et al., 2002), in turn determining the output of the Hh 
pathway at the membrane. Oxysterols (Corcoran and Scott, 2006; Dwyer et al., 2007), 
particularly 20-OHC (Nachtergaele et al., 2012), are so far the only metabolites that activate the 
vertebrate Hh pathway. We describe the azasterol 22-NHC, an inhibitor of Hh signaling that acts 
by a novel mechanism, namely by competing with 20-OHC binding to Smo. 22-NHC inhibits 
Shh noncompetitively, consistent with 22-NHC binding the allosteric Smo Site B. To our 
surprise, Site B maps to the extracellular CRD of Smo, and we show that it is completely 
separable from Site A (Figure 2.7a). We demonstrate that 20-OHC binding to SmoCRD is 
required for high Smo activation. Notably, Shh can still activate Smo mutants lacking a 
functional Site B, although it does so to a greatly reduced extent; thus, Site A is sufficient for 
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Smo to respond to Shh. These results suggest that during Hh signaling, Smo is activated by two 
synergistic inputs: Shh-Ptc–dependent activation of Site A and allosteric activation by oxysterol 
binding to Site B (Figure 2.7b). Many aspects of this mechanism remain to be deciphered, such 
as measuring endogenous 20-OHC, elucidating its biosynthesis and determining whether 20-
OHC binding to Site B is controlled by Shh-Ptc or whether it represents an independent input. 
Mapping the 20-OHC binding site to the SmoCRD confirms the prediction that the CRD 
of Frizzled family members is related to sterol binding proteins such as the soluble lysosomal 
cholesterol carrier, NPC2 (Bazan and de Sauvage, 2009). We used the crystal structure of the 
 
 
Figure 2.7 Mechanism for modulation of the vertebrate Hh pathway by oxysterols 
(a) Schematic of the mSmo protein and of the location of Sites A and B. For each site, activators 
are in blue, while inhibitors are in red. 
(b) Model for regulation of vertebrate Smo. Inhibition of Ptc by Shh results in activation of Site 
A of Smo. This is potentiated by the allosteric activator, 20-OHC, which binds to Site B in the 
extracellular domain of Smo. Active Smo then signals to the cytoplasm. 
b a 
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mFz8-Xwnt8 complex (Janda et al., 2012) to mutate mSmoCRD residues that align with 
mFz8CRD residues involved in binding the palmityl moiety of Xwnt8. These Smo mutants were 
defective in 20-OHC binding, suggesting that oxysterol binding to SmoCRD likely resembles 
binding of palmitate to mFz8CRD; structural studies will be needed to determine the exact mode 
of 20-OHC binding to SmoCRD. Interestingly, in the case of two other sterol-binding membrane 
proteins, the sterol binding sites also map to soluble portions of the protein: the Niemann-Pick 
protein 1 (NPC1) binds oxysterols via its N-terminal domain located in the lumen of the 
lysosome (Infante et al., 2008), and the SREBP cleavage-activating protein (SCAP) binds 
cholesterol via a large ER luminal loop (Motamed et al., 2011). It will be important to determine 
if this is a general feature among sterol-binding membrane proteins. 
An important question is how Sites A and B of Smo are regulated during Hh signaling. 
No endogenous small molecule that binds Site A has been identified so far, and it is unclear 
whether such a molecule would be an agonist (which Ptc would prevent from reaching Smo) or 
antagonist (which Ptc would deliver to Smo). Our results indicate that Ptc controls Smo at least 
in part through regulation of Site A, but they cannot distinguish between these two alternative 
mechanisms. The situation is clearer for Site B, which, during Hh signaling, needs to be 
occupied by an endogenous activator, perhaps 20-OHC. This conclusion is based on the 
inhibitory effect of sterol depletion and of blocking 20-OHC binding to Smo. The endogenous 
concentration of oxysterols like 20-OHC is currently unknown, but is likely much lower than the 
micromolar EC50 for Hh pathway activation by oxysterols. Although higher local concentrations 
might exist in cells, endogenous oxysterol levels are perhaps too low to activate Smo just by 
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themselves, but high enough to synergize with Site A activation. One advantage of such a 
mechanism is that it allows a Shh-independent way to modulate Hh signaling, while ensuring 
that pathway activation remains strictly dependent on Shh and Ptc. Oxysterol levels might vary 
in different tissues, thus allowing for different levels of Hh signaling. Whole animal studies will 
be important in determining if the Hh pathway is differentially modulated by oxysterols in 
various tissues undergoing Hh signaling. 
Another important question is how the allosteric interaction between Sites B and A result 
in Smo activation during Hh signaling triggered by Shh? It seems likely that SmoCRD binds 20-
OHC and the resulting complex interacts with the heptahelical bundle of Smo, contributing to 
stabilizing the active conformation of Site A. An active Site A is required for oxysterols to 
stimulate Hh signaling, as Site A inhibitors such as Cyc and SANT1 inhibit oxysterols (Corcoran 
and Scott, 2006; Dwyer et al., 2007; Nachtergaele et al., 2012). SmoCRD, however, is not 
required for Smo activation by synthetic agonists such as SAG that bind Site A, suggesting that 
Site B has only a modulating role during Shh stimulation. Perhaps endogenous activation of Site 
A is weaker than that elicited by SAG, and as a result oxysterols are required for high-level Smo 
activation. Detailed biochemical and structural studies will be needed to determine how the 
interaction between Sites A and B controls vertebrate Smo activity. 
The azasterol 22-NHC represents the first Site B-specific inhibitor of Smo. 22-NHC 
inhibits Hh pathway activation by Shh and by oxysterols, but cannot inhibit Smo activated by 
SAG, or the constitutively active SmoM2 mutant. Thus 22-NHC recapitulates the inhibitory 
effect of sterol depletion or of cholesterol biosynthesis defects on vertebrate Hh signalling 
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(Cooper et al., 2003). The simplest interpretation is that sterol depletion removes the endogenous 
activator of Site B, which is perhaps 20-OHC. It should be pointed out that blocking HMG-CoA 
reductase with statins without also depleting sterols does not block Hh signaling (Cooper et al., 
2003), and thus the effect of 22-NHC is not explained by general inhibition of cholesterol 
biosynthesis. We cannot exclude the possibility that, in addition to binding Smo, 22-NHC might 
also block conversion of cholesterol into an unknown metabolite, such as an oxysterol. 
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2.7 Methods 
2.7.1 Antibodies 
Polyclonal antibodies against Cherry were generated in rabbits (Cocalico Biologicals) 
and were affinity purified against recombinant Cherry immobilized on Affigel-10 beads 
(BioRad). Rabbit anti-Smo polyclonal antibodies were described before (Tukachinsky et al., 
2010). The monoclonal anti-acetylated tubulin antibody was obtained from Sigma. 
2.7.2 DNA constructs 
Expression constructs were assembled by PCR in the mammalian expression vector 
pCS2+, from which they were subcloned into a vector for lentiviral production. Constructs 
encoding membrane proteins were tagged with Cherry at their C-terminus. These constructs 
were: full-length mouse Smo (mSmo), full-length Drosophila Smo (DrSmo), full-length mouse 
Frizzled (mFz7), mSmoΔICD (aminoacids 1-554 of mSmo), mSmoM2 (constitutively active point 
mutant W539L), mSmoΔCRD (amino acids 183-793 of mSmo, preceded by the signal sequence of 
human calreticulin), mSmoDrSmoCRDmut (amino acids 112-119 of mSmo, LWSGLRNA, replaced 
by amino acids 129-136 of DrSmo, DYYALKHV), mSmoL112D, mSmoW113Y, mSmoS114Y, 
mSmoL112D/W113Y. Full-length Xenopus Smo (xSmo) was tagged with eGFP at the C-
terminus and was expressed in Sf9 cells by baculoviral infection. The baculovirus was generated 
using the Bac-to-bac system (Life Sciences), according to the manufacturer’s instructions. 
Constructs for expressing secreted extracellular cysteine-rich domains (CRDs) of Smo proteins 
contained the signal sequence of human calreticulin, followed by the CRD sequence lacking the 
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Smo signal sequence, followed by a hemagglutinin (HA) tag and 8 histidine residues. The CRD 
sequences were: mSmoCRD (amino acids 32-236 of mSmo), DrSmoCRD (amino acids 32-257 
of DrSmo) and mSmoCRDDrSmoCRDmut (amino acids 32-236 of mSmoDrSmoCRDmut). 
2.7.3 Cell culture and generation of stable cell lines 
NIH-3T3 and Shh Light II cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% bovine calf serum, penicillin and streptomycin. Mouse 
embryonic fibroblasts (MEFs) and 293T cells were grown in DMEM with 10% fetal bovine 
serum, penicillin and streptomycin. Stable cell lines were generated by lentiviral transduction, 
followed by selection with blasticidin 50µg/mL for 3 days. Smo-/- MEFs expressing low amounts 
of various Cherry-tagged Smo proteins were isolated by fluorescence-activated cell sorting. 
Expression of the tagged construct was confirmed by immunofluorescence and by QPCR assays 
of Hh pathway stimulation. The following compounds were obtained from commercial sources: 
cyclopamine (LC Laboratories), BODIPY-cyclopamine (TRC), SAG (Axxora), forskolin 
(Sigma), itraconazole (Sigma), SANT1 (Calbiochem), GDC0449 (LC Laboratories), 20-
hydroxycholesterol (Steraloids), 7-hydroxycholesterol (Steraloids).  
2.7.4 Hh ligand production 
Hh ligand was produced by transiently transfecting 293T cells with an expression 
plasmid encoding amino acids 1-198 of human Shh. Shh was collected for 48 hours into 
starvation medium (DMEM supplemented with penicillin and streptomycin). For maximal 
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stimulation of the Hh pathway, Shh- conditioned medium was used diluted 1:3 -1:4 into fresh 
starvation medium. 
2.7.5 Reporter assays 
Hh activity assays were performed in Shh Light II cells (obtained from ATCC), a line of 
NIH-3T3 cells expressing firefly luciferase from a Gli-responsive promoter and Renilla 
luciferase from a constitutive promoter (Taipale et al., 2000). Confluent Shh Light II cultures 
were starved overnight in DMEM. The medium was then replaced with DMEM supplemented 
with the appropriate Hh pathway agonist, antagonist, and/or test compound. All small molecules 
were added to cellular media from concentrated stocks in DMSO, except 20-OHC-Pent-3β-MeO, 
which was added as a soluble complex with methyl-β-cyclodextrin (MCD), prepared as 
described (Klein et al., 1995). After 30 hours, Renilla and firefly luciferase levels were measured 
using the Dual-Glo kit (Promega). Hh pathway activity was expressed as the ratio of firefly to 
Renilla luciferase, normalized to 100% for maximally stimulated cells (cells treated with 1µM 
SAG, 10 µM oxysterol, or 1:3 Shh ligand, depending on the experiment). Each experiment was 
performed in quadruplicate, and error bars represent the standard deviation of the mean. For 
plotting dose-response curves, non-linear regression to a four-parameter curve was performed 
using Prism (GraphPad). 
2.7.6 Real-time PCR assays of the Hh pathway 
Confluent NIH-3T3 cells or MEFs were starved overnight in starvation medium, after 
which they were incubated for 24 hours in starvation medium supplemented with the desired 
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compounds. Total RNA was isolated from cells with RNA-Bee (TelTest), treated with RNase-
free DNase (Promega), and purified using the GenCatch total RNA Extraction System (Epoch 
Biolabs). Reverse transcription was performed using random hexamers and Transcriptor reverse 
transcriptase (Roche). Transcription of the Hh target gene Gli1 was measured by real-time PCR 
using FastStart SYBR Green Master reagent (Roche) on a Rotor-Gene 6000 (Corbett Robotics). 
Relative gene expression was calculated using a Two Standard Curve method in which the gene-
of-interest was normalized to the Ribosomal Protein L27 gene. The sequences for gene-specific 
primers are: L27: 5’-GTCGAGATGGGCAAGTTCAT-3’ and 5’- 
GCTTGGCGATCTTCTTCTTG-3’, Gli1: 5’-GGCCAATCACAAGTCAAGGT-3’ and 5’-
TTCAGGAGGAGGGTACAACG -3’. Each experiment was performed in triplicate, and error 
bars represent standard error of the mean. 
2.7.7 Immunofluorescence 
Cells were grown on glass coverslips and were fixed in PBS with 4% formaldehyde, 
followed by permeabilization with TBST. Non-specific binding sites were blocked by incubation 
in TBST with 50 mg/mL bovine serum albumin (TBST-BSA). Endogenous mSmo was detected 
with anti-Smo antibodies (Tukachinsky et al., 2010) and Cherry-tagged proteins were detected 
with anti-Cherry antibodies. Primary cilia were stained with anti-acetylated tubulin antibodies. 
Primary and secondary antibodies were used diluted in TBST-BSA. The primary antibodies 
were: rabbit polyclonal against Cherry (final concentration 1 µg/mL), rabbit polyclonal against 
mSmo (final concentration 2 µg/mL), mouse anti-acetylated tubulin monoclonal antibody 
(Sigma, final dilution dilution of 1:5,000). Alexa-594- and Alexa-488-conjugated secondary 
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antibodies (Life Sciences) were used at a final concentration of 1 µg/mL. The coverslips were 
mounted on glass slides in mounting media (0.5% p-phenylenediamine, 20 mM Tris pH 8.8, 90% 
glycerol). The cells were imaged by epifluorescence on a Nikon TE2000E microscope equipped 
with an OrcaER camera (Hammamatsu) and 40x PlanApo 0.95NA or 100x PlanApo 1.4NA oil 
objective (Nikon). Images were acquired using the Metamorph software (Applied Precision). 
Ciliary localization of Smo was measured either manually or using custom image analysis 
software implemented in MATLAB. Briefly, the software first identifies cilia by local adaptive 
thresholding of images of cells stained for acetylated tubulin. The segmented images are cleaned 
by automatic removal of objects whose size and shape fall outside the normal range for a typical 
cilium. Next, the pixel intensity of the protein of interest (Smo) in each cilium is corrected by 
subtracting the local background, defined as the median intensity of the pixels surrounding the 
cilium. Ciliary Smo is then quantified as the total corrected intensity in each cilium, normalized 
to the area of the cilium. To count Smo-positive cilia, fluorescence in the Smo channel is first 
calculated for the cilia in the negative control sample (untreated cells in case of scoring 
endogenous Smo, or Smo-/- cells in case of scoring Cherry-tagged fusions proteins stably 
expressed in Smo-/- MEFs). This data is used to calculate a threshold value that is above the 
fluorescence intensity for >95% of cilia in the negative control sample; note that this method 
overestimates the number of Smo-positive cilia in the negative control, by allowing a false 
positive rate of up to 5% in this sample. Using the calculated threshold value, cilia are then 
scored in all remaining samples, and the fraction of Smo-positive cilia is graphed. Ciliary 
intensity of Smo is also graphed using box plots; for each condition, the lower and upper bounds 
 84 
of the box represent the 25th and 75th percentile of the Smo intensity distribution, while the 
horizontal line represents the median intensity across the entire cilia population. A more detailed 
description of the algorithm is provided in the Appendix. For the experiments presented in this 
study, between 150-550 cilia per condition were analyzed in this manner. For some experiments, 
ciliary localization of Smo was measured manually, by scoring the presence or absence of Smo 
in 150 cilia for each condition. 
2.7.8 BODIPY-cyclopamine and BODIPY-SANT1 binding assays 
Various Smo proteins, tagged at their C-termini with Cherry, were expressed in 293T 
cells either stably or by transient transfection. The cells were incubated for 1 hour in DMEM 
with 10 nM BODIPY- cyclopamine or 10 nM BODIPY-SANT1, in the presence or absence of 
the indicated concentration of competitor drug. The cells were washed with DMEM, fixed in 
PBS with 4% formaldehyde for 20 minutes, followed by 5 washes with TBST (10 mM Tris pH 
7.5, 150 mM NaCl, 0.2% Triton X-100). The cells were then imaged by epifluorescence 
microscopy, capturing for each field of view an image of the Smo-Cherry fusion and one of the 
BODIPY compound. 
2.7.9 Preparation of ligand affinity matrices 
Free amine derivatives of 22-NHC or 20-OHC were dissolved in dry isopropanol (20 mM 
final concentration), and were added to amine-reactive Affigel-10 beads (BioRad). After addition 
of dry triethylamine (100 mM final), the beads were incubated at room temperature overnight, 
with end-over- end rotation. Unreacted sites on the beads were consumed by incubation with 
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ethanolamine (1M final in isopropanol), after which the beads were washed extensively with 
isopropanol. The beads were then washed extensively with water, followed by 3 washes with the 
wash buffer used in ligand affinity experiments (20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% 
dodecyl-β-maltoside). Control beads were generated in parallel, by reacting Affigel-10 beads 
with the ethylene glycol diamine linker (4,7,10-trioxa- 1,13-tridecanediamine, 200 mM final) 
used in the synthesis of 22-NHC or 20-OHC amine derivatives. 
2.7.10 Ligand affinity assays 
Recombinant protein for ligand affinity assays was produced by stable or transient 
expression in 293T cells, except for xSmo-eGFP, which was produced in Sf9 cells by 
baculovirus infection. Cell expressing various transmembrane Smo constructs, C-terminally 
tagged with Cherry or eGFP, were harvested and lysed on ice for 30 minutes in lysis buffer (20 
mM HEPES, pH 7.5, 150 mM NaCl, 0.5% dodecyl-β- maltoside), supplemented with protease 
inhibitors (leupeptin, pepstatin and chymostatin at 10 µg/mL final concentration). The detergent 
extract was clarified by centrifugation at 20,000g, for 30 min at 4C. The supernatant was first 
incubated with the desired competitor compound or DMSO control for 5 minutes on ice. All 
compounds were added to binding reactions from DMSO stock solutions. After this incubation, 
22-NHC beads, 20-OHC beads or control beads were added, followed by end-over-end rotation 
for 1 hour at 4C. The beads were washed three times with wash buffer (20 mM HEPES pH 7.5, 
150 mM NaCl, 0.1% dodecyl-β-maltoside), after which bound proteins were eluted in SDS-
PAGE sample buffer with DTT (50 mM final) at 37C. The proteins were separated by SDS-
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PAGE, followed by immunoblotting with anti- Cherry or anti-GFP antibodies. A portion of the 
clarified detergent extract was used as input. 
Cells expressing HA-tagged secreted SmoCRD contructs were incubated for 48 hours in 
DMEM supplemented with 0.5% fetal bovine serum, penicillin and streptomycin. The 
conditioned media containing soluble SmoCRD protein was harvested, subjected to 
centrifugation to remove cellular debris, and concentrated 10-fold by ultrafiltration through a 10 
kDa cutoff concentration device (Amicon). The media was then supplemented with dodecyl-β-
maltoside (0.5% final concentration) and protease inhibitors, and was used in ligand affinity 
assays as described above for detergent extracts of cells expressing full-length Smo proteins. 
2.8 Chemicals 
A complete description of the syntheses of sterol derivatives and of BODIPY-SANT1 is 
provided in the Appendix. 
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3.1 Author contributions 
I performed cellular and biochemical experiments. Y.X. and I developed the automated 
image analysis software, and I analyzed all the imaging data.  
3.2 Abstract 
Signal transduction in the vertebrate Hedgehog (Hh) pathway is sequestered at the 
primary cilium, which serves as an anchor point for the Hh pathway components such as Patched 
(Ptc) and Smoothened (Smo). However, it is unclear how these proteins reach the primary 
cilium, and what happens subsequent to activation. In this work, we identify two degenerate 
ciliary localization sequences in Smo. We further map a cytosolic domain of Smo strictly 
required for activation of downstream components, and show that while the ciliary localization 
aspect is unique to vertebrates, signaling to downstream components is conserved across phyla. 
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3.3 Introduction 
The primary cilium is a highly conserved structure, which exists in most animal cells and 
serves as an anchoring point to a variety of receptors including some G-Protein Coupled 
Receptors to increase their local concentration; the cilium thus serves as a cellular antenna for 
sensing the presence of nutrients or growth factors. Structurally, the cilium is comprised of a 
hair-like membrane projection with a unique lipid composition which surrounds a bundle of 
microtubules – the axoneme.  
Cell-cell signaling via the Hedgehog (Hh) pathway is critical for numerous aspects of 
metazoan embryonic development and regeneration, while excessive Hh signaling is involved in 
many cancers (Ingham and McMahon, 2001; Lum and Beachy, 2004). Signaling in the pathway 
is triggered when the secreted protein Hedgehog (Hh, or one of three vertebrate orthologs, 
primarily Sonic hedgehog, Shh) binds to its membrane receptor, Patched (Ptc) (Stone et al., 
1996). Ptc normally inhibits the 7-pass transmembrane protein Smoothened (Smo). Binding of 
Hh inhibits Patched resulting in Smo activation; active Smo then triggers the activators of the 
cytoplasmic steps of the signaling pathway, which ultimately induce transcription of the Hh 
target genes(Rohatgi and Scott, 2007). The spatial localization of the Hedgehog pathway 
components in vertebrates provides an additional layer of regulation, as primary cilia are 
essential for transduction of the Hedgehog signal across the membrane (Huangfu and Anderson, 
2005). In the absence of signal, Smo appears primarily in intracellular vesicles, while Ptc 
localizes to the base of the primary cilium. Upon activation by Shh, Ptc is internalized which 
allows Smo to accumulate at the primary cilium where the intracellular components of the Hh 
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signaling pathway reside, to physically associate with the ciliary protein Evc2, and to activate 
downstream signaling; Smo also localizes to the cilium when overexpressed (Corbit et al., 2005; 
Dorn et al., 2012; Rohatgi et al., 2007; Rohatgi and Scott, 2007). However, the mechanism of 
Smo translocation to the cilium remains unclear.  
No protein synthesis takes place at the primary cilium, thus all the proteins in the cilium 
are synthesized in the cell body and then delivered to the cilium via specific targeting 
mechanisms; cargo is then moved along the cilium to and from the distal tip by intraflagellar 
transport (IFT) proteins; interestingly, this includes the tubulin building blocks required for 
elongation of the cilium. Genetic screens have identified two protein complexes involved in 
ciliary transport - IFT-A and IFT-B (Ou et al., 2005). The cilium is a unique structure in that, 
while contiguous with the plasma membrane, it is essentially isolated from the plasma membrane 
as a separate compartment. The IFT-A and IFT-B complexes function together in both 
anterograde and retrograde transport, as they associate with each other prior to movement along 
the cilium. The BBSome is a coat protein complex essential for ciliary formation which catalyzes 
the assembly of cargo-loaded IFT complexes at the base of the cilium. The IFT-A/IFT-B 
complexes transport both cargo and substoichiometric amounts of BBSome to the distal end of 
the cilium where the complex dissociates and the cargo is unloaded. The BBSome at the ciliary 
tip then facilitates the reassociation of the IFT-A and IFT-B, which in turn recycles both 
components as well as cargo (which includes the BBSome) back to the base of the cilium. The 
BBSome thus functions to associate IFT-A to IFT-B in both the basal body and at the ciliary tip 
(Wei et al., 2012). 
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Ciliary access is tightly regulated, as ciliary proteins must contain a cis-acting ciliary 
localization sequence (CLS) to access the primary cilium; several different CLS have been 
identified to date, but there is no conservation of sequence among them (Pazour and Bloodgood, 
2008). Interestingly, certain functional CLS resemble nuclear localization sequences and consist 
of stretches of basic residues on soluble proteins (Dishinger et al., 2010) or a motif of adjacent 
hydrophobic and basic residues immediately C-terminal to the seventh transmembrane domain of 
certain seven spanners, in particular olfactory GPCRs (Dwyer et al., 2001). Opsin trafficking to 
the outer segments of vertebrate photoreceptors requires the presence of a conserved C-terminal 
VxP motif. However, it must be noted that other CLS exist, such as the N-terminal RVxP motif 
of Polycystin-2 (Geng et al., 2006), or the conserved AX[S/A]XQ motif found in the third 
intracellular loop of many ciliary-targeted GPCRs such as the serotonin receptor 6 (5HT6), the 
somatostatin receptor 3 (SSTR3) and the melanocortin concentrating hormone receptor 1 
(MCHR1); this latter sequence is bound directly by the BBSome rather than by importins, and 
facilitates ciliary entry through a parallel mechanism (Berbari et al., 2008; Jin et al., 2010). 
Without exception, the CLS identified to date are all cytosolic domains, indicating that sorting 
into the ciliary membrane involves soluble regions. Smo ciliary localization, however, has been 
shown previously to be regulated by the extracellular cysteine-rich domain (CRD) (Aanstad et 
al., 2009); in Chapter 2, we demonstrate that the CRD functions as a sterol binding domain, and 
that it does not contain the ciliary localization sequence of Smo, as the mSmoΔCRD mutant 
localizes robustly to the cilium in response to SAG (Figure 2.S5). Thus, the identity of the cis-
acting CLS of Smo remains unknown. Here we demonstrate that the CLS of Smo is found within 
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its cytosolic tail, the intracellular domain (ICD), and that it is degenerate as two separate 
sequences can mediate Smo ciliary localization; we further show that the CLS is essential but not 
sufficient for relaying the signal to downstream components. 
 
 
3.4 Results 
3.4.1 Only vertebrate but not arthropod Smo localizes to the cilia 
Although Smo is conserved between vertebrates and Drosophila, we have previously 
shown (Chapter 2) that only vertebrate Smo binds oxysterols, raising the question of whether 
regulation of Smo is conserved across phyla. To begin addressing this issue, we asked if 
Drosophila Smo (DrSmo) retains any signaling activity in vertebrate cells. When stably 
expressed in Smo-/- MEFs, DrSmo did not localize to cilia (Figure 3.1a) and was thus inactive 
(Figure 3.1b); this result was not surprising, as cilia are not involved in Hh signaling in 
Drosophila but are essential for Hh signaling in vertebrates; it is conceivable that DrSmo cannot 
interact with the downstream vertebrate pathway components as they are sequestered in the 
ciliary compartment. Alternatively, it is also possible that DrSmo does not interact with any of 
the vertebrate Hh pathway components, as would be suggested by the divergent regulation of 
signaling downstream of Smo in arthropods and vertebrates. To distinguish these possibilities, 
we needed to direct DrSmo to cilia, and for this we characterized the ciliary localization 
determinants of murine Smo (mSmo). 
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Figure 3.1 Vertebrate but not arthropod Smo localizes to the cilia 
(a) DrSmo tagged with mCherry at the C-terminus, was stably expressed in Smo-/- MEFs. Smo-/- 
MEFs rescued with mCherry-tagged mSmo were used as positive control. Confluent cultures 
were starved overnight in DMEM (to promote ciliogenesis), after which the cells were fixed and 
processed for immunofluorescence with anti-mCherry antibodies (to visualize the fusion protein) 
and anti-acetylated tubulin antibodies (to visualize cilia). The micrographs show representative 
images of cilia. DrSmo does not localize to cilia, in contrast to mSmo. 
(b) As in (a) but with overnight incubation in the presence of DMSO control, SAG (1 µM), 
SANT1 (1 µM), or 20-OHC (10 µM). Cells were harvested and the transcription of the target 
gene Gli1 was measured by Q-PCR. DrSmo does not rescue Hh signaling in Smo-/- MEFs, in 
contrast to mSmo. 
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3.4.2 The previously reported ciliary localization defective mutant does in fact localize to 
the primary cilium. The SAG binding site in the transmembrane region does not mediate 
ciliary localization. 
Since Smo translocates to the cilium primarily through lateral diffusion from the plasma 
membrane in response to Shh (Milenkovic et al., 2009), and since the SAG binding site is 
embedded within the heptahelical transmembrane domain core of the protein, we hypothesized 
that Smo ciliary localization is mediated by interactions between a Smo transmembrane region 
and some other transmembrane protein.  
We generated chimeras in which individual transmembrane domains of mSmo are 
replaced with the corresponding TM domains of DrSmo. The transmembrane domains show 
higher conservation of residues between Drosophila and vertebrates than the rest of the protein, 
and swapping individual domains between the two species to generate chimeras is more likely to 
result in a protein that folds properly (Figure 3.2a). 
We have identified several mutants that are inactive when overexpressed, in stark 
contrast with wildtype Smo which has a high basal activity; however, all chimeras with the 
exception of mSmoDrSmoTM7 respond well to stimulation by SAG. This raised the possibility that 
the vertebrate Smo TM7 mediates its ciliary localization; this was particularly interesting as the 
constitutively active mutant mSmoM2 has a point mutation which maps to a residue within TM7. 
However, all mutants including mSmoDrSmoTM7 respond to stimulation with Shh or oxysterols by 
localizing to the cilium (data not shown) and triggering downstream activation (Figure 3.2b). 
Furthermore, when localized to the cilium by treatment with 20-OHC, mSmoDrSmoTM7 binds the  
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Figure 3.2 mSmo mutants show variable responses to ligands, but localize to the cilium 
(a) Sequence alignment of the transmembrane region of mouse and Drosophila Smo. Shaded 
residues are conserved across species. Individual transmembrane (TM) domains are highlighted 
in the alignment and were individually swapped from Drosophila Smo into mouse Smo to create 
the mSmoDrSmoTMx chimeras  
(b) mouse Smo domain swap mutants, in which individual transmembrane domains were 
replaced with the corresponding Drosophila Smo transmembrane domain, localize to the cilium 
by immunofluorescence. Smo-/- MEFs, stably expressing wildtype mSmo, mSmoDrSmoTM1, 
mSmoDrSmoTM2, mSmoDrSmoTM3, mSmoDrSmoTM4, mSmoDrSmoTM5, mSmoDrSmoTM6, mSmoDrSmoTM7, 
mSmoCLD, mSmoTM1LL or DrSmo constructs fused at the C-terminus to mCherry, were incubated 
with DMEM overnight, then washed and incubated with control medium, 200nM SAG, 1µM 
SANT-1 or 10µM 20-OHC in DMEM for another 24hrs. The cells were fixed and processed for 
immunofluorescence with anti-mCherry antibodies (to visualize the fusion protein) and anti-
acetylated tubulin antibodies (to visualize cilia); the positive cilia were scored visually. All 
mutants localize to the cilium in response to 20-OHC, even mSmoCLD which was previously 
reported as a ciliary localization defective mutant. All mutants except mSmoDrSmoTM5 and 
mSmoDrSmoTM7 also localize to the cilium when overexpressed.  
(c) as in (b) but the cells were processed for Q-PCR, to measure Gli1 transcription. Each 
experiment was performed in triplicate, and the error bars show the standard deviation of the 
mean.
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Figure 3.2 (continued) mSmo mutants show variable responses to ligands, but localize to 
the cilium 
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fluorescent cyclopamine derivative BODIPY-cyclopamine in a competitive manner. This 
suggests that rather than playing a role in ciliary recruitment, TM7 is intimately linked to the 
cyclopamine and SAG binding site, and while allowing the ligand to bind, the mSmoDrSmoTM7 
mutant fails to relay the signal to the intracellular effector part of Smo. Taken together, the 
mSmoDrSmoTM7 mutant has an intact ciliary localization sequence but a defective response to 
binding at the SAG binding site.  
Previous work has identified a putative ciliary localization motif consisting of an 
aromatic residue followed by a basic residue in the cytosolic tail of Smo, in close proximity to 
TM7 (Corbit et al., 2005). The ciliary localization defective mutant mSmoCLD mutant replaces 
this conserved motif, residues W549 and R550, with alanines and fails to localize at the primary 
cilium. The motif is also present in DrSmo which however does not localize to the cilium, 
casting doubt that it functions as a CLS in the first place. Thus, we asked whether the mutant was 
indeed unable to localize to the primary cilium, or perhaps the mutation merely stabilized the 
inactive conformation of Smo similarly to the effect of binding of antagonists. When stably 
expressed in Smo-/- MEFs, mSmoCLD fails to localize to the cilium and does not activate the 
downstream pathway components; however, in these cells mSmoCLD translocates robustly to 
the primary cilium in response to agonists such as SAG or 20-OHC, and is capable of rescuing 
the pathway defect in Smo-/- MEFs (Figure 3.2b, Figure 3.2c). Contrary to the previous report, 
we thus prove that the CLD mutation does not affect a ciliary localization sequence, but instead 
simply shifts the conformational equilibrium of Smo at rest towards the inactive state.  
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Finally, we investigated whether oligomerization of Smo is involved in ciliary 
translocation. In yeast, the oligomerization of the alpha-factor receptor (STE2, a GPCR) involves 
a GXXXG motif located in TM1 (Overton et al., 2003), while a similar motif in TM5 of the 
adiponectin receptor 1 triggers its dimerization (Kosel et al., 2010). Acylation and 
oligomerization regulate the association of proteins with lipid rafts (Shogomori et al., 2005), thus 
we hypothesized that they may also regulate lipid raft-mediated sortint into the ciliary 
compartment. A similar GXXXG motif appears in the TM1 of mouse but not Drosophila Smo 
suggesting that dimerization/oligomerization may have evolved as a regulatory mechanism for 
ciliary translocation. However, when this motif is mutated to LXXXL in mSmoTM1LL, the mutant 
localizes well to the cilium and is transcriptionally active (Figure 3.2b, Figure 3.2c). Therefore, 
dimerization of Smo via the GXXXG motif does not regulate its ciliary entry – however, whether 
Smo actually forms dimers/oligomers through this motif remains unknown. 
 
3.4.3 The intracellular domain (ICD) is necessary for targeting vertebrate Smo to the 
primary cilium 
When overexpressed, vertebrate Smo localizes to the primary cilium. To test if the 
soluble cytosolic tail of vertebrate Smo is responsible for its ciliary localization, we examined 
the ciliary localization of mSmoΔICD which lacks the complete cytosolic tail. We observed that 
the mutant mSmoΔICD is unable to reach the primary cilium even in the presence of SAG (Figure 
3.3a). This suggests that the vertebrate ICD is essential for correct sorting into the ciliary 
membrane compartment. mSmoΔICD is properly folded as it binds SAG and BODIPY-
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Cyclopamine in a competitive manner (Chen et al., 2002); however, it is not known whether it 
can localize at the cilium.  
A sequence comparison of Smo from different vertebrate species highlights significant 
sequence homology in the cytosolic tail (ICD). In contrast, the cytosolic tail of arthropod Smo is 
diverged, as would be expected in the case where the cytosolic tail mediates the differential 
regulation of Smo in the two phyla. The ICD of vertebrate Smo contains two conserved stretches 
of basic amino acid residues (indicated with red lines in Figure 3.3b). These stretches each lie in 
close proximity to a conserved cysteine residue (denoted with * in Figure 3.3b), which could 
potentially function as sites of palmitoylation. Palmitoylation is used as a membrane targeting 
moiety, and is essential for correct ciliary localization of several transmembrane proteins such as 
fibrocystin (Follit et al., 2010). 
In order to map the sequence requirements of the Smo CLS, we expressed a series of 
truncation constructs containing progressively larger C-terminal deletions and assessed their 
localization at the cilium. We observed that a construct lacking the first half of the cytosolic tail, 
(residues 543-674) is unable to localize properly to the cilium even in the presence of SAG, 
while absence of the second half of the ICD (residues 675-793) did not affect ciliary localization. 
Additional truncation constructs (Figure 3.3c) revealed that amino acid residues 614-637 are 
essential for ciliary localization of Smo, and thus likely contain the CLS. Furthermore, the 
presence or absence of the CRD did not affect the ciliary localization of the protein, as expected 
given our findings in Chapter 2 that. Interestingly, all C-terminal truncation mutants up to 
residue 637 show lower expression levels at the cilium upon overexpression and in the absence  
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Figure 3.3 The intracellular domain is necessary for Smo ciliary targeting 
(a) Immunofluorescence of Smo-/- MEFs stably expressing mSmo WT or mSmoΔICD fused at 
their respective C-terminus to mCherry. Cells were incubated with DMEM overnight, then 
washed and incubated with control medium or 200nM SAG in DMEM for another 24hrs, then 
fixed and processed for immunofluorescence with anti-mCherry antibodies (to visualize the 
fusion protein) and anti-acetylated tubulin antibodies (to visualize cilia). mSmo WT but not 
mSmoΔICD localize to the primary cilium. Micrographs show representative cilia. 
(b) Sequence alignment of the intracellular domain (ICD) of mouse Smo (mSmo), human Smo 
(hSmo), Xenopus Smo (xSmo), zebrafish Smo (Drerio Smo) and Drosophila Smo (DrSmo). 
Conserved residues are shaded. Two basic amino-acid stretches are indicated with red lines and 
contain residues conserved in vertebrate but not arthropod Smo. The basic residues in either one 
or both of these stretches are mutated to Alanines in the mSmo mutants mSmoA11, mSmoA10 and 
mSmoA21 as indicated. Asterisks (*) indicate conserved cysteine residues which lie in close 
proximity to either of the two basic stretch, and which could potentially function as a 
palmitoylation site. 
(c) Smo-/- MEFs, stably expressing constructs truncated C-terminally at the residues indicated by 
number and/or truncated at the N-terminus to eliminate the CRD domain (as described in 
Chapter 2); the constructs are fused at their respective C-terminus to mCherry. Cells were 
incubated with DMEM overnight, then washed and incubated with control medium or 200nM 
SAG another 24hrs, then fixed and processed for immunofluorescence with anti-mCherry 
antibodies (to visualize the fusion protein) and anti-acetylated tubulin antibodies (to visualize 
cilia). Micrographs show representative cilia.  
(d) as in (c) but the cells were processed for Q-PCR, to measure Gli1 transcription. Each 
experiment was performed in triplicate, and the error bars show the standard deviation of the 
mean. 
(e) Smo-/- MEFs, stably expressing wildtype mSmo, mSmoA11, mSmoA10, mSmoA21 or mSmoΔICD 
constructs fused at the C-terminus to mCherry, were incubated with DMEM overnight, then 
washed and incubated with control medium or 200nM SAG delivered as 1000X DMSO stock in 
DMEM for another 24hrs. The cells were processed for Q-PCR, to measure Gli1 transcription. 
Deletion of the ICD completely ablates the pathway response; the defect is not due to misfolding, 
as mSmoΔICD binds the fluorescent Smo antagonist BODIPY-Cyclopamine(Chen et al., 2002). 
Each experiment was performed in triplicate, and the error bars show the standard deviation of 
the mean. 
(f) as in (e), but the cells were fixed and processed for immunofluorescence with anti-mCherry 
antibodies (to visualize the fusion protein) and anti-acetylated tubulin antibodies (to visualize 
cilia). The percentage of cells that show ciliary localization of the fusion protein was determined 
by automated scoring the indicated number of cilia for each condition.   
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Figure 3.3 (continued) The intracellular domain is necessary for Smo ciliary targeting 
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Figure 3.3 (continued) The intracellular domain is necessary for Smo ciliary targeting 
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Figure 3.3 (continued) The intracellular domain is necessary for Smo ciliary targeting 
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Figure 3.3 (continued) The intracellular domain is necessary for Smo ciliary targeting 
(g) Same experiment as in (f) but with box plots showing fluorescence intensity of Smo at cilia, 
in arbitrary units. The lower and upper bounds of each box represent the 25th and 75th percentile 
of the distribution of ciliary fluorescence intensity, while the horizontal line represents the 
median intensity across the entire population of cilia. 
(h) Same experiment as in (f) but showing the number of cilia counted 
 
of stimulation; all of these mutants localize to the cilium robustly in response to SAG, indicating 
that the ciliary localization sequence is not affected by the deletions, but that the conformational 
equilibrium of the unstimulated protein is shifted towards the inactive conformation as if 
enhancer elements were lost in the deletions. mSmoΔ638-793 but not mSmoΔ615-793 localize to the 
primary cilium, indicating that the residues 615-637 of the ICD are critical for ciliary localization 
and likely contain the Smo CLS. However, an internal deletion construct lacking these residues 
(mSmoΔ615-684) is still able to localize to the cilium in response to SAG, similar to the wildtype 
protein. This suggests the presence of a second CLS within residues 685-793 which is sufficient 
to localize membrane proteins to the cilium but is not necessary in the context of Smo. As 
expected, a truncation construct lacking both putative CLS (mSmoΔ615-793) fails to localize to the 
cilium. 
We then assessed the effect of these truncations on the hedgehog pathway activity. While 
the progressively larger deletion in our truncation mutants did not affect the ability of Smo to 
localize to the cilium, they nevertheless impacted the ability of Smo to activate the downstream 
pathway components as evidenced by the levels of Gli1 mRNA induction when overexpressed in 
Smo-/- MEFs (Figure 3.3d). A progressively larger truncation correlates with a lower ability to 
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activate the downstream pathway components. However, signaling to downstream components is 
never blocked completely, as overexpression of even the mSmoΔ638-793 truncation stimulates the 
pathway above baseline. Deletion of the CRD in addition to C-terminal deletions has a 
synergistic effect, presumably due to folding issues. Taken together, the data suggest that the 
ICD contains both a CLS around the residues 615-637 as well as an additional CLS within 
residues 685-793; the ICD also likely contains elements in the region 637-793 that help stabilize 
the active conformation of the protein and enhance the response to stimulation.  
Finally, since the basic stretches observed in the ICD sequence resemble palmitoylation 
sites, we tested whether they have any significance for the ciliary localization of Smo. We 
generated constructs replacing one of the basic amino acid stretches (mSmoA11 for the first 
stretch, or mSmoA10 for the second stretch) or both (mSmoA21) with alanine residues. mSmoA11 
and the combined mutant mSmoA21 but not mSmoA10 also show a severe signaling defect (Figure 
3.3e). When stably expressed in Smo-/- MEFs, mSmoA10 rescues the pathway defect and responds 
well to SAG, while mSmoA11 or mSmoA21 fail to do so Figure 3.3e). This indicates that the 
stretch of basic residues in the region 565-581 is essential for signaling downstream. 
Interestingly, these mutants are not defective in ciliary localization. They also show an unaltered 
ciliary response to SAG, and even mSmoA21 shows a number of positive cilia similar to wildtype 
Smo (Figure 3.3f-h). Interestingly, while mSmoΔICD fails to localize to the cilium and is thus 
completely inactive (as seen in Figure 3.3a), mSmoA11 cannot activate downstream components 
even in the presence of 200nM SAG - yet mSmoA11 localizes well to the cilium, and its ciliary 
localization is further enhanced by stimulation with SAG. In conclusion, the basic residues in the 
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region 565-581 are involved in relaying the signal to downstream components through an 
interaction which is ablated in the mutants, and furthermore this region does not serve as the 
CLS of Smo. 
 
3.4.4 The ICD is sufficient for targeting transmembrane proteins to the primary cilium, but 
not for signaling 
Since mSmoΔICD does not localize to cilia, we tested if mSmoICD is sufficient for ciliary 
localization. We generated chimeras in which mSmoICD replaced the cytoplasmic tail of two 
seven-spanners that do not traffic to cilia, mouse Frizzled7 (mFz7) and the rat muscarinic 
acetylcholine receptor M2 (rMAChR). 
Stably expressed mFz7mSmoICD localized to cilia in Smo-/- MEFs constitutively, while 
rMAChRmSmoICD did not but was strongly recruited to cilia by treatment with either agonist 
(acetylcholine) or antagonist (scopolamine) (Figure 3.4 a). We interpret this behavior of 
rMAChRmSmoICD as the result of improved folding caused by agonist or antagonist binding. Both 
mFz7mSmoICD and rMAChRmSmoICD were inactive in Hh signaling, even in the presence of the 
agonists acetylcholine, respectively (Figure 3.4b) and Wnt3a (Figure 3.4c). These results show 
that mSmoICD is sufficient for ciliary localization but is not sufficient to activate Hh signaling. 
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Figure 3.4 The mSmo ICD is sufficient for targeting membrane proteins to the primary 
cilium, but not for signaling 
(a) Immunofluorescence shows that the mSmo ICD is sufficient to target a heterologous GPCR 
to the cilium. The cytoplasmic tail of the rat muscarinic acetylcholine receptor M2 (rMAcChR) 
or of the mouse Frizzled7 protein (mFz7) was replaced with the intracellular domain of mSmo 
(mSmoICD), to generate the chimeras rMAcChRmSmoICD and mFz7mSmoICD, respectively. These 
chimeras were C-terminally tagged with mCherry, and were stably expressed in Smo-/- MEFs. 
Confluent cultures were starved overnight in DMEM (to promote ciliogenesis) then treated as 
indicated for another 24hrs with ligands delivered in DMEM. In the case of rMAcChRmSmoICD,  
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Figure 3.4 (continued) The mSmo ICD is sufficient for targeting membrane proteins to the 
primary cilium, but not for signaling  
the cells were incubated overnight with DMEM, or DMEM supplemented with the known 
agonist acetylcholine (100 µM) or antagonist scopolamine (100 µM). In the case of 
mFz7mSmoICD, the cells were incubated overnight in DMEM. The cells were fixed and processed 
for immunofluorescence with anti-mCherry antibodies (to visualize the fusion protein) and anti-
acetylated tubulin antibodies (to visualize cilia). The percentage of cells that show ciliary 
localization of the fusion protein was determined by visually scoring the indicated number of 
cilia for each condition. The micrographs show representative images of cilia. While 
mFz7mSmoICD localizes to cilia constitutively, rMAcChRmSmoICD localizes to cilia only upon 
treatment with either agonist (acetylcholine) or antagonist (scopolamine). 
(b) Despite ciliary localization, the ICD cannot activate transcription of Hedgehog target genes 
when present on a heterologous protein. Smo-/- MEFs, stably expressing mSmo or the cilia-
localized chimera rMAcChRmSmoICD, were incubated with control medium, Shh, 20-OHC (10 
µM), or Acetylcholine (AcCh, 100µM). The cells were processed for Q-PCR, to measure Gli1 
transcription. rMAcChRmSmoICD does not rescue Hh signaling in Smo-/- cells, in the presence or 
absence of AcCh. Each experiment was performed in triplicate, and the error bars show the 
standard deviation of the mean. 
(c) As in (b) but here Smo-/- cells with stable expression of mSmo or the cilia-localized chimera 
mFz7mSmoICD were incubated with control medium, Shh, 20-OHC (10 µM), or the Fz7 ligand 
wnt3a. mFz7mSmoICD did not rescue Hh signaling in Smo-/- cells, irrespective of the presence of 
the Wnt3a ligand. Each experiment was performed in triplicate, and the error bars show the 
standard deviation of the mean. 
 
3.4.5 The ICD contains redundant ciliary targeting sequences 
We then tried to define the minimal ciliary targeting sequence within the ICD which is 
sufficient to bring a heterologous membrane protein to the cilium, to supplement the previous 
truncation analysis. A preferred assay for candidate sequences to function as ciliary localization 
sequences is to fuse them to the single-spanning transmembrane receptor CD8a, replacing its 
cytosolic domain with the CLS of interest. This chimeric approach has successfully proven the 
sufficiency of several CLS to date (Jin et al., 2010; Xia et al., 2001). We observed that the C-
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terminal portion of the ICD (residues 685-793) contains a CLS and was sufficient for ciliary 
targeting of the chimera (Figure 3.5a). Similarly, the same CLS functions in the CD8α-mSmo 
675-793 chimera and targets that fusion protein to the cilium. In neither case did the presence of 
oxysterols affect the ciliary localization, confirming our findings from Chapter 2 where we prove 
that the oxysterols bind directly to the Smo CRD and not to the ICD. Surprisingly, the full-length 
ICD in this context was not able to target the chimera to the cilium. The most likely cause of this 
is a folding defect, although it cannot be ruled out that the residues 543-674 may contain a 
domain that functions as a repressor of ciliary targeting, and that under certain conditions this 
domain is derepressed to allow the ciliary trafficking to proceed. 
To investigate whether the vertebrate Smo ICD is sufficient on its own to localize to the 
primary cilium when simply attached to lipid rafts rather than to a transmembrane protein, we 
fused the ICD to an N-terminal myristoylation sequence. Upon overexpression, the ICD alone is 
fully soluble and never enters the cilium. However, the presence of a myristoyl moiety tethers 
the chimera to the plasma membrane, and presumably facilitates association with lipid rafts. 
Similar to our previous observation in the case of the CD8α-mSmo 543-793, we were not able to 
observe any ciliary translocation of the myristoylated full-length ICD or of the ICD residues 543-
674. However, a myristoylated construct containing only residues 675-793 of the mSmo ICD 
successfully translocated to the cilium (Figure 3.5b). Together with our observations from the 
truncation analysis, this strongly suggests that the vertebrate Smo ICD contains multiple 
redundant ciliary localization sequences: CLS-1 between residues 615-637, and CLS-2 located in 
the C-terminal residues 685-793 (and which may itself be degenerate). Each CLS is dispensable 
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for ciliary targeting of full-length Smo (Figure 3.5c). CLS-2 on its own is sufficient to direct 
transmembrane or membrane-tethered proteins to the cilium. We also interpret the inability of 
the myristoylated full-length ICD construct to localize to the cilium as a folding defect. What the 
minimal sequence sufficient for ciliary localization within these CLS is, how the two separate 
CLS are regulated in the endogenous protein, and whether their regulation implies additional 
post-translational modifications (such as palmitoylation) remains to be determined.  
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Figure 3.5 The vertebrate Smo ICD contains a C-terminal CLS sufficient for ciliary 
targeting of membrane proteins 
(a) Immunofluorescence of indicated Smo ICD – CD8α fusion proteins reveals a C-terminal 
CLS. The intracellular portion of CD8α was replaced starting with residue 213 with the 
intracellular domain of mSmo (mSmoICD), or with portions thereof as indicated, to generate the 
chimeras CD8α-mSmo 543-793, CD8α-mSmo 675-793 and CD8α-mSmo 685-793. mSmo 
residues 675-684 represent the more c-terminal of the two basic stretches described earlier, and 
the chimeras allow us to test whether acylation in this region is involved at all in ciliary 
localization. These chimeras were C-terminally tagged with mCherry, and were stably expressed 
in Smo-/- MEFs. Confluent cultures were starved overnight in DMEM (to promote ciliogenesis) 
then treated with control medium or 10µM 20-OHC in DMEM for another 24hrs. The cells were 
fixed and processed for immunofluorescence with anti-mCherry antibodies (to visualize the 
fusion protein) and anti-acetylated tubulin antibodies (to visualize cilia). The micrographs show 
representative images of cilia. 
(b) as in (a) but with 3T3 cells transiently transfected with Cs2p constructs expressing a 
myristoyl signal fused to the full length mSmo ICD or to portions of the mSmo ICD. Chimeras 
were C-terminally tagged with mCherry, and cells were transfected at 60% confluency using 
Mirus 3T3 transfection reagent. Cells were allowed to reach confluency in DMEM containing 
10% bovine calf serum, penicillin and streptomycin. Confluent cells were starved overnight in 
DMEM, then fixed and processed for immunofluorescence with anti-mCherry antibodies (to 
visualize the fusion protein) and anti-acetylated tubulin antibodies (to visualize cilia). The 
micrographs show representative images of cilia. As negative controls, cells were transfected 
with constructs expressing mCherry or mCherry containing a myristoylation signal (Myr-
mCherry). The mSmo ICD residues 675-793 contain a CLS that is sufficient for ciliary targeting 
when membrane anchored through a myristoyl moiety. 
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3.4.6 Conservation and divergence in Smo regulation 
Vertebrate Smo but not Drosophila Smo signals at the primary cilium. Since the ciliary 
localization is mediated by two regions of the vertebrate Smo ICD, but the ICD alone is not 
sufficient for signaling downstream, we wondered if the downstream signaling function of Smo 
is conserved. To determine if DrSmo can signal at vertebrate cilia, we generated a chimera 
(DrSmomSmoICD) that consists of the CRD and heptahelical bundle of DrSmo, followed by the 
ICD of mSmo. As expected, DrSmomSmoICD localized to cilia in Smo-/- MEFs (Figure 3.6a). 
Interestingly, DrSmomSmoICD strongly activated Hh signaling (Figure 3.6b), indicating that the 
DrSmo portion of the chimera transduced vertebrate Hh signals. DrSmomSmoICD was 
constitutively active, and could not be further stimulated by treatment with 20-OHC, SAG or Shh 
(Figure 3.6b); it was, however, inhibited by Protein Kinase A activation by forskolin, which 
blocks Hh signaling at a step downstream of Smo (Figure 3.6c). The lack of a response to 20- 
OHC and SAG is consistent with DrSmomSmoICD not binding these two molecules. The inability 
of Shh to further stimulate DrSmomSmoICD indicates that mouse Ptc cannot repress DrSmomSmoICD 
even though the latter is targeted to cilia, thus suggesting that DrSmo is regulated differently 
from mSmo. Finally, in contrast to mSmo, DrSmomSmoICD was not inhibited by sterol depletion  
(Figure 3.6d-f), indicating that oxysterols are not required for activation of DrSmomSmoICD. This 
suggests that binding of oxysterols has evolved as an additional mechanism of regulation of 
vertebrate Smo. 
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Figure 3.6 Conservation and divergence in Smo regulation 
(a) The intracellular domain of DrSmo was replaced with the intracellular domain of mSmo, to 
generate the chimera DrSmomSmoICD, which was tagged with mCherry at the C-terminus. This 
fusion was stably expressed in Smo-/- MEFs, and Smo-/- MEFs expressing mCherry-tagged 
mSmo were used as positive control for ciliary localization. DrSmomSmoICD localizes to cilia 
robustly, like mSmoSmo-/- MEFs stably expressing mSmo or the chimera DrSmomSmoICD show 
robust constitutive ciliary localization. Confluent cultures were starved overnight in DMEM (to 
promote ciliogenesis) then the medium changed and starved for another 24hrs in DMEM, after 
which the cells were fixed and processed for immunofluorescence with anti-mCherry antibodies 
(to visualize the fusion protein) and anti-acetylated tubulin antibodies (to visualize cilia). The 
micrographs show representative images of cilia; cilia counts performed visually in triplicate, 
and the fraction of Smo-positive cilia along with the standard deviation of the mean is reported. 
(b) Smo-/- MEFs, stably expressing DrSmo or the cilia-localized chimera DrSmomSmoICD were 
incubated with control medium, 20-OHC (10 µM), Shh or SAG (1µM). qPCR DrSmomSmoICD is 
constitutively active, and is not further activated by 20-OHC, Shh, or SAG. In contrast, DrSmo is 
inactive in Smo-/- MEFs. The cells were processed for Q-PCR, to measure Gli1 transcription. 
Each experiment was performed in triplicate, and the error bars show the standard deviation of 
the mean. 
(c) As in (b), but with addition of 20 µM forskolin (FSK), to block Hh signaling downstream of 
Smo. Signaling by both mSmo and DrSmomSmoICD is completely blocked by FSK, indicating that 
the DrSmomSmoICD chimera signals through the endogenous Hh pathway components. 
 (d) Smo-/- MEFs stably expressing low levels of mCherry-tagged DrSmomSmoICD or mSmo were 
isolated by drug selection, followed by FACS sorting. Confluent cultures were depleted of 
sterols by acute treatment with 1.5% methyl-β-cyclodextrin (MCD) for 30 minutes, followed by 
continuous incubation with pravastatin (40 µM) to block de novo sterol biosynthesis. Cholesterol 
was added back as soluble MCD-cholesterol (Chol) complexes (100 µM in DMEM) prepared as 
described (Klein et al., 1995). Following sterol depletion and add-back, the cultures were 
incubated overnight in the presence or absence of Shh as indicated. The cells were fixed then 
processed for immunofluorescence with anti-mCherry antibodies (to detect Smo) and anti-
acetylated tubulin antibodies (ciliary marker). The graph shows the percentage of cells with 
Smo- positive cilia. DrSmomSmoICD localizes to cilia, with or without sterol depletion; in contrast, 
mSmo accumulates in cilia upon Shh stimulation, and this accumulation is blocked by sterol 
depletion. 
(e) As in (d), but with box plots showing fluorescence intensity of Smo at cilia, in arbitrary units. 
The lower and upper bounds of each box represent the 25th and 75th percentile of the 
distribution of ciliary fluorescence intensity, while the horizontal line represents the median 
intensity across the entire population of cilia. 
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Figure 3.6 (continued) Conservation and divergence in Smo regulation 
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(f) The Smo ICD does not mediate sterol sensitivity. As in (d) but the cells were processed for Q-
PCR, to measure Gli1 transcription relative to the L27 transcript. Each experiment was 
performed in triplicate, and the error bars show the standard deviation of the mean. 
 
3.5 Discussion 
We found that the vertebrate Smo ICD contains at least two redundant ciliary localization 
sequences: CLS-1 is embedded within residues 615-637 of mouse Smo, while CLS-2 is 
contained in amino acid residues 685-793. The two distinct CLS most likely function 
synergistically to enhance ciliary targeting; in the context of full-length Smo they appear 
redundant for ciliary localization, and ablation of either CLS still results in a protein that is 
ciliary targeted through the action of the other CLS (as summarized in Figure 3.7). Furthermore, 
CLS-2 is sufficient to direct other membrane proteins and even membrane-attached proteins to 
the primary cilium on its own. It is tempting to speculate that the different CLS are regulated 
differently – and perhaps have even evolved differently to satisfy distinct criteria required for 
Smo regulation in vertebrates. The ICD stretch 685-793 may itself contain one or more motifs 
sufficient for ciliary targeting. In order to pinpoint the CLS-2 at higher resolution, additional 
mapping is needed using constructs with shorter deletions, while the complementary fusion 
constructs to heterologous membrane proteins would test the sufficiency for ciliary targeting. 
Separately, we show that the ciliary localization of Smo and the ability of Smo to activate 
downstream components are mediated by different sequence motifs in the ICD. An immediate 
Figure 3.6 (continued) Conservation and divergence in Smo regulation 
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Figure 3.7 Summary of Smo deletion mapping constructs 
The structure of the Smo ICD and the various deletion constructs is shown. The signal sequence 
(ss), the CRD and the 7 transmembrane domains, as well as the N-terminal CD8α portion used in 
the chimeras (which includes the CD8a transmembrane domain) and the myristoylation signal 
are color coded. The two regions containing the putative CLS identified are indicated. 
 
next step will be to map the minimal domain required for activation of downstream components. 
The work presented herein provides a framework for such additional mapping of the downstream 
activating domain.  
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How is the translocation of Smo to the cilium regulated? One possibility is that additional 
dynamic post-translational modifications such as palmitoylation of cysteine residues and the 
ensuing incorporation into lipid rafts would be important for trafficking Smo to the primary 
cilium. This idea is supported by the fact that other membrane proteins such as the photoreceptor  
opsin or fibrocystin rely on palmitoylation for proper sorting into the ciliary compartment (Follit 
et al., 2010; Tam et al., 2000). Furthermore, oligomerization of Drosophila Smo and its 
association with lipid rafts are essential for downstream pathway activation (Shi et al., 2013). We 
hypothesized that Smo may be dynamically palmitoylated in response to binding ligands that 
trigger its ciliary translocation, and then associates with lipid rafts for cilium-directed trafficking. 
The vertebrate Smo ICD contains 5 cysteine residues which could be acylated, but the mutational 
analysis of these residues is complicated by my finding that Smo contains redundant CLS. 
However, genetic screens have not identified any palmitoyl transferases with a clear role in the 
Hh pathway downstream of Smo. 
The vertebrate Smo ICD contains two stretches of basic residues in close proximity to 
cysteines, which are hallmarks of palmitoylation sites (Figure 3.3b) (Bijlmakers and Marsh, 
2003). We found that ablation of the first basic stretch or of the full complement of basic 
residues in both stretches results in proteins (mSmoA11 or mSmoA21) that are unable to signal 
downstream – but localize robustly to the cilium in a regulated fashion. In the mSmoA21 mutant, 
palmitoylation would not be expected. However, since Smo contains two separate CLS, it is 
conceivable that only one of the CLS is palmitoylation dependent, while the other one is not; in 
this case, the presence of a palmitoylation-independent CLS would mask the effect of loss of 
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palmitoylation on the palmitoylation-dependent CLS, and Smo would still localize to the cilium. 
The amino acid residues 615-637 in the Smo ICD, which encompass CLS-1 we identified, do not 
contain any cysteine residues that could be acylated, while CLS-2 we identified in the stretch 
685-793 contains four cysteines but is dispensable for ciliary localization. Thus, while 
palmitoylation (or S-acylation in general) at those cysteine residues is not essential for the ciliary 
targeting of full-length Smo, it may play a crucial role in downstream signaling. In order to prove 
a direct role for acylation, all cysteine residues in the ICD should be mutated. A different, as yet 
unknown mechanism pushes Smo to the cilium. Whether this mechanism acts in addition to 
palmitoylation or whether ciliary localization is completely unrelated to palmitoylation remains 
to be established. It will be worth examining the effect of the ablation of basic stretches in the 
context of a Smo construct lacking either of the two CLS, such as mSmoΔ615-684 or mSmoΔ685-793. 
If Smo signaling to downstream components is indeed regulated through palmitoylation 
of its ICD, then the removal of the palmitoyl moiety may likely be regulated as well, in order to 
maintain Smo homeostasis in the OFF state. Interestingly, cyclopamine brings inactive Smo to 
the primary cilium; cyclopamine may interfere with acylation of Smo, and thus block the 
interaction with downstream components – similar to the effect of the mSmoA11 mutation. 
Palmitoylation of Smo can be tested directly by treating cells with radioactive [3H]-palmitate 
(Follit et al., 2010) followed by immunoprecipitation of Smo to detect the incorporation of 
radioactivity; in a complementary approach, an S-acylation-defective mutant could be 
constructed by replacing all 5 cysteine residues within the ICD with serine or alanine residues. 
Whether palmitoylation of Smo occurs in a signal-dependent manner, whether depalmitoylation 
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is involved in maintaining Smo in the OFF state outside of the cilium in the absence of signaling, 
and in that case what the identity of the Smo depalmitoylase is – are attractive future directions 
of research opened up by the present work. 
Mammals have 23 proposed S-palmitoyl transferases localized to specific cellular 
compartments: most of them reside in the ER or the Golgi, but some localize primarily at the 
plasma membrane and transfer the palmitoyl moiety in a compartment-specific manner (Ohno et 
al., 2006); however, no palmitoyl-transferases have been reported at the primary cilium. A 
speculative model that reconciles the lateral movement observed for Smo with palmitoylation-
mediated signaling to downstream components involves the coordinated palmitoylation of Smo 
under strict spatial control at the plasma membrane in a ligand-dependent manner – but how the 
activation state is relayed to such palmitoyl transferase remains unknown. Accordingly, a plasma 
membrane-resident palmitoyl transferase acts as a gate-keeper and acylates activated Smo as it is 
targeted to the primary cilium; at the cilium, the acyl group on Smo mediates an interaction with 
downstream components either directly, or indirectly by favouring the association of Smo with 
lipid rafts already containing a downstream component. 
A crucial question is what happens at the cilium subsequent to Smo activation, in order to 
signal downstream. I find that the mSmoA11 and mSmoA21 mutants, which both lack the basic 
stretch within residues 565-581 of the ICD, fail to signal downstream components at the cilium. 
This stretch of basic residues lies in close proximity to cysteine 554, and resembles a 
palmitoylation site. My observation suggests the existence of a dynamic association either in the 
form of a direct interaction between Smo and the downstream pathway components at the level 
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of these residues, or in the form of a dynamic acylation of the nearby cysteine. Acylation may in 
turn regulate the association of Smo with lipid rafts containing downstream pathway 
components; alternatively, acylation may mediate the interaction with a downstream pathway 
component directly. Such interaction appears essential for Smo function, and we can only 
speculate that one possibility here is the cilium-dependent interaction with Evc2. Evc2 forms a 
complex with activated Smo. The interaction is spatially restricted to the transition zone of the 
primary cilium and is essential for transduction of the signal to the complex of Suppresor of 
Fused and Gli (SuFu-Gli) (Dorn et al., 2012). The mechanistic details of the interaction between 
Smo and Evc2 remain unknown at present. Since Smo and Evc2 co-immunoprecipitate, it will be 
interesting to test whether this interaction is maintained in the signaling defective mSmoA11 and 
mSmoA21 mutants. Furthermore, it will be interesting to map the minimal domain of Smo that 
interacts with Evc2, and to test whether the S-acylation-defective Smo mutant described above 
affects this interaction. 
3.6 Methods 
3.6.1 Antibodies 
Polyclonal antibodies against mCherry were generated in rabbits (Cocalico Biologicals) 
and were affinity purified against recombinant mCherry immobilized on Affigel-10 beads 
(BioRad). The monoclonal anti-acetylated tubulin antibody was obtained from Sigma. 
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3.6.2 DNA constructs 
Expression constructs were assembled by PCR in the mammalian expression vector 
pCS2p+, from which they were subcloned into a vector for lentiviral production. Constructs 
encoding membrane proteins were tagged with mCherry at their C-terminus. These constructs 
were: DrSmomSmoICD (amino acids 1- 556 of DrSmo fused to amino acids 543-793 of mSmo), 
mFz7mSmoICD (amino acids 1-548 of mouse Frizzled7 fused to amino acids 543-793 of mSmo), 
rMAChRmSmoICD (amino acids 1-442 of the rat muscarinic acetylcholine receptor M2 fused to 
amino acids 543-793 of mSmo), mSmo 684, mSmo 674, mSmo 657, mSmo 637, mSmoΔCRD, 
mSmoΔCRD 657, mSmoΔCRD 637, mSmo A11, mSmo A10, mSmo A21. 
CD8α chimeric constructs consist of the first 212 residues of the single-spanning 
transmembrane protein CD8α fused at the C-terminus to either residues 543-793 of Smo (the full 
mSmo ICD), or residues 675-793, or residues 685-793; all chimeras were assembled by PCR and 
tagged at their C-terminus with mCherry in the mammalian expression vector pCS2p+, from 
which they were subcloned into a vector for lentiviral production.  
To generate the myristoylated constructs, mSmo ICD residues 543-793 (the full mSmo 
ICD), or residues 543-674, or residues 675-793 were fused at the N-terminus to the Src N-
terminal myristoylation signal (Jia et al., 2003) and tagged at their C-terminus with mCherry in 
the mammalian expression vector pCS2p+. 
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3.6.3 Cell culture and generation of stable cell lines 
Mouse embryonic fibroblasts (MEFs) and 293T cells were grown in DMEM with 10% 
fetal bovine serum, penicillin and streptomycin. Stable cell lines were generated by lentiviral 
transduction, followed by selection with blasticidin 50µg/mL for 3 days. Smo-/- MEFs expressing 
low amounts of various mCherry-tagged Smo proteins were isolated by fluorescence-activated 
cell sorting. Expression of the tagged construct was confirmed by immunofluorescence and by 
QPCR assays of Hh pathway stimulation. The following compounds were obtained from 
commercial sources: cyclopamine (LC Laboratories), BODIPY-cyclopamine (TRC), SAG 
(Axxora), forskolin (Sigma), SANT1 (Calbiochem), 20-hydroxycholesterol (Steraloids), 7-
hydroxycholesterol (Steraloids), Acetyl choline (Sigma), Scopolamine (Sigma). 
3.6.4 Hh ligand production 
Hh ligand was produced by transiently transfecting 293T cells with an expression 
plasmid encoding amino acids 1-198 of human Shh. Shh was collected for 48 hours into 
starvation medium (DMEM supplemented with penicillin and streptomycin). For maximal 
stimulation of the Hh pathway, Shh- conditioned medium was used diluted 1:3 -1:4 into fresh 
starvation medium. 
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3.6.5 Wnt3a ligand production 
Wnt3a ligand was produced by from a stable line of L cells expressing the the full-length 
protein as described (Willert et al., 2003). Wnt3a-containing supernatant was collected for 48 
hours into medium (DMEM supplemented with 5% fetal bovine serum, penicillin and 
streptomycin). Wnt3a-conditioned medium was used diluted 1:2 -1:3 into fresh starvation 
medium (DMEM supplemented with penicillin and streptomycin). 
3.6.6 Immunofluorescence 
Cells were grown on glass coverslips to confluency and starved in DMEM overnight, 
then washed and incubated with control medium, 200nM or 1µM SAG, 1µM SANT-1 or 10µM 
20-OHC delivered as 1000X DMSO stock in DMEM for another 24hrs, as indicated. Cells were 
fixed in PBS with 3.7% formaldehyde, followed by permeabilization with TBST (TBS 
containing 0.2% Triton X-100). Non-specific binding sites were blocked by incubation in TBST 
with 50 mg/mL bovine serum albumin (TBST-BSA). Endogenous mSmo was detected with anti-
Smo antibodies (Tukachinsky et al., 2010) and mCherry-tagged proteins were detected with anti-
mCherry antibodies. Primary cilia were stained with anti-acetylated tubulin antibodies. Primary 
and secondary antibodies were used diluted in TBST-BSA. The primary antibodies were: rabbit 
polyclonal against mCherry (final concentration 1 µg/mL), rabbit polyclonal against mSmo (final 
concentration 2 µg/mL), mouse anti-acetylated tubulin monoclonal antibody (Sigma, final 
dilution dilution of 1:5,000). Alexa-594- and Alexa-488-conjugated secondary antibodies (Life 
Sciences) were used at a final concentration of 1 µg/mL. The coverslips were mounted on glass 
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slides in mounting media (0.5% p-phenylenediamine, 20 mM Tris pH 8.8, 90% glycerol). The 
cells were imaged by epifluorescence on a Nikon TE2000E microscope equipped with an 
OrcaER camera (Hammamatsu) and 40x PlanApo 0.95NA or 100x PlanApo 1.4NA oil objective 
(Nikon). Images were acquired using the Metamorph software (Applied Precision). Ciliary 
localization of Smo was measured either manually or using custom image analysis software 
implemented in MATLAB. Briefly, the software first identifies cilia by local adaptive 
thresholding of images of cells stained for acetylated tubulin. The segmented images are cleaned 
by automatic removal of objects whose size and shape fall outside the normal range for a typical 
cilium. Next, the pixel intensity of the protein of interest (Smo) in each cilium is corrected by 
subtracting the local background, defined as the median intensity of the pixels surrounding the 
cilium. Ciliary Smo is then quantified as the total corrected intensity in each cilium, normalized 
to the area of the cilium. To count Smo-positive cilia, fluorescence in the Smo channel is first 
calculated for the cilia in the negative control sample (untreated cells in case of scoring 
endogenous Smo, or Smo-/- cells in case of scoring mCherry-tagged fusions proteins stably 
expressed in Smo-/- MEFs). This data is used to calculate a threshold value that is above the 
fluorescence intensity for >95% of cilia in the negative control sample; note that this method 
overestimates the number of Smo-positive cilia in the negative control, by allowing a false 
positive rate of up to 5% in this sample. Using the calculated threshold value, cilia are then 
scored in all remaining samples, and the fraction of Smo-positive cilia is graphed. Ciliary 
intensity of Smo is also graphed using box plots; for each condition, the lower and upper bounds 
of the box represent the 25th and 75th percentile of the Smo intensity distribution, while the 
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horizontal line represents the median intensity across the entire cilia population. A more detailed 
description of the algorithm is provided in the Appendix. For the experiments presented in this 
study, between 150-550 cilia per condition were analyzed in this manner. For some experiments, 
ciliary localization of Smo was measured manually, by scoring the presence or absence of Smo 
in 150 cilia for each condition. 
3.6.7 Real-time PCR assays of the Hh pathway 
Confluent NIH-3T3 cells or MEFs were starved overnight in starvation medium, after 
which they were incubated for 24 hours in starvation medium supplemented with the desired 
compounds. Total RNA was isolated from cells with RNA-Bee (TelTest), treated with RNase-
free DNase (Promega), and purified using the GenCatch total RNA Extraction System (Epoch 
Biolabs). Reverse transcription was performed using random hexamers and Transcriptor reverse 
transcriptase (Roche). Transcription of the Hh target gene Gli1 was measured by real-time PCR 
using FastStart SYBR Green Master reagent (Roche) on a Rotor-Gene 6000 (Corbett Robotics). 
Relative gene expression was calculated using a Two Standard Curve method in which the gene-
of-interest was normalized to the Ribosomal Protein L27 gene. The sequences for gene-specific 
primers are: L27: 5’-GTCGAGATGGGCAAGTTCAT-3’ and 5’- 
GCTTGGCGATCTTCTTCTTG-3’, Gli1: 5’-GGCCAATCACAAGTCAAGGT-3’ and 5’-
TTCAGGAGGAGGGTACAACG -3’. Each experiment was performed in triplicate, and error 
bars represent standard error of the mean. 
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3.6.8 Sterol depletion 
Sterol depletion was performed on starved, confluent cultures of stable lines derived from 
Smo-/- MEFs. The cultures were incubated for 30 minutes with 1.5% methyl-β-cyclodextrin 
(MCD) in DMEM (to remove sterols), after which all subsequent incubations were in DMEM 
with 40 µM pravastatin (to block new sterol synthesis), with or without the indicated additives. 
For rescue experiments, cholesterol prepared as described (Klein et al., 1995) was added back by 
incubating the cells for 1 hour with soluble cholesterol-MCD complexes prepared (100 µM in 
DMEM supplemented with 20 µM pravastatin). After overnight incubation with the desired 
compounds, the cells were processed for immunofluorescence or for Q-PCR, as described above. 
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 Discussion and Future Directions Chapter 4:
4.1 Smo is modular 
An important finding of my work is that Smo contains separate modules, each with a 
distinct function. The seven-spanner portion of the protein contains a ligand binding site where 
cyclopamine binds. A crystal structure exists of this region (Wang et al., 2013) showing an 
inhibitor bound deeply inside the transmembrane barrel, and this cyclopamine-binding site is 
targeted by all Smo inhibitors developed to date. In Chapter 2, I show that the CRD contains an 
oxysterol-regulated module required for maximal activation of Smo. While a second ligand 
binding site on Smo was previously hypothesized to exist (Nachtergaele et al., 2012), this is the 
first report to discover the existence of a second ligand binding site on Smo that is completely 
distinct from the cyclopamine-binding site, and furthermore to pinpoint its location. In Chapter 3 
I show that Smo contains a ciliary localization module and I map this ciliary localization module 
to a region of the cytosolic intracellular domain (ICD). I demonstrate that this module is 
sufficient to target a heterologous protein to the cilium, but is not sufficient to activate 
downstream components.  
How, then, do the different modules interact? How does binding of a ligand at the 
oxysterol-binding site within the CRD elicit a response in the heptahelical bundle and then in the 
cytosolic tail? How does the activation state get relayed from the ligand binding sites to the 
effector domains that expose the ciliary targeting sequence of Smo and result in ciliary 
translocation? Allosteric effects most likely play a significant role in relaying the signal. The 
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only crystal structure of Smo solved to date contains the seven transmembrane domain region, 
while the CRD and the ICD, as well as the critical aspects that define the interaction between 
modules are missing (Wang et al., 2013). 
In order to gain an understanding of how the CRD communicates with the rest of the 
protein, it would be very interesting to map the residues that form the sterol-binding pocket – and 
whether any residues from the heptahelical bundle or the extracellular loops contributes to ligand 
binding at this CRD site. To this end, a crystal structure of full-length Smo would be ideal but 
also difficult to obtain. In the absence of crystallography data, a surrogate approach would make 
use of my finding that 6-azi,25-OHC binds Smo specifically at the oxysterol-binding site in a 
competitive manner, as shown in Figure S6 in the Appendix. This sterol is photoactivatable, and 
exposure to UV radiation generates a reactive species that will crosslink to any amino acid 
residues in its immediate vicinity. Upon incubation of a Smo extract with 6-azi,25-OHC and 
photocrosslinking, the covalent adducts of the sterol to individual peptides can be detected by 
tryptic digest followed by mass spectrometry (MALDI-TOF). Such an in-vitro experiment 
requires a source of large amounts of protein – in Chapter 2 I showed that Xenopus Laevis Smo 
expressed in Spodoptera frugiperda Sf9 insect cells is active in detergent extracts and binds 
sterols at the CRD site. 
In Chapter 2, I showed that Smo CRD mutations (mSmoL112D, mSmoW113Y or the 
combined mSmoLW) ablate the response to oxysterols, yet still responds to SAG or the 
endogenous Shh ligand. In Chapter 3, I demonstrate that a Smo mutant in which the seventh 
transmembrane domain was replaced with the Drosophila counterpart (mSmoDrSmoTM7) fails to 
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respond to the Smo agonist SAG, but responds to oxysterols or the endogenous Shh ligand. An 
immediate question is whether a combination of a mutation at the cyclopamine binding site with 
a mutation at the oxysterol binding site results in a completely inactive protein that fails to 
respond to the endogenous ligand – or whether it still responds to the endogenous ligand, in 
which case additional elements in the sequence of Smo are required for activation. To test this 
hypothesis, a combined mSmoLW,DrSmoTM7 mutant would be overexpressed in Smo-null MEFs, 
and the transcriptional response measured by qPCR at rest or upon stimulation with Shh ligand 
relative to WT Smo. In addition, the ciliary localization of the mutant would be scored in a 
complementary experiment. While a mutant that fails to respond to agonists would be expected 
as both ligand-binding sites would be killed, a mutant that still responds to Shh ligand would 
indicate that Smo activation does not rely solely on those two ligand-binding sites, and that 
additional sequence elements contribute to the activated state. To limit the chance that the double 
mutant is inactive due to misfolding, individual point mutations corresponding to the divergent 
residues between the mouse and Drosophila TM7 can be introduced one at a time into the 
cyclopamine-binding site of the mSmoLW mutant instead of the whole DrSmo TM7 domain. 
Correct folding can be tested by the presence of the mature, post-Golgi Smo band that migrates 
slower by SDS-PAGE. A possibility would be that while the point mutations are sufficient to 
ablate the response to SAG or oxysterols, they do not affect all the residues that mediate the 
binding of the actual endogenous ligand, and thus the endogenous ligand can still (partially) 
bind. 
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The fact that Smo is regulated at two independent sites is intriguing; my work in Chapter 
2 suggests that the oxysterol-binding site is required for maximal activation of Smo for cells in 
tissue culture. It is possible that Smo regulation involves two separate mechanisms, and that 
regulation through sterols at the oxysterol-binding site in the CRD serves as a context-dependent 
additional layer of regulation. What is the role of the two sites in the endogenous context, and 
what is the relative importance of these two sites of Smo regulation? Is Smo differentially 
regulated in response to the levels of sterols in tissues? To answer this question, a mouse model 
of the mSmoLW would need to be generated. I would expect the mice to show subtle phenotypes, 
but the defects would be indicative of the relative importance of regulation of one particular site 
over the other. For instance, if one type of tissue requires maximal activation of Smo through the 
action of a sterol, then a defect will be visible, whereas no defect will be observed if Smo 
activation through the cyclopamine-binding site suffices. In the developing limb bud, a spatio-
temporal gradient of Shh ligand specifies different digit identities (Harfe et al., 2004); in the 
developing neural tube, a gradient of Shh ligand specifies distinct identities for the ventral 
neuron types (Briscoe and Ericson, 2001). The mouse model described above will show whether 
the Shh gradient correlates with different levels of Smo activation – and thus the different 
developmental outcomes. In Drosophila, the Smo CRD is dispensable, but Drosophila Smo also 
lacks regulation by sterols; this mouse model will show whether the CRD is dispensable in 
vertebrates, and will pinpoint the location in the developing embryo where regulation of Smo 
through sterols plays a significant role. 
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4.2 Pharmaceutical inhibition of Smo ligand-binding sites 
Smo contains two distinct ligand binding sites which can both be inhibited 
pharmaceutically. The cyclopamine-binding site can be inhibited by SANT-1, Vismodegib and 
the vast majority of Smo inhibitors developed to date. In Chapter 2 I introduce 22-aza cholesterol 
as the first Smo inhibitor specific to the oxysterol-binding site. The compound inactivates Smo 
with an IC50 of ~3µM. I suspect the main limiting effect is the high lipophilicity which forces 22-
aza cholesterol to distribute into cell membranes and thus lowers its availability in solution. 
Together with my work defining the structure-activity relationship of the sterols that bind at the 
CRD site, 22-aza cholesterol can serve as lead compound for a medicinal chemistry optimization 
protocol to identify analogs with improved binding affinities and lower lipophilicity.  
From a therapeutic perspective, inhibition of both ligand binding sites on Smo is highly 
desirable. I have shown in Chapter 2 that a Smo mutant completely lacking the CRD, and thus 
the oxysterol binding site, still shows a low-level response to agonists. This suggests that the 
endogenous ligand activates Smo primarily at the oxysterol-binding site, but also that ligand 
binding at both sites is required for a full response. Inhibition at the cyclopamine site with 
Vismodegib is efficient and has received FDA approval for use in patients with metastatic basal 
cell carcinoma. However, treatment with Vismodegib eventually results in drug resistant Smo 
mutants such as mSmoD473H, which maps to the cyclopamine binding site and renders it unable to 
bind Vismodegib (Yauch et al., 2009). While the cyclopamine-binding site is affected in this 
mutant, the oxysterol-binding site is fully active and thus explains why the protein can still 
function while accumulating the mutations in the cyclopamine site. It is therefore conceivable 
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that targeting both sites simultaneously will minimize the occurrence of drug resistance by 
limiting the likelihood of a mutant protein with both ligand binding sites affected to still signal to 
downstream components. It will be very interesting to identify synergistic combinations of a 
cyclopamine-binding site inhibitor and of an oxysterol-binding site inhibitor.  
An even better approach for a therapeutically relevant Smo inhibitor would be to develop 
a bidentate ligand that simultaneously targets both the cyclopamine binding and the oxysterol 
binding sites. Such a molecule would likely contain ligands for either site tethered to each other 
through a linker. Since the affinity of inhibitors at the cyclopamine binding site is low 
nanomolar, while 22-aza cholesterol has an IC50 of about 3µM, one advantage of this approach 
would be that the bidentate ligand will first bind to the cyclopamine site through the high-affinity 
moiety, thus tremendously increasing the local concentration of ligand at the oxysterol binding 
site and in effect increasing the affinity for the oxysterol binding site by several orders of 
magnitude compared to the untethered inhibitor. However, the specifics of such a bidentate 
ligand are not trivial in the absence of a crystal structure of full-length Smo, as the length of the 
linker must be chosen such that it places both the moiety targeting the cyclopamine-binding site 
as well as the moiety targeting the oxysterol-binding site at an optimal distance relative to each 
other so that both sites can be bound simultaneously.  
4.3 Open questions and future directions 
An important unanswered question in the Hedgehog field is how Ptc inhibits Smo. 
Several lines of evidence suggest a catalytic mechanism of inhibition through regulation of a 
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small molecule. Ptc bears resemblance to molecular pumps of the RND superfamily; 
furthermore, Ptc shows significant homology to another RND member, NPC1, which has been 
shown to transport cholesterol esters. Mutations that inactivate the pump activity of RND 
permeases also inactivate Ptc and are found in Gorlin syndrome patients (Taipale et al., 2002). 
Thus, it appears that Ptc may itself regulate a small molecule such as a sterol, but direct evidence 
of a pump activity for Ptc has not been reported, and no direct binding of sterols to Ptc has been 
reported. The identity of the small molecule intermediate between Ptc and Smo remains 
unknown, and I can only speculate as to what the endogenous small molecule actually is. For 
instance, In Chapter 2 I show that the endogenous Smo regulator is not a sterol ester, as in 
biological settings sterols are esterified only at the 3-OH position; in the case of sterols that 
activate Smo at the oxysterol-binding site, that free 3-OH position is critical and must remain 
unmodified. Furthermore, the iso-octyl sidechain requires at least 6 carbon atoms in order to both 
push Smo to the cilium as well as to stimulate the downstream pathway effectors. This evidence 
rules out a whole class of compounds, steroids, which are based off the structure of 
pregnenolone, and which generally lack the iso-octyl sidechain altogether. If there is only one 
endogenous small molecule regulator of Smo, and it is indeed a cholesterol derivative, it remains 
to be established how it can regulate both the cyclopamine-binding site and the oxysterol-binding 
site in the CRD – ideally through a crystal structure of the full-length Smo bound to the 
endogenous small molecule. 
The identity of the sterol modulator of Smo at the CRD oxysterol-binding site remains 
elusive. A possible approach to identify the endogenous ligand would be the biochemical 
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purification of Smo-modulating lipids from cilia – the Smo-modulating capability of a fraction 
can be tested by assessing the Smo ciliary localization as well as by measuring the transcriptional 
response of the pathway. A major caveat to this approach is the isolation of ciliary membranes in 
large enough quantities to serve as a source for the lipid fractionation; my results indicate a 
divergence between the regulation of Smo in Drosophila and in vertebrates, therefore the 
biochemical fractionation should be applied to vertebrate cell membranes, while more abundant 
ciliary membranes from organisms like Chlamydomonas reinhardtii would not be expected to 
provide an informative answer. Chloral hydrate has been reported to deciliate kidney epithelial 
cells, and cilia can be recovered from the solution (Praetorius and Spring, 2003); this method 
may provide a sufficient supply of ciliary membranes to support a biochemical investigation. 
In the absence of biochemical evidence, an indirect reverse-genetic approach to identify 
this elusive sterol involves targeting of its biosynthetic pathway; in brief, RNAi would be 
directed at all genes in the genome that resemble oxigenase enzymes, including here all CYP450 
enzymes. This latter approach may highlight individual biosynthetic genes that may form the 
sterol modulator of Smo. However, if Smo is regulated by a ubiquitous small-molecule and not 
by a dedicated oxysterol with a single cellular function, pleiotropic effects due to absence of this 
small molecule (for instance on vesicular transport or on sorting into the proper post-ER 
compartment) will likely mask the Hh pathway phenotype. 
The possibility that Hedgehog signal transduction is regulated through a small molecule 
such as a direct cholesterol metabolite is a very promising venue from a therapeutic perspective. 
A variety of chemical compounds that inhibit the biosynthesis of cholesterol such as statins are 
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currently approved for human use; the findings presented herein may lead to novel therapeutic 
uses of such compounds.  
In Chapter 2 I find that DrSmo does not bind oxysterols. How then is DrSmo activated, 
and is this mechanism conserved? Unlike vertebrate Smo, which has two distinct small molecule 
binding sites, no small molecules (synthetic or endogenous) are known that bind DrSmo. Ptc and 
Smo are conserved across phyla; in fact, the transmembrane domains show the highest 
conservation of residues between Drosophila and vertebrate Smo. Furthermore, in vertebrate 
Smo, the cyclopamine-binding site maps to this transmembrane region. Taken together, the 
evidence points to a common Smo activation mechanism through a small molecule, and suggests 
that an endogenous small-molecule might bind Drosophila Smo in the transmembrane region as 
well in order to trigger its activation. In Chapter 3, I assayed the activity of a portion of DrSmo 
consisting of the CRD and heptahelical bundle in mammalian cells by targeting it to primary 
cilia by fusion with the intracellular domain (ICD) of mSmo. This DrSmomSmoICD construct is 
constitutively active and refractory to inhibition by Ptc or by sterol depletion, suggesting that 
DrSmo might be regulated differently from vertebrate Smo, in spite of the conservation of Ptc. I 
further show that the vertebrate Smo ICD is not sufficient for signaling downstream, thus the 
activation state of the DrSmomSmoICD mutant must be relayed downstream by the seven spanning 
region. In Chapter 2 I find that the vertebrate Smo CRD binds oxysterols but that Smo can be 
activated partially in response to pathway stimulation with the endogenous Hh ligand even in the 
absence of the CRD. Interestingly, DrSmoΔCRD is completely inactive in Drosophila (Nakano et 
al., 2004), in contrast to vertebrate SmoΔCRD (Aanstad et al., 2009; Taipale et al., 2002). Thus 
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DrSmo CRD does not bind sterols but is absolutely required for function, perhaps by playing a 
critical role in stabilizing the active conformation of DrSmo. An important implication of my 
findings is that Drosophila and vertebrate Smo share a similar mechanism for activation, and 
most likely involve a similar though not identical small-molecule ligand that binds Smo within 
the transmembrane region. The ciliary localization of Hh pathway components in vertebrates, 
and the divergence of the Smo tails as well as the insensitivity of Drosophila Smo to oxysterols, 
all suggest that an additional layer of regulation of Smo has evolved since the divergence of 
Drosophila and vertebrates. This translates to the possibility that vertebrate Smo is regulated by 
two separate small molecules: one that binds the cyclopamine-binding site within the 
transmembrane barrel and is similar to the small molecule that activates the Drosophila homolog, 
and a second one that binds the oxysterol-binding site in the vertebrate CRD. It is plausible that 
this additional mechanism of regulation is separate from the small-molecule-mediated regulation 
by Ptc – and this process most likely involves a second small molecule such as an oxysterol, the 
identity of which remains unknown. Whether vertebrate Ptc regulates a single small molecule 
that only targets one of the Smo sites, or perhaps regulates two separate small molecules that 
each target a separate site on Smo has yet to be determined. Understanding the mechanistic basis 
for the evolutionary divergence in Smo regulation is an important future goal. 
The ciliary events subsequent to Smo activation and translocation that lead to activation 
of the downstream components remain unclear from a mechanistic perspective. This aspect is of 
particular importance given the divergence of Hedgehog pathway components downstream of 
Smo in vertebrates as opposed to arthropods, and may involve ciliary proteins in more direct 
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transduction roles than simply in the maintenance of cilia. In vertebrates, Suppresor of Fused 
(SuFu) forms a complex with Gli that promotes processing of Gli by the proteasome to the Gli-R 
repressor form. In the basal state of the pathway, the complex traffics into and out of the cilium; 
upon activation of Smo, however, the SuFu-Gli complex dissociates at the cilium. This liberates 
and stabilizes full-length activator form of Gli, which translocates to the nucleus and transcribes 
the Hedgehog target genes (Tukachinsky et al., 2010). From a mechanistic perspective, how the 
signal is transduced from Smo to SuFu and Gli is not known. Furthermore, what happens to the 
SuFu-Gli complex upon pathway activation, how the complex falls apart at the cilium, and how 
the full-length Gli activator form is stabilized and protected to avoid processing by the 
proteasome are all poorly understood.  One possibility is that activated Smo interacts directly 
with the SuFu-Gli complex at the cilium and induces its dissociation; alternatively, Smo may 
activate a different ciliary protein, which in turn catalyzes the dissociation of the SuFu-Gli 
complex 
Recent work has implicated Evc2, a ciliary protein which resides in a compartment 
immediately adjacent to the transition zone, in mediating Hh signaling at the cilium downstream 
of Smo (Dorn et al., 2012). Defects in Evc2 cause two human ciliopathies, Ellis-van Creveld and 
Weyers Acrofacial Dysostosis – which both lead to cilia with normal structure, but affected 
individuals show cardiac, orofacial and skeletal phenotypes resembling Hh pathway defects. 
Evc2 forms a complex with activated Smo; the interaction is spatially restricted to the transition 
zone and is essential for transduction of the signal to the SuFu-Gli complex (Dorn et al., 2012). 
Recessive Evc2 mutations cause Evc2 to fail to localize to the cilium, while dominant mutations 
 142 
in Evc2 are mislocalized across the entire length of the cilium. Intriguingly, Evc2 or its paralog 
Evc are not expressed in certain tissues where Hh signaling is important, such as the nervous 
system, and therefore tissue-specific interactions of Smo with other ciliary proteins are likely 
(Dorn et al., 2012). While the Smo-Evc2 complex has been characterized, it is not known at 
present which domains(s) or residues of Smo mediate this interaction and how the activation 
state of Smo regulates the presentation of these domains to Evc2. In order to answer these 
questions, a deletion analysis similar to the work I present in Chapter 3 would be necessary to 
pinpoint the domains of Smo that interact with Evc2. The Smo-Evc2 complex can be readily 
identified by reciprocal immunoprecipitation followed by Western blotting of the complex 
partner. The deletion constructs can be tested for proper folding through their ability to bind 
BODIPY-cyclopamine; then, any Smo deletion constructs that fail to immunoprecipitate with 
Evc2 likely contain deletions in the region that interacts with Evc2. Both Evc2 and the Smo 
deletion constructs would be overexpressed in 293T cells, which cannot respond to Hedgehog 
signaling; if the forced interaction of Evc2 and the Smo deletion construct is lost even in this 
unregulated overexpression system, the deletion likely spans a domain of Smo required for 
binding Evc2. In order to prove that a candidate region interacts indeed with Evc2, a test for 
sufficiency is required. To this end, any candidate region of Smo that is suspected to interact 
with Evc2 can be fused to a heterologous protein such as the soluble eGFP; if Evc2 and the 
eGFP-Smo chimera co-immunoprecipitate in reciprocal experiments, this would confirm the 
identification of the region of Smo interacting with Evc2.  
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The vertebrate Smo ICD contains two stretches of basic residues in close proximity to 
cysteines, which are hallmarks of palmitoylation sites (Bijlmakers and Marsh, 2003). I found that 
ablation of the first basic stretch or of the full complement of basic residues in both stretches 
results in proteins (mSmoA11 or mSmoA21) that are unable to signal downstream – but localize 
robustly to the cilium in a regulated fashion. One possibility is that the region 565-581 of the 
ICD mediates the interaction with Evc2 directly; alternatively, the region 565-581 may serve as a 
recognition site for a palmitoyl-transferase to acylate a nearby cysteine residue, and the presence 
of the palmitoyl moiety on Smo in turn facilitates the interaction with Evc2. In the mSmoA21 
mutant, palmitoylation would not be expected; the fact that this mutant fails to signal 
downstream but otherwise behaves like the wildtype protein indicates that palmitoylation may 
play a crucial role in signaling downstream.  
In order to prove a direct role for acylation, all cysteine residues in the ICD should be 
mutated. Palmitoylation of Smo can be tested directly by treating cells with radioactive [3H]-
palmitate (Follit et al., 2010) followed by immunoprecipitation of Smo to detect the 
incorporation of radioactivity. Alternatively, a bio-orthogonal probe such as 15-
azidopentadecanoic acid can be used instead of the radioactive palmitate; the Click chemistry 
detection involves the copper(I)-catalyzed cycloaddition after immune-precipitation against Smo 
to an alkyne-fluorophore conjugate for in-gel detection (Charron et al., 2009), and the method 
can easily be coupled to immunofluorescence microscopy to specifically quantitate palmitoylated 
Smo at the cilium. 
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However, the interaction of activated Smo with Evc2 is not the only ciliary event 
required for correct signal transduction. Two proteins of the IFT-B complex, IFT25 and IFT27, 
form a binary complex that is conserved throughout vertebrates but is missing in Drosophila. The 
IFT25-IFT27 complex is not required for ciliogenesis, but appears essential for transduction of 
the Hh signal in vertebrates. The loss of IFT25 leads to mislocalization of Ptc, Smo and Gli2 at 
the cilium and disrupts the Hh pathway response upon stimulation. More specifically, Gli2 does 
not accumulate at the cilium in response to signaling, while Patched and Smo are constitutively 
localized at the cilium regardless of the presence or absence of the Hh ligand. Interestingly, 
despite the loss of IFT25, the cilia appear morphologically normal, and also show normal 
localization as well as normal amounts of other IFT proteins such as IFT88. Knock-out animals 
survive to birth but show severe abnormalities indicative of Hh signaling defects (Keady et al., 
2012). Thus, rather than facilitating transport into the primary cilium, the IFT25-IFT27 complex 
enables the export of proteins from the cilium and allows the dynamic redistribution of Hh 
pathway components in response to signaling. In the absence of signaling Smo is efficiently 
removed from the cilium by the IFT25-IFT27 complex, while in the presence of stimulation Ptc 
is instead removed from the cilium. Which part of Smo interacts with the IFT25-IFT27 complex, 
whether this is a direct interaction or perhaps involves a different protein intermediary, and 
whether the interaction is regulated by the activation state of Smo remains to be determined.  
I show that the ciliary localization of Smo and the ability of Smo to activate downstream 
components are mediated by different sequence motifs in the ICD. It would be very interesting to 
map the minimal domain required for activation of downstream components, and the work 
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presented herein provides a framework for such additional mapping of the downstream activating 
domain. To this end, one possible approach would be to fuse a heterologous well-defined CLS 
(for instance, the 18 amino acid CLS of Fibrocystin (Follit et al., 2010)) C-terminally to a Smo 
construct lacking both endogenous CLS, such as mSmoΔ615-793; after additional mapping of the 
CLS-2, a better construct would contain two short internal deletions corresponding to the two 
CLS, while having the majority of the ICD intact. I expect that such a chimeric construct will be 
targeted to the cilium by the exogenous CLS, that it rescues the Smo-/- defect and that it activates 
the downstream pathway components. Then, internal deletions of short ICD stretches can be 
introduced in this construct and tested in the context of downstream pathway activation, to map 
out the minimal downstream activating domain. Furthermore, all constructs generated this way 
can be tested for successful folding by their ability to bind BODIPY-cyclopamine. 
A broader biological question is what the role of the transition zone, and in particular of 
the Tctn1-containing transition zone complex, is in both normal ciliary function and in the 
context of Hedgehog signaling at the cilium. While many transition zone proteins are essential 
for ciliogenesis as they establish a diffusion barrier between the plasma membrane and the ciliary 
membrane at the base of the cilium, the Tctn1-containing complex is not essential for 
ciliogenesis but instead is required for proper Hh signal transduction at the cilium. Tctn1 does 
not associate with Smo, but loss of Tctn1 causes Smo to localize poorly to cilia even in the 
presence of SAG (Garcia-Gonzalo et al., 2011). Separately, Evc2 localizes to the distal end of 
the transition zone but does not associate with Tctn1 in the same complex. Evc2 however 
associates with Smo and is essential for Hh signaling (Dorn et al., 2012). Interestingly, targeting 
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Smo to the Evc2 expression zone artificially and thus limiting its spread throughout the axoneme 
results in moderate but below-maximal pathway activation, while Evc2 mutations that lead to its 
expression across the entire length of the cilium have dominant negative effects on the Hh 
pathway (Dorn et al., 2012). This raises the possibility that a hierarchical sequence of multiple 
events at the transition zone relays the signal from Smo to the Gli-SuFu complex before the Gli-
SuFu complex reaches the tip of the cilium where it dissociates in response to signaling.  
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A.1 Supplementary Results 
 
Supplementary Figure S1 related to Figure 2.1:  
(a) 22-NHC does not block the disappearance of mPtch1 from primary cilia in response to Shh. 
Ptch1-/- MEFs stably expressing Cherry-tagged mPtch1 were incubated with Shh overnight, in 
the presence or absence of 22-NHC (10 µM). Cells were then fixed and processed for 
immunofluorescence with rabbit anti-Cherry antibodies (to visualize mPtch1) and mouse anti-
acetylated tubulin antibodies (to visualize primary cilia). The micrographs show representative 
images of cilia, with Ptch1-positive cilia counts shown below the panels.  
(b) 22-NHC does not block constitutive Hh signaling in SuFu-/- MEFs. SuFu-/- MEFs were 
incubated in the absence or presence of 22-NHC (10 µM), and the transcriptional response of the 
Hh pathway was measured by Q-PCR of the target gene Gli1. The same concentration of 22-
NHC blocks Gli1 transcription in NIH-3T3 cells stimulated with Shh. All experiments were 
performed in triplicate, and error bars indicate the standard deviation of the mean. 
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Supplementary Figure S2 related to Figure 2.2: 
(a) 22-NHC does not impair ciliary localization of activated Smo in the presence of Shh. 3T3 
cells were starved overnight in DMEM, then treated with control medium, 10µM 22-NHC (in 
DMEM) and/or Shh for another 24 hours. The cells were processed for immunofluorescence 
with anti-Cherry antibodies (to detect Smo) and anti-acetylated tubulin antibodies (ciliary 
marker). The bar graph on the left shows the percentage of cells with Smo-positive cilia. The box 
plot on the right shows fluorescence intensity of Smo at cilia, in arbitrary units; the lower and 
upper bounds of each box represent the 25th and 75th percentile of the distribution of ciliary 
fluorescence intensity, while the horizontal line represents the median intensity across the entire 
population of cilia. 
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Supplementary Figure S2 (continued) 
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Supplementary Figure S2 (continued) 
(b) Timecourse of ciliary accumulation of Smo in response to 22-NHC. 3T3 cells were starved 
overnight in DMEM, then treated with 10µM 22-NHC for 0, 1, 3 and 24hrs. The cells were fixed 
at the indicated times and processed for immunofluorescence with anti-Cherry antibodies (to 
detect Smo) and anti-acetylated tubulin antibodies (ciliary marker). The bar graph on the left 
shows the percentage of cells with Smo-positive cilia. The box plot on the right shows 
fluorescence intensity of Smo at cilia, in arbitrary units; the lower and upper bounds of each box 
represent the 25th and 75th percentile of the distribution of ciliary fluorescence intensity, while 
the horizontal line represents the median intensity across the entire population of cilia. 
(c) 22-NHC does not compete with binding of BODIPY-cyclopamine (BODIPY-Cyc, top two 
rows of micrographs) or BODIPY-SANT1 (bottom two rows of micrographs) to mSmo. Human 
293T cells expressing mSmo-Cherry were incubated with 10 nM BODIPY derivative, in the 
presence or absence of 10 µM 20-OHC, 10 µM 22-NHC or 4 µM SANT1. Cells were fixed, 
washed, and imaged by fluorescence microscopy, to detect mSmo-Cherry and the BODIPY 
conjugate. 
(d) Structures of SANT1 and of the BODIPY-SANT1 derivative synthesized in this study.  
(e) Shh Light II cells were stimulated with Shh in the presence of increasing concentrations of 
SANT1 and BODIPY-SANT1, and Hh pathway activity was measured by luciferase assay. Both 
SANT1 and BODIPY-SANT1 inhibit Hh signaling in a dose-dependent manner. All experiments 
in this panel were performed in quadruplicate, and error bars represent the standard deviation of 
the mean. Hh pathway activity was normalized to activity of Shh alone (100%).  
(f) Structures of the 22-NHC analogs, 22-NHC-Et and 22-NHC-Pr. For each analog, the two 
diastereomers resulting from the two possible C20 configurations are shown (R and S).  
(g) As in (c), but with Shh stimulation in the presence of the indicated concentrations of 22(S)-
NHC, 22(R)-NHC-Et, 22(S)-NHC-Et, 22(R)-NHC-Pr and 22(S)-NHC-Pr. Both R and S 
diastereomers of 22- NHC-Et and 22-NHC-Pr inhibit Hh signaling. 
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Supplementary Figure S3 related to Figure 2.4: 
(a) Human 293T cells expressing mSmo-Cherry or mSmoΔCRD-Cherry were incubated with 10 
nM BODIPY-Cyc, in the presence or absence of 2 µM SANT1. Cells were fixed, washed, and 
imaged by fluorescence microscopy, to detect the Cherry fusions and the BODIPY conjugate. 
Both mSmo and mSmoΔCRD bind BODIPY-Cyc. 
(b) Detergent extracts of 293T cells expressing mSmo-Cherry, or supernatants containing HA-
tagged mSmoCRD were incubated with 20-OHC beads, in the presence of 7-OHC (negative 
control), or the active oxysterols 20-OHC and 25-OHC, or the inactive 7-keto-cholesterol (7-
KC). Bound mSmo-Cherry and mSmoΔCRD-HA were analyzed by SDS-PAGE and 
immunoblotting. Binding of mSmo and mSmoCRD to 20-OHC beads is competed by 20-OHC 
and 25-OHC, but not by 7-KC.  
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Supplementary Figure S4 related to Figure 2.5 
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Supplementary Figure S4 (continued) 
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Supplementary Figure S4 (continued): 
(a) Shh Light II cells were treated for 30 hours with the indicated concentrations of the oxysterol 
analogs 20-OHC-Me, 20(S)-OHC-Et, 20(R)-OHC-Et, 20(S)-OHC-Pr, 20(R)-OHC-Pr, 20(R)-
OHC-Bu, 20(R)-OHC-Pent and 20(R)-OHC-PentSat, followed by measuring Hh pathway 
activity by luciferase assay. The inactive oxysterol, 7-OHC, was used as negative control, while 
SAG (1 µM) was used as positive control. All experiments were performed in quadruplicate, and 
error bars represent the standard deviation of the mean. 
(b) As in (a) but with addition of Shh, to test if the oxysterol analogs have inhibitory activity on 
Hh signaling. The Smo inhibitor, SANT1 (1 µM) was used as positive control for Shh inhibition. 
All experiments were performed in quadruplicate, and error bars represent the standard deviation 
of the mean.  
(c) Structures of 20-OHC-Pent-3β−OAc or 20-OHC-Pent-3β−OMe derivatives. The ester bond 
of 20-OHC-Pent-3β−OAc is labile under prolonged exposure in aqueous solutions, while the 
ether bond in 20-OHC-Pent-3β−OMe is chemically inert under normal assay conditions 
(d) As in (a) but with addition of 20-OHC-Pent-3β−OMe, in the absence or presence of Shh. 
SAG1 (1 µM) was used as positive control for pathway activation, while SANT1 (1 µM) was 
used as positive control for Shh inhibition. The ether derivative 20-OHC-Pent-3β−OMe does not 
inhibit or activate Hh signaling. The ester bond in 20-OHC-Pent-3β−OAc hydrolizes under these 
assay conditions and was not included. 
(e) Detergent extracts of 293T cells expressing mSmo-Cherry were incubated for one hour with 
22-NHC beads, in the absence or presence of 100 µM 7-OHC, 20-OHC, 20-OHC-Pent-3β−OAc 
or 20-OHC-Pent-3β−OMe. After washing, protein bound to beads was eluted, separated by SDS-
PAGE and immunoblotted with anti-Cherry antibodies. Neither 20-OHC-Pent-3β−OAc nor 20-
OHC-Pent-3β−OMe compete binding of mSmo to 22-NHC beads, in contrast to 20-OHC. 
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Supplementary Figure S5 related to Figure 2.6 
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Supplementary Figure S5 (continued): 
(a) Detergent extracts from 293T cells expressing Cherry-tagged mSmo or mSmoDrSmoCRDmut 
were incubated with control beads or 22-NHC beads, in the absence or presence of 100 µM 22-
NHC or 20-OHC. After washing, protein bound to beads was eluted, separated by SDS-PAGE 
and immunoblotted with anti-Cherry antibodies. The CRD mutant of mSmo does not bind 22-
NHC beads, in contrast to wild-type mSmo.  
(b) Secreted HA-tagged mSmoCRD and mSmoCRDDrSmoCRDmut were incubated with control 
beads or 20- OHC beads, in the presence or absence of 100 µM free 20-OHC. Binding to beads 
was assayed as in (a), using anti-HA to detect mSmoCRD and mSmoCRDDrSmoCRDmut. 
mSmoCRDDrSmoCRDmut does not bind 20- OHC beads, in contrast to mSmoCRD. 
(c) Human 293T cells expressing Cherry-tagged mSmo or mSmoDrSmoCRDmut were incubated 
with 10 nM BODIPY-Cyc, in the presence or absence of 2 µM SANT1. Cells were fixed, 
washed, and imaged by fluorescence microscopy, to detect the Cherry fusion proteins and the 
BODIPY conjugate. Both proteins bind BODIPY-Cyc specifically. 
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Supplementary Figure S5 (continued): 
(d) Smo-/- MEFs, stably expressing Cherry-tagged mSmo, mSmoΔCRD or mSmoDrSmoCRDmut 
were incubated overnight inß the presence of DMSO control, SAG (1 µM) or 20-OHC (10 µM). 
The cells were processed for immunofluorescence with anti-Cherry antibodies (to detect mSmo) 
and anti-acetylated tubulin antibodies (to visualize cilia). The graph shows the percentage of 
cells with Smo-positive cilia. MSmoΔCRD and mSmoDrSmoCRDmut respond to SAG but have a 
defective response to 20-OHC; in contrast, wild-type mSmo responds to both SAG and 20-
OHC.   
(e) As in (d), but with box plots showing the fluorescence intensity of Cherry-tagged proteins at 
cilia. For each condition, the Cherry signal was normalized to the intensity of the SAG treatment 
for the respective cell line. The lower and upper bounds of each box represent the 25th and 75th 
percentile of the distribution of ciliary fluorescence intensity, while the horizontal line represents 
the median intensity across the entire population of cilia.  
(f) As in (d), but cells were processed for Q-PCR, to measure mRNA levels of the Hh target 
gene, Gli1. For each treatment, Gli1 levels were normalized to the level induced by SAG 
treatment in the respective cell line. Smo-/- MEFs were included as negative control. Each 
experiment was performed in triplicate, and the error bars show the standard deviation of the 
mean. mSmoΔCRD and mSmoDrSmoCRDmut respond to SAG but do not respond to 20-OHC; in 
contrast, wild-type mSmo responds to both SAG and 20-OHC.  
(g) As in (c) but with expression of mSmo-Cherry, mSmoL112D-Cherry, mSmoW113Y-Cherry 
or mSmoS114Y-Cherry. All 4 proteins bind BODIPY-Cyc specifically.  
(h) Smo-/- MEFs, stably expressing Cherry-tagged mSmo or mSmoΔCRD were incubated 
overnight with DMSO control, SAG (1 µM), 20-OHC (10 µM) or Shh. Smo-/- MEFs were 
included as negative control. Levels of Gli1 mRNA were measured by Q-PCR, as in (d). 
mSmoΔCRD does not respond to 20-OHC and has a reduced responsiveness to Shh. 
(i) As in (h), but with Smo-/- MEFs stably expressing Cherry-tagged mSmo or the double point 
mutant mSmoL112D/W113Y. mSmoL112D/W113Y does not respond to 20-OHC and has a 
reduced responsiveness to Shh. 
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A.2 A photoactivatable probe for the oxysterol-binding site of Smo 
6-azi,25-hydroxycholesterol (photo 25-hydroxycholesterol, Figure S6a) is a 
photoactivatable cholesterol derivative that was previously used to show direct binding of 25-
hydroxycholesterol to SCAP (Adams et al., 2004). The compound contains a diazirine ring 
which is activated by exposure to UV radiation to eliminate nitrogen; this generates a reactive 
carbene radical which inserts into C-H bonds and thus crosslinks to nearby amino-acid residues. 
6-azi,25-OHC also contains an iso-octyl sidechain similar to that of the Smo-activating oxysterol 
25-OHC, making it likely to interact directly with Smo. 
We tested whether 6-azi,25-OHC could be used to probe the oxysterol-binding site of 
Smo. The compound competitively inhibits binding of both full-length Smo as well as of the 
Smo CRD to 22-NHC beads (Figure S6b). This confirms that 6-azi,25-OHC binds directly to the 
oxysterol-binding site. Furthermore, we observed a similar inhibition profile as for 22-NHC: 6-
azi,25-OHC inhibits the Hedgehog pathway stimulation by Shh and by oxysterols, but not by 
SAG (and in fact at lower doses shows a similar synergistic effect on SAG stimulation as seen 
for 22-NHC). In conclusion, 6-azi,25-OHC binds the same site as oxysterols and azasterols. 6-
azi,25-OHC is a useful probe to map the residues which line the oxysterol-binding pocket within 
the Smo CRD, and any other residues which touch the bound sterols. The covalent adducts can 
be identified by mass spectrometric detection, or by incorporation of radioactivity if a 
radiolabelled 6-azi,25-OHC is used instead. To this end, the 3 position of the sterol is accessible 
and can be modified to generate radioactive [3H]-6-azi,25-OHC using a procedure similar to that 
used for [3H]-photocholesterol (Gehrig-Burger et al., 2005). 
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Supplementary Figure S6 6-azi, 25-hydroxycholesterol (photocholesterol) is a 
photoactivatable Smo inhibitor of the oxysterol-binding site 
(a) structure of 6-azi, 25-hydroxycholesterol (6-azi,25-OHC). Highlighted in red are the 
structural modifications relative to the cholesterol structure.  
(b) Detergent extracts of 293T cells expressing mSmo-Cherry, or supernatants containing HA-
tagged mSmoCRD were incubated with 22-NHC beads, in the presence of 7-OHC (100µM, 
negative control) or 6-azi,25-OHC (5µM, 10µM, 25µM, 50µM, 100µM in the case of full-length 
mSmo, or 1µM, 2µM, 5µM, 10µM, 25µM, 50µM, 100µM) in the case of the CRD). Bound 
mSmo-Cherry and mSmoΔCRD-HA were analyzed by SDS-PAGE and immunoblotting. Binding 
of mSmo and mSmoCRD to 22-NHC beads is competed by 6-azi,25-OHC.  
(c) 6-azi, 25-OHC inhibits the stimulation by Shh (left panel) and by oxysterols such as 20-OHC-
Pent (right panel) but not the stimulation by SAG (middle panel), thus recapitulating the 
inhibition profile of 22-NHC. Shh Light II cells were treated for 30 hours with the indicated 
concentrations of 6-azi, 25-OHC in the presence of Shh, 50µM SAG or 10µM 20-OHC-Pent 
followed by measuring Hh pathway activity by luciferase assay. Control medium was used as  
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Supplementary Figure S6 (continued): 
negative control, while SAG (1 µM) was used as positive control. All experiments were 
performed in quadruplicate, the pathway response normalized to the level of stimulation in the 
absence of 6-azi,25-OHC and error bars represent the standard deviation of the mean. 
A.3 Automated Image Analysis 
A.3.1 Initial segmentation 
In order to distinguish individual cilia from the local background, a locally-adaptive 
thresholding algorithm is used. In brief, the algorithm takes as input a 12-bit grayscale image 
obtained with staining for the ciliary marker acetylated Tubulin. The pixel intensities are first 
rescaled on a scale from 0 to 1, corresponding to the minimum and maximum pixel intensities in 
the picture respectively. Then, local thresholds are calculated for each pixel using a window of 
100x100 neighbouring pixels. Each threshold value represents the weighted mean of the local 
neighbourhood minus an offset value. Pixels with thresholding values within a chosen region 
above the minimum are considered positive; the minimum and maximum thresholding values are 
chosen such that very bright or very dim pixels should not bias the filter, and the parameters may 
vary depending on the staining conditions or exposure settings across experiments, but stay the 
same within one complete experiment.  
Positive pixels in close proximity to each other are then recognized as multi-connected 
objects, and given a unique identification number. The algorithm parses the entire list of multi-
connected objects and filters them according to several criteria. Cilia have a unique elongated 
shape, and are easily recognizable by eye; to select cilia correctly, minimum and maximum size 
constraints are imposed initially on the multi-connected objects, to rule out noise or any non-
ciliary staining. Then, an aspect ratio criterion is imposed such that only elongated objects are 
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filtered, and curved objects are generally eliminated; in conjunction with the size constraint, this 
criterion indirectly also filters out cilia that do not appear in focus. If the population of multi-
connected objects is larger than 10, additional filtering takes place to eliminate outliers based on 
length or size, to ensure a more homogeneous population of cilia is recognized on the slide. 
Finally, each multi-connected region is extended by a 5 pixel radius, to ensure that the cilium is 
fully covered; the acetylated tubulin marker is internal to the primary cilium, while most of our 
analysis focuses on membrane staining, therefore it is imperative to integrate all the membrane 
staining signal. 
 
Supplementary Figure S7 Segmentation of cilia 
(a) original image stained for the ciliary marker, acetylated tubulin 
(b) large particles recognized that may alter the thresholding algorithm 
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Supplementary Figure S7 (continued) 
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Supplementary Figure S7 (continued) 
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Supplementary Figure S7 (continued): 
(c) original image, with large bright objects averaged out, to ensure no impact on thresholding 
(d) positive pixels as a result of initial thresholding 
(e) pixels recognized as multi-connected objects  
(f) ciliary masks are filtered based on size and shape criteria, then the area around each 
remaining mask is expanded by a radius of 5 pixels, to ensure the entire cilium is covered by the 
mask. The mask around each cilium is shown in a different color 
 
A.3.2 Calculation of results 
We apply the masks created above based on the ciliary marker to the image of the protein 
to be scored (Smo or Ptc), integrates the pixel intensity in each region, and reports the mean per-
pixel intensity as the ratio of the total integrated signal divided by the mask area for each cilium. 
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Then, we extend the original mask for each cilium by a 10 pixel radius; the local background is 
calculated as the per-pixel intensity in this 10-pixel donut-shaped extension around each cilium 
analized, and is subtracted from the per-pixel intensity in the original ciliary mask.  
Since detection of low levels of signal is imperfect and can be confused with background 
noise, the per-pixel intensities across cilia follow a skewed distribution and not a normal one; to 
accurately capture this behaviour of cilia and to properly graph the high-signal tail of the 
distribution, we calculate the average as well as the 25th and 75th quantiles of the per-pixel 
intensities at the cilium across the population of cilia within each sample. Average intensities are 
reported as box plots, with the lower and upper bonds of the box representing the 25th and 75th 
quantiles respectively, and the average is indicated by a horizontal line. 
In order to score positive cilia, a baseline per-pixel intensity is calculated from an 
untreated sample, or from a sample containing the untreated parental line in the case of 
overexpressed protein (thus, for the Smo-/- mSmo-mCherry fusion lines in Chapter 2, the baseline 
is calculated from the untreated Smo-/- sample stained at the same time as all outher samples); the 
baseline intensity is chosen such that either 10%, 5% or 1% false-positive results are deemed 
acceptable, based on the experiment. For each experimental sample, the algorithm pools the per-
pixel intensities for each cilium across all the images analyzed for that particular condition and 
counts as positive those cilia which have a per-pixel intensity above the baseline. The result is 
reported as the fraction of the total cilia detected for each condition. Finally, in order to estimate 
the error due to sampling of only a small set of the cilia present on the coverslip, each pool of 
cilia (corresponding to each experimental condition) is divided in five equal sub-pools at 
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random, and the fraction of positive cilia in each sub-pool is calculated as for the initial large 
pool; the standard deviation of the fraction of positive cilia across the sub-pools represents an 
accurate description of the statistical sampling error, and is reported as error bars in the graphs of 
cilia counts. 
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A.4 Chemical Synthesis of Reagents used in Chapter Two 
A.4.1 General methods for synthesis 
All solvents and reagents were obtained from commercial sources and were used without 
further purification. NMR spectra were recorded on a Varian 400 MHz NMR spectrometer or a 
Varian Oxford 600 MHz NMR spectrometer. NMR chemical shifts were expressed in ppm 
relative to internal solvent peaks, and coupling constants were measured in Hz. High-resolution 
mass spectra were obtained at the Harvard University Mass Spectrometry Facility, or were 
obtained in-house on a Bruker microTOF-QII instrument, using an ESI source. LC/MS was 
performed on a Waters Micromass ZQ instrument using an ESI source coupled to a Waters 2525 
HPLC system operating in reverse mode with a Waters SunfireTM C18 5µm 4.6×50 mm column. 
Flash chromatography was performed on silica gel columns using a Biotage Isolera One flash 
purification system. Diastereomers of 20-hydroxycholesterol analogs were purified on a chiral 
RegisCell (25 cm×21.1 mm) column using a preparative HPLC system composed of a Waters 
1525 binary pump and Waters 2467 UV absorbance detector. 
A.4.2 Preparation of 22-azacholesterol derivatives (1-6) 
A.4.2.1 General procedure for reductive amination of pregnenolone 
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Following a reductive amination protocol (Abdel-Magid et al., 1996), pregnenolone (5-
pregnen-3β-ol-20-one, 1.0 eq) and amine (1.0 eq) were mixed in 1,2-dichloroethane (c = 0.2 
mol/L) and were then treated with sodium triacetoxyborohydride (1.5 eq) and AcOH (1.0 eq). 
The mixture was stirred at room temperature under nitrogen for 16 h. The reaction was quenched 
with 1M NaOH, and the product was extracted 3 times with diethyl ether. The ether layer was 
washed with brine and dried over Na2SO4. The solvent was evaporated to give the crude free 
base, which was purified by flash chromatography (silica gel, CH2Cl2/MeOH, gradient elution) 
to provide the 22-azacholesterol analog as a mixture of diastereomers. The ratio between the 
diastereomers in the mixture was estimated by LC/MS. This mixture was further purified by 
flash chromatography (silica gel, CH2Cl2/CHCl3: MeOH:NH4OH 89:10:1, gradient elution) to 
yield the pure diastereomers. 
 
A.4.2.2 Preparation of (3S,8S,9S,10R,13S,14S,17S)-17-(1-(isopentylamino)ethyl)-10,13-
dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-ol (1) 
 
Following the general procedure, compound 1 was obtained from pregnenolone (1.01 g, 
3.2 mmol) and 3-methylbutan-1-amine (279 mg, 3.2 mmol) as a mixture of diastereomers 
(20R:20S; 1:11.8) (152 mg, 12%), from which the major diastereomer 1(20S) was purified as a 
white solid. This diastereomer was assigned the 20S/a configuration based on the reported 
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properties of 22-azacholesterol diasteromers (mp of 20a: 128–129°C, mp of 20b: 151-152°C in 
reference(Lu et al., 1972), and mp of 20a: 120–121°C in reference(Counsell et al., 1965)). In the 
case of the other analogs of 22-azacholesterol (2-6), configuration of diastereomers was assigned 
based on similarity to the diastereomers of 1 in retention time (LC/MS, reverse-phase) and in 
chemical shift of H3-20 (doublet). For all 22-azacholesterol analogs described here, the 20R 
diastereomer has a smaller retention time than 20S, and the H3-20 chemical shift of the 20R 
diastereomer is smaller than that of 20S by 0.05-0.12 ppm. 
 
1(20S/a): mp 128–129°C; [a] = -25.2 (c = 0.38, MeOH); 1H NMR (400 MHz, CDCl3): δ 
5.32-5.36 (m, 1H), 3.46-3.56 (m, 1H), 2.66-2.74 (m, 1H), 2.38-2.54 (m, 2H), 2.18-2.32 (m, 2H), 
1.79-2.02 (m, 6H), 1.40-1.68 (m, 8H), 1.28-1.40 (m, 4H), 1.12-1.24 (m, 2H), 1.02-1.12 (m, 5H), 
1.00 (s, 3H), 0.91-0.99 (m, 1H), 0.90 (d, J = 2.0 Hz, 3H), 0.89 (d, J = 2.0 Hz, 3H), 0.70 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ 140.8, 121.5, 71.6, 56.6, 56.3, 50.0, 44.9, 42.3, 41.9, 39.4, 39.3, 
37.2, 36.5, 31.8, 31.7, 31.6, 27.1, 26.2, 24.2, 22.8, 22.5, 20.9, 19.4, 19.3, 12.2; HRMS: (ESI, 
m/z) calcd [M+H]+ for C26H45NO: 388.3574, found 388.3582. 
 
A.4.2.3 Preparation of (3S,8S,9S,10R,13S,14S,17S)-17-(1-(ethylamino)ethyl)-10,13-
dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-ol (2) 
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Following the general procedure, compound 2 was obtained from pregnenolone (1.01 g, 
3.2 mmol) and ethylamine (144 mg, 3.2 mmol) as a mixture of diastereomers (20R:20S; 1.5:1) 
(500 mg, 45%), which was further separated to yield each pure diastereomer (2a and 2b) as a 
white solid. 
 
2a(20R): [a]  = -68.5 (c = 0.55, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.32-5.35 (m, 
1H), 3.47-3.57 (m, 1H), 2.69-2.80 (m, 1H), 2.57-2.66 (m, 1H), 2.44-2.54 (m, 1H), 2.18-2.32 (m, 
2H), 1.92-2.02 (m, 2H), 1.71-1.87 (m, 3H), 1.41-1.65 (m, 7H), 1.20-1.40 (m, 3H), 1.02-1.15 (m, 
6H), 0.91-1.02 (m, 8H), 0.72 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 140.9, 121.3, 71.3, 56.3, 
55.9, 55.7, 49.9, 42.3, 41.9, 40.9, 40.2, 37.2, 36.4, 31.7, 31.7, 31.6, 26.6, 24.1, 21.0, 19.3, 19.1, 
15.5, 12.3; HRMS: (ESI, m/z) calcd [M+H]+ for C23H39NO: 346.3104, found 346.3105.  
 
2b(20S): [a]  = -29.0 (c = 0.34, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.32-5.36 (m, 
1H), 3.46-3.56 (m, 1H), 2.70-2.80 (m, 1H), 2.44-2.58 (m, 2H), 2.18-2.32 (m, 2H), 1.70-2.02 (m, 
5H), 1.42-1.68 (m, 7H), 1.14-1.41 (m, 4H), 1.06-1.14 (m, 8H), 0.90-1.06 (m, 5H), 0.70 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ 140.8, 121.5, 71.6, 56.6, 56.4, 56.2, 49.9, 42.3, 41.9, 40.8, 39.3, 
37.2, 36.5, 31.8, 31.7, 31.6, 27.1, 24.1, 20.9, 19.4, 19.2, 15.4, 12.2; HRMS: (ESI, m/z) calcd 
[M+H]+ for C23H39NO: 346.3104, found 346.3108.  
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A.4.2.4 Preparation of (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(1-
(propylamino)ethyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-ol (3) 
 
Following the general procedure, compound 3 was obtained from pregnenolone (1.01 g, 
3.2 mmol) and propylamine (189 mg, 3.2 mmol) as a mixture of diastereomers (20R:20S; 1:1.3) 
(504 mg, 44%), which was further separated to yield each pure diastereomer (3a and 3b) as a 
white solid. 
 
3a(20R): [a]  = -58.0 (c = 0.43, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.32-5.35 (m, 
1H), 3.46-3.56 (m, 1H), 2.65-2.75 (m, 1H), 2.53-2.62 (m, 1H), 2.34-2.42 (m, 1H), 2.18-2.22 (m, 
2H), 1.93-2.02 (m, 2H), 1.71-1.87 (m, 3H), 1.41-1.65 (m, 9H), 1.20-1.38 (m, 3H), 1.02-1.17 (m, 
3H), 0.95-1.02 (m, 8H), 0.93 (t, J = 7.2 Hz, 3H), 0.72 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
140.8, 121.5, 71.5, 56.4, 56.2, 56.0, 50.0, 49.0, 42.3, 42.0, 40.2, 37.2, 36.5, 31.8, 31.8, 31.6, 26.7, 
24.2, 23.5, 21.1, 19.4, 19.2, 12.3, 12.0; HRMS: (ESI, m/z) calcd [M+H]+ for C24H41NO: 
360.3261, found 360.3257.  
 
3b(20S): [a]  = -27.3 (c = 0.39, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.32-5.36 (m, 
1H), 3.46-3.56 (m, 1H), 2.61-2.69 (m, 1H), 2.46-2.54 (m, 1H), 2.36-2.44 (m, 1H), 2.18-2.32 (m, 
2H), 1.78-2.02 (m, 5H), 1.40-1.68 (m, 9H), 1.28-1.40 (m, 2H), 1.05-1.24 (m, 6H), 0.94-1.05 (m, 
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5H), 0.88-0.96 (m, 4H), 0.69 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 140.8, 121.4, 71.5, 56.6, 
56.3, 56.3, 49.9, 48.7, 42.3, 41.8, 39.3, 37.2, 36.5, 31.8, 31.7, 31.6, 27.0, 24.1, 23.4, 20.9, 19.3, 
19.2, 12.2, 11.9; HRMS: (ESI, m/z) calcd [M+H]+ for C24H41NO: 360.3261, found 360.3262.  
 
A.4.2.5 Preparation of (3S,8S,9S,10R,13S,14S,17S)-17-(16-amino-7,10,13-trioxa-3-
azahexadecan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (6) 
 
Following the general procedure, compound 6 was obtained from pregnenolone (1.01 g, 
3.2 mmol) and 4,7,10-trioxa-1,13-tridecanediamine (2.2 g, 10 mmol) after silica gel column 
chromatography as a mixture of diastereomers (20R:20S; 2.6:1) as a yellow oil (749 mg, 45%) 
and was used in the next step without further purification. 
 
6: 1H NMR (600 MHz, CDCl3): δ 5.33-5.36 (m, 1H), 3.47-3.67 (m, 13H), 2.77-2.89 (m, 
3H), 2.45-2.70 (m, 6H), 2.20-2.32 (m, 2H), 1.91-2.05 (m, 3H), 1.69-1.89 (m, 7H), 1.39-1.69 (m, 
7H), 0.90-1.39 (m, 11H), 0.72, 0.70 (2.6:1; s, 3H); HRMS: (ESI, m/z) calcd [M+H]+ for 
C31H56N2O4: 521.4313, found 521.4311. 
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A.4.3 Preparation of 20-hydroxycholesterol analogs (7-16) 
A.4.3.1 General procedure for Grignard reactions of pregnenolone 
 
 
 
Pregnenolone (1.0 eq.) was dissolved in dry THF (0.16 mol/L) and the resulting solution 
was cooled to 0 °C under nitrogen. A solution of alkylmagnesium bromide or chloride (3.0 eq.) 
was added drop-wise over 10 min. The reaction mixture was stirred at 25 °C for 16 h and was 
then cooled to 0 °C. A saturagted solution of NH4Cl was added and the mixture was stirred for 
30 min, after which it was extracted 3 times with EtOAc. The organic phase was washed with 
brine and dried over anhydrous Na2SO4. Evaporation of the solvent gave a residue, which was 
purified by flash chromatography on silica gel (step-wise gradient elution, 0-70% 
EtOAc/hexane) to provide the 20-hydroxycholesterol analog as a mixture of diasteromers. This 
mixture was subjected to normal-phase chiral HPLC purification (6% i-PrOH/Hexane), to yield 
the pure diastereomers. The configuration of the diastereomers of compounds 8-12 was assigned 
by comparison with the reported NMR characterization of nat-20(R)-hydroxycholesterol and 
related compounds (Nachtergaele et al., 2012), based on the trend in the chemical shifts of C-20 
and H3-21 (singlet). For all 20-hydroxycholesterol analogs examined here, the C-20 chemical 
shift of the 20S diastereomer is around 75.2 ppm while it is 75.8 ppm for 20R, and the H3-21 
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chemical shift of the 20S diastereomer is around 1.26 ppm while it is 1.12 ppm for 20R. This 
assignment is consistent with results of biological activity assays, as the 20R diastereomers of 
10-12 activate the Hedgehog pathway in cells and bind Smoothened, while the 20S diastereomers 
of 10-12 are inactive (see text). We also observed that the 20S diastereomers have a smaller 
retention time during the chiral HPLC separation. 
 
A.4.3.2 Preparation of (3S,10R,13S,17S)-17-(2-Hydroxypropan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-ol (7) 
 
Following the general procedure, compound 7 was obtained from pregnenolone (1.0 g) 
and methylmagnesium bromide (3.2 mL of 3.0 M solution in Et2O) in dry THF (20 mL), as a 
white solid (117 mg, 11% yield after HPLC purification).  
 
7: [a] =-43.7 (c = 0.21, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.33-5.37 (m, 1H), 
3.47-3.57 (m, 1H), 2.19-2.34 (m, 2H), 2.07-2.14 (m, 1H), 1.94-2.03 (m, 1H), 1.80-1.88 (m, 2H), 
1.70-1.78 (m, 2H), 1.60-1.70 (m, 2H), 1.41-1.59 (m, 6H), 1.31 (s, 3H), 1.20-1.28 (m, 2H), 1.20 
(s, 3H), 1.03-1.18 (m, 2H), 1.01 (s, 3H), 0.88-1.00 (m, 2H), 0.85 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 140.8, 121.6, 73.5, 71.8, 60.2, 56.8, 50.0, 42.7, 42.3, 40.1, 37.2, 36.5, 31.8, 31.6, 31.3, 
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31.0, 30.1, 23.8, 23.1, 20.9, 19.4, 13.5; HRMS: (ESI, m/z) calcd [M+Na]+ for C22H36O2, 
355.2613; found, 355.2630. 
 
A.4.3.3 Preparation of (3S,10R,13S,17S)-17-(2-Hydroxybutan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-ol (8) 
 
Following the general procedure, compound 8 was obtained from pregnenolone (1.0 g) 
and ethylmagnesium bromide (3.2 mL of 3.0 M solution in Et2O) in dry THF (20 mL) as a white 
solid (136 mg, 12%). Further preparative chiral HPLC separation yielded the pure diastereomers 
(8a and 8b) as white solids. 
 
8a(20S): [a]  = -40.3 (c = 0.18, MeOH); 1H NMR (600 MHz, CDCl3): δ 5.34-5.37 (m, 
1H), 3.49-3.55 (m, 1H), 2.28-2.32 (m, 1H), 2.20-2.27 (m, 1H), 2.07-2.12 (m, 1H), 1.95-2.01 (m, 
1H), 1.82-1.87 (m, 2H), 1.70-1.78 (m, 1H), 1.57-1.70 (m, 2H), 1.44-1.57 (m, 8H), 1.36-1.44 (m, 
1H), 1.25 (s, 3H), 1.02-1.24 (m, 4H), 1.01 (s, 3H), 0.90-1.00 (m, 2H), 0.87 (s, 3H), 0.86 (t, J = 
7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 140.8, 121.6, 75.4, 71.8, 57.2, 56.9, 50.0, 42.6, 
42.3, 40.1, 37.2, 36.5, 36.1, 31.8, 31.6, 31.3, 25.7, 23.8, 22.3, 20.9, 19.4, 13.6, 8.5; HRMS: (ESI, 
m/z) calcd [M+Na]+ for C23H38O2, 369.2770; found, 369.2771. 
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8b(20R): [a]  = -24.4 (c = 0.14, MeOH); 1H NMR (600 MHz, CDCl3): δ 5.34-5.37 (m, 
1H), 3.48-3.56 (m, 1H), 2.27-2.32 (m, 1H), 2.22-2.27 (m, 1H), 2.08-2.13 (m, 1H), 1.95-2.01 (m, 
1H), 1.82-1.87 (m, 2H), 1.55-1.78 (m, 3H), 1.43-1.55 (m, 7H), 1.20-1.28 (m, 2H), 1.11-1.18 (m, 
2H), 1.11 (s, 3H), 1.02-1.10 (m, 2H), 1.01 (s, 3H), 0.93-1.00 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H), 
0.86 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 140.8, 121.6, 75.9, 71.8, 58.0, 56.9, 50.0, 42.8, 
42.3, 40.2, 37.2, 36.5, 34.9, 31.8, 31.6, 31.3, 26.3, 23.8, 23.2, 20.9, 19.4, 13.7, 8.4; HRMS: (ESI, 
m/z) calcd [M+H-2H2O]+ for C23H38O2, 311.2739; found, 311.2746. 
 
A.4.3.4 Preparation of (3S,10R,13S)-17-(2-Hydroxypentan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-ol (9) 
   
Following the general procedure, compound 9 was obtained from pregnenolone and (1.0 
g) and propylmagnesium chloride (4.7 mL of a 2.0 M solution in Et2O) in dry THF (20 mL) as a 
white solid (81 mg, 7%). Further preparative chiral HPLC separation yielded the pure 
diastereomers (9a and 9b) as white solids. 
 
9a(20S): [a]  = -39.7 (c = 0.20, MeOH); 1H NMR (600 MHz, CDCl3): δ 5.34-5.37 (m, 
1H), 3.48-3.55 (m, 1H), 2.27-2.32 (m, 1H), 2.20-2.27 (m, 1H), 2.07-2.12 (m, 1H), 1.95-2.00 (m, 
1H), 1.81-1.87 (m, 2H), 1.70-1.80 (m, 1H), 1.57-1.70 (m, 2H), 1.40-1.57 (m, 8H), 1.24-1.35 (m, 
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6H), 1.04-1.23 (m, 4H), 1.01 (s, 3H), 0.87-1.00 (m, 5H), 0.86 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 140.8, 121.6, 75.2, 71.8, 57.7, 56.9, 50.0, 46.4, 42.6, 42.3, 40.1, 37.2, 36.5, 31.8, 31.6, 
31.3, 26.4, 23.8, 22.4, 20.9, 19.4, 17.5, 14.7, 13.6; HRMS: (ESI, m/z) calcd [M+Na]+ for 
C24H40O2, 383.2926; found, 383.2936. 
 
9b(20R): [a]  = -38.5 (c = 0.60, MeOH); 1H NMR (400 MHz, CDCl3): δ 5.33-5.37 (m, 
1H), 3.47-3.57 (m, 1H), 2.18-2.33 (m, 2H), 2.06-2.12 (m, 1H), 1.93-2.02 (m, 1H), 1.79-1.87 (m, 
2H), 1.44-1.79 (m, 12H), 1.33-1.44 (m, 2H), 1.21-1.30 (m, 2H), 1.05-1.20 (m, 5H), 0.97-1.05 (m, 
4H), 0.88-0.97 (m, 4H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 140.8, 121.6, 75.8, 71.7, 
58.2, 56.9, 50.0, 45.1, 42.9, 42.3, 40.1, 37.2, 36.5, 31.8, 31.6, 31.3, 27.0, 23.8, 23.1, 20.9, 19.4, 
17.3, 14.7, 13.7; HRMS: (ESI, m/z) calcd [M+Na]+ for C24H40O2, 383.2926; found, 383.2925. 
 
A.4.3.5 Preparation of (3S,10R,13S)-17-(2-Hydroxypentan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-ol (10)  
 
Following the general procedure, compound 10 was obtained from pregnenolone (1.0 g) 
and butylmagnesium chloride (4.7 mL of a 2.0 M solution in THF) in dry THF (20 mL) as a 
white solid (415 mg, 35%). Further preparative chiral HPLC separation yielded the pure 
diastereomers (10a and 10b) as white solids. 
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10a(20S): [a]  = -54.7 (c = 0.42, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 5.33-5.37 (m, 
1H), 3.47-3.57 (m, 1H), 2.18-2.33 (m, 2H), 2.06-2.13 (m, 1H), 1.93-2.03 (m, 1H), 1.78-1.87 (m, 
2H), 1.70-1.78 (m, 1H), 1.41-1.70 (m, 11H), 1.05-1.36 (m, 11H), 0.97-1.05 (m, 4H), 0.87-0.96 
(m, 4H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 140.8, 121.6, 75.2, 71.8, 57.6, 56.9, 50.0, 
43.7, 42.6, 42.3, 40.1, 37.2, 36.5, 31.8, 31.6, 31.3, 26.5, 26.4, 23.8, 23.3, 22.3, 20.9, 19.4, 14.1, 
13.6; HRMS: (ESI, m/z) calcd [M+Na]+ for C25H42O2, 397.3083; found, 397.3083. 
 
10b(20R): [a]  = -49.4 (c = 0.16, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 5.33-5.37 (m, 
1H), 3.48-3.57 (m, 1H), 2.18-2.33 (m, 2H), 2.06-2.12 (m, 1H), 1.93-2.03 (m, 1H), 1.78-1.88 (m, 
2H), 1.60-1.78 (m, 2H), 1.42-1.60 (m, 10H), 1.21-1.38 (m, 6H), 1.09-1.18 (m, 4H), 0.97-1.09 (m, 
5H), 0.88-0.97 (m, 4H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 140.8, 121.6, 75.8, 71.8, 
58.2, 56.9, 50.0, 42.9, 42.6, 42.3, 40.1, 37.2, 36.5, 31.8, 31.6, 31.3, 27.0, 26.3, 23.8, 23.4, 23.2, 
20.9, 19.4, 14.2, 13.7; HRMS: (ESI, m/z) calcd [M+Na]+ for C25H42O2, 397.3083; found, 
397.3079. 
 
A.4.3.6 Preparation of (3S,10R,13S,17S)-17-(2-Hydroxyheptan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
3-ol (11) 
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Following the general procedure, compound 5 was obtained from pregnenolone (1.0 g) 
and pentylmagnesium bromide (4.7 mL of a 2.0 M solution in Et2O) in dry THF (20 mL) as a 
white solid (553 mg, 45%). Further preparative chiral HPLC separation yielded the pure 
diastereomers (11a and 11b) as white solids. 
 
11a(20S): [a]  = -54.5 (c = 0.31, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 5.34-5.37 (m, 
1H), 3.47-3.57 (m, 1H), 2.19-2.34 (m, 2H), 2.06-2.13 (m, 1H), 1.93-2.02 (m, 1H), 1.79-1.88 (m, 
2H), 1.40-1.78 (m, 12H), 1.05-1.37 (m, 13H), 0.97-1.05 (m, 4H), 0.85-0.97 (m, 7H); 13C NMR 
(100 MHz, CDCl3): δ 140.8, 121.6, 75.2, 71.7, 57.6, 56.9, 50.0, 44.0, 42.6, 42.3, 40.1, 37.2, 36.5, 
32.5, 31.8, 31.6, 31.3, 26.4, 24.0, 23.8, 22.7, 22.3, 20.9, 19.4, 14.1, 13.6; HRMS: (ESI, m/z) 
calcd [M+Na]+ for C26H44O2, 411.3239; found, 411.3235. 
 
11b(20R): [a]  = -49.7 (c = 0.26, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 5.33-5.37 (m, 
1H), 3.48-3.57 (m, 1H), 2.18-2.34 (m, 2H), 2.06-2.12 (m, 1H), 1.94-2.02 (m, 1H), 1.79-1.88 (m, 
2H), 1.42-1.78 (m, 12H), 1.20-1.40 (m, 8H), 1.09-1.18 (m, 4H), 0.97-1.09 (m, 5H), 0.85-0.97 (m, 
7H); 13C NMR (100 MHz, CDCl3): δ 140.8, 121.6, 75.8, 71.8, 58.2, 56.9, 50.0, 42.9, 42.8, 42.3, 
40.1, 37.2, 36.5, 32.5, 31.8, 31.6, 31.3, 27.0, 23.8, 23.7, 23.1, 22.7, 20.9, 19.4, 14.1, 13.7; 
HRMS: (ESI, m/z) calcd [M+Na]+ for C26H44O2, 411.3239; found, 411.3240. 
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A.4.3.7 Preparation of (3S,5S,10S,13S)-17-(2-Hydroxyheptan-2-yl)-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-ol (12) 
 
Following the general procedure, compound 12 was obtained from 5α-pregnan-3β-ol-20-
one (1.0 g) and pentylmagnesium bromide (4.7 mL of a 2.0 M solution in Et2O) in dry THF (20 
mL) as a white solid (354 mg, 29%). Further chiral HPLC separation yielded the pure 
diastereomers (12a and 12b) as white solids. 
 
12a(20S): [a]  = 2.6  (c = 0.32, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 3.54-3.63 (m, 
1H), 2.01-2.07 (m, 1H), 1.20-1.83 (m, 27H), 1.03-1.20 (m, 4H), 0.94-1.03 (m, 2H), 0.85-0.94 (m, 
4H), 0.83 (s, 3H), 0.80 (s, 3H), 0.57-0.65 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 75.2, 71.3, 
57.7, 56.6, 54.3, 44.8, 43.9, 42.9, 40.4, 38.1, 37.0, 35.4, 34.8, 32.5, 31.9, 31.5, 28.7, 26.3, 23.9, 
23.7, 22.6, 22.3, 21.1, 14.1, 13.8, 12.3; HRMS: (ESI, m/z) calcd [M+H-H2O]+ for C26H46O2, 
373.3470; found, 373.3464. 
 
12b(20R): [a]  = 10.9 (c = 0.34, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 3.54-3.63 (m, 
1H), 2.01-2.08 (m, 1H), 1.43-1.84 (m, 12H), 1.15-1.43 (m, 15H), 1.03-1.15 (m, 4H), 0.94-1.03 
(m, 2H), 0.85-0.94 (m, 4H), 0.84 (s, 3H), 0.80 (s, 3H), 0.57-0.65 (m, 1H); 13C NMR (100 MHz, 
CDCl3): δ 75.8, 71.3, 58.4, 56.6, 54.3, 44.8, 43.2, 42.7, 40.4, 38.2, 37.0, 35.4, 34.9, 32.5, 31.9, 
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31.5, 28.7, 27.0, 23.8, 23.7, 23.1, 22.7, 21.1, 14.1, 13.9, 12.3; HRMS: (ESI, m/z) calcd [M+H-
H2O]+ for C26H46O2, 373.3470; found, 373.3482. 
 
A.4.3.8 Preparation of (3S,10R,13S,17S)-17-(8-((tert-butyldimethylsilyl)oxy)-2-
hydroxyoctan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (13) 
 
In a 2-necked round bottom flask equipped with a condenser, magnesium turnings (2.2 g, 
89.1 mmol) were stirred in anhydrous THF (2 mL) under nitrogen. (6-Bromohexyloxy)-tert-
butyldimethylsilane (5.3 g, 17.8 mmol) was dissolved in anhydrous THF (18 mL) and 1/10 of 
this solution was added to the flask, followed by a few drops of 1,2-dibromoethane. The mixture 
was warmed and stirred vigorously until cloudiness and bubbling was observed. The rest of the 
THF solution of (6-bromohexyloxy)-tert-butyldimethylsilane was slowly added to the flask to 
keep the reaction going. The reaction mixture was heated to reflux for an additional hour, and 
then cooled to room temperature. The Grignard reagent thus prepared was transferred dropwise 
via syringe to a solution of pregnenolone (1.9 g, 5.9 mmol) in anhydrous THF (10 mL) at 0°C. 
The reaction was stirred at room temperature for 12 h under nitrogen and was quenched with 
aqueous NH4Cl, followed by extraction with EtOAc. The organic extract was washed with brine, 
dried over Na2SO4, and concentrated in vacuo. The residue was purified by flash 
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chromatography on silica gel (step-wise gradient elution, 0-30% EtOAc/Hexanes) to yield 
compound 13 (1.4 g, 46%) as a colorless, amorphous solid  (mixture of diasteromers).  
 
13: 1H NMR (600 MHz, CDCl3): δ 5.29-5.32 (m, 1H), 3.53-3.62 (m, 3H), 3.44-3.51 (m, 
1H), 2.22-2.27 (m, 1H), 2.16-2.22 (m, 1H), 2.02-2.06 (m, 1H), 1.90-1.96 (m, 1H), 1.76-1.82 (m, 
2H), 1.55-1.74 (m, 4H), 1.38-1.55 (m, 8H), 1.18-1.34 (m, 8H), 0.99-1.18 (m, 4H), 0.91-0.99 (m, 
4H), 0.83-0.91 (m, 12H), 0.82 (s, 3H), 0.00 (s, 6H); 13C NMR (150 MHz, CDCl3) (as the major 
diasteromer): δ 140.8, 121.6, 75.2, 71.7, 63.3, 57.6, 56.9, 50.0, 43.9, 42.6, 42.3, 40.1, 37.2, 36.5, 
32.8, 31.8, 31.6, 31.3, 30.1, 26.4, 26.0, 25.8, 24.3, 23.8, 22.3, 20.9, 19.4, 18.4, 13.6, -5.3.  
 
A.4.3.9 Preparation of 7-((3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
17-yl)octane-1,7-diol (14) 
 
To compound 13 (1.1g, 2.1 mmol) in dry THF (15 mL) was added tetrabutylammonium 
fluoride (6.3 mL of a 1.0 M solution in THF, 6.3 mmol), and the reaction was stirred for 4 h. 
Upon reaction completion, water was added and most of the product was precipitated by addition 
of a large excess of Et2O. The organic phase was separated and the solvent was removed by 
rotary evaporation. The resulting residue was washed with water and CH2Cl2, and was combined 
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with the solid obtained by ether precipitation. The combined solids were dried in vacuo to yield 
the crude 14 (0.72 g, 82 %) as a white solid (mixture of diasteromers). 
 
14: 1H NMR (600 MHz, CDCl3): δ 5.34-5.37 (m, 1H), 3.62-3.67 (m, 2H), 3.48-3.56 (m, 
1H), 2.27-2.32 (m, 1H), 2.20-2.26 (m, 1H), 2.06-2.11 (m, 1H), 1.95-2.01 (m, 1H), 1.81-1.87 (m, 
2H), 1.62-1.78 (m, 3H), 1.43-1.62 (m, 10H), 1.24-1.41 (m, 9H), 1.04-1.24 (m, 6H), 0.96-1.04 (m, 
4H), 0.90-0.96 (m, 1H), 0.86 (s, 3H); 13C NMR (150 MHz, CDCl3) (as a mixture of 
diasteromers): δ 140.8, 121.6, 75.8, 75.2, 71.8, 63.0(x2), 58.3, 57.7, 56.9(x2), 50.0, 43.8, 42.9, 
42.7, 42.6, 42.3, 40.1(x2), 37.2, 36.5, 32.8, 32.7, 31.8, 31.6, 31.3(x2), 30.1, 30.0, 27.0, 26.4, 
25.8, 25.7, 24.2, 24.0, 23.8(x2), 23.2, 22.4, 20.9, 19.4, 13.7, 13.6. 
 
A.4.3.10 Preparation of 7-hydroxy-7-((3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
17-yl)octanal (15) 
Compound 15 was obtained by a modification of a procedure to selectively oxidize primary 
alcohols to aldehydes (Gunbas and Brouwer, 2012). A solution of triol 14 (711 mg, 1.7 mmol), 
2,2,6,6-tetramethyl-1-piperidinyloxy (26.6 mg, 0.17 mmol), tetrabutylammonium chloride (47.2 
mg, 0.17 mmol) in THF (15 mL) and 15 mL of an aqueous solution of NaHCO3 (0.5 M) and 
K2CO3 (0.05 M) were vigorously stirred at room temperature. N-chlorosuccinimide (340.5 mg, 
2.6 mmol) was then added, and stirring was maintained for 16 h. The organic phase was 
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separated, and the aqueous phase was diluted with brine and extracted 3 times with CH2Cl2 
(some precipitate might form and just filter to collect the solid and filtrate). The combined 
organic phases were concentrated in vacuo, the residue was dissolved in a small amount of 
CH2Cl2/MeOH and was subjected to purification by flash chromatography on silica gel (step-
wise gradient elution, 0-40% EtOAc/hexanes) to yield aldehyde 15 (443 mg, 54%) as a white 
solid (mixture of diasteromers). 
15: 1H NMR (600 MHz, CDCl3): δ 9.76-9.77 (m, 1H), 5.34-5.37 (m, 1H), 3.48-3.56 (m, 
1H), 2.41-2.46 (m, 2H), 2.27-2.32 (m, 1H), 2.20-2.27 (m, 1H), 2.05-2.11 (m, 1H), 1.95-2.01 (m, 
1H), 1.81-1.87 (m, 2H), 1.59-1.79 (m, 6H), 1.42-1.58 (m, 8H), 1.24-1.38 (m, 7H), 1.04-1.24 (m, 
4H), 0.96-1.03 (m, 4H), 0.90-0.96 (m, 1H), 0.86 (s, 3H); 13C NMR (150 MHz, CDCl3) (as the 
major diasteromer): δ 202.8, 140.8, 121.5, 75.1, 71.7, 57.8, 56.9, 50.0, 43.8, 43.6, 42.6, 42.2, 
40.1, 37.2, 36.5, 31.7, 31.6, 31.3, 29.7, 26.3, 23.9, 23.7, 22.3, 22.0, 20.9, 19.4, 13.6. 
 
A.4.3.11 Preparation of 1-amino-21-((3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-
17-yl)-4,7,10-trioxa-14-azadocosan-21-ol (16) 
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Compound 15 (208 mg, 0.5 mmol) and 4,7,10-trioxa-1,13-tridecanediamine (220 mg, 1 
mmol) were mixed in 1,2-dichloroethane (5 mL) and then treated with sodium 
triacetoxyborohydride (159 mg, 0.75 mmol). The mixture was stirred at room temperature for 16 
h until the reactants were consumed, as determined by TLC. The reaction mix was concentrated 
in vacuo, the residue was dissolved in DMSO and was purified by preparative reverse-phase 
HPLC on a Waters Symmetry C18 column (19 x 50 mm, 5µM). Elution was with a gradient of 
15-80% MeOH in water with 0.035% trifluoroacetic acid, over 15 min and at a flow rate of 20 
mL/min. The product 16 (mixture of diasteromers) was obtained as the di(trifluoroacetate) salt 
(yellow oil, 154 mg, 36%). 
 
16: 1H NMR (400 MHz, CDCl3): δ 9.16 (br, 2H), 7.99 (br, 3H), 5.33-5.37 (m, 1H), 3.74 
(t, J = 5.2 Hz, 2H), 3.56-3.66 (m, 10H), 3.47-3.56 (m, 3H), 3.04-3.22 (m, 4H), 2.72-2.98 (m, 
6H), 2.18-2.33 (m, 2H), 1.93-2.11 (m, 4H), 1.79-1.88 (m, 2H), 1.58-1.79 (m, 4H), 1.38-1.54 (m, 
6H), 1.22-1.38 (m, 9H), 1.06-1.22 (m, 4H), 0.87-1.06 (m, 5H), 0.85 (s, 3H); 13C NMR (100 
MHz, CDCl3) (as the major diasteromer): δ 140.7, 121.6, 75.2, 71.8, 71.0, 70.0, 69.8, 69.5, 69.4, 
68.4, 57.8, 56.8, 50.0, 48.3, 46.1, 43.6, 42.6, 42.2, 40.3, 40.0, 37.2, 36.5, 31.7, 31.6, 31.3, 29.5, 
26.5, 26.1, 25.8, 25.7, 25.5, 23.8, 23.7, 22.3, 20.9, 19.4, 13.6. LC/MS: (ESI, m/z) calcd [M+H]+ 
for C37H68N2O5: 621.5, found 621.4. 
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A.4.4 Preparation of BODIPY-SANT1 (17-21) 
A.4.4.1 Preparation of tert-butyl 4-iodobenzylcarbamate (17) 
  
4-Iodobenzylamine (349.6 mg, 1.5 mmol) and triethylamine (0.44 mL, 3.15 mmol) were 
dissolved in dichloromethane (6 mL), and Boc anhydride (343.7 mg, 1.6 mmol) in 
dichloromethane (6 mL) was added dropwise. After stirring for 16 h at room temperature, the 
reaction mixture was washed with 1N HCl, saturated aqueous NaHCO3, and brine, then dried 
over anhydrous Na2SO4 and concentrated to yield compound 17 as a white solid  (499 mg, 
100 %).  
 
17: 1H NMR (600 MHz, CDCl3): δ 7.65 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 7.8 Hz, 2H), 
4.83 (br, 1H), 4.25(d, J = 4.2 Hz, 2H), 1.45 (s, 9H). Characterization matched the data reported 
for compound 17(Antilla et al., 2004). 
 
I
NHBoc
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Et3N, CH2Cl2, 25 °C
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A.4.4.2 Preparation of tert-butyl 4-(4-formyl-3,5-dimethyl-1H-pyrazol-1-yl)benzyl-
carbamate (18) 
  
Compound 18 was obtained by N-arylation following a reported protocol(Fahmy et al., 
2002). To a screwcap glass vial were added CuI (4.6 mg, 0.024 mmol, 5 mol%), 3,5-dimethyl-
1H-pyrazole-4-carbaldehyde (59.5 mg, 0.48 mmol), K2CO3 (139.3 mg, 1.0 mmol), and a stir bar. 
The reaction vessel was fitted with a rubber septum, was evacuated and back-filled with argon, 
and this sequence was repeated twice. Aryl iodide 17 (191.8 mg, 0.58 mmol), (1S,2S)-N1,N2-
dimethylcyclohexane-1,2-diamine (13.6 mg, 0.96 mmol, 20 mol%) and toluene (2 mL) were then 
added successively under a stream of argon. The reaction vial was sealed and immersed in an oil 
bath preheated to 110 °C, and the reaction was stirred for 24 h. The reaction mixture was cooled 
to room temperature, diluted with EtOAc and filtered through Celite. The filtrate was washed 
with aqueous NH4OH (v/v, 1/1) and brine, then was dried over Na2SO4 and concentrated in 
vacuo. The resulting residue was purified by flash chromatography on silica gel (step-wise 
gradient from 9:1 to 2:3 hexane/EtOAc) to provide compound 18 as a yellow oil (17.0 mg, 
11 %).  
 
18: 1H NMR (600 MHz, CDCl3): δ 10.22 (s, 1H), 7.62 (d, J = 7.2 Hz, 2H), 7.57 (d, J = 
7.8 Hz, 2H), 5.12 (br, 1H), 4.59 (br, 2H), 2.74 (s, 3H), 2.72 (s, 3H), 1.67 (s, 9H); LC/MS: (ESI, 
m/z) calcd [M+H]+ for C18H23N3O3, 330.2, found 330.2. 
I
NHBoc
N
NH
OHC
+
NH HN
5 mol% CuI, K2CO3
toluene, 110 °C, Ar
N
N
NHBocOHC
20 mol%
17 18
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A.4.4.3 Preparation of (E)-tert-butyl 4-(4-(((4-benzylpiperazin-1-yl)imino)methyl)-3,5-
dimethyl-1H-pyrazol-1-yl)benzylcarbamate (19) 
Following a reported protocol(Fahmy et al., 2002), an equimolar mixture of 18 (14.8 mg, 45.0 
µmol) and 1-amino-4-benzylpiperazine (8.6 mg, 45.0 µmol) in absolute ethanol (0.5 mL) was 
heated under reflux for 12 h. After concentration, the resulting residue was purified by flash 
chromatography on silica gel (step-wise gradient elution from 100:1 to 9:1 CH2Cl2/MeOH) to 
provide compound 19 as a yellow oil (22.5 mg, 100 %).  
 
19: 1H NMR (600 MHz, CDCl3): δ 7.53 (s, 1H), 7.17-7.31 (m, 9H), 4.88 (br, 1H), 4.28 
(d, J = 5.4 Hz, 2H), 3.53 (s, 2H), 3.08-3.11 (m, 4H), 2.57-2.63 (m, 4H), 2.33 (s, 3H), 2.32 (s, 
3H), 1.39 (s, 9H); LC/MS: (ESI, m/z) calcd [M+H]+ for C29H38N6O2: 503.3, found 503.1. 
 
A.4.4.4 Preparation of (E)-N-((1-(4-(aminomethyl)phenyl)-3,5-dimethyl-1H-pyrazol-4-
yl)methylene)-4-benzylpiperazin-1-amine (20) 
 
Compound 19 (7.5 mg, 15.0 µmol) was dissolved in a 1:1 mixture of TFA (0.8 mL) and 
CH2Cl2 (0.8 mL,) and was stirred at room temperature for 50 min. Volatiles were evaporated in 
vacuo and the resulting residue was used in the next step without further purification.  
 
N
N
NHBocOHC N
N NH2
EtOH
reflux
N
N N
N
N
NHBoc+
18 19
N
N N
N
N
NH2
N
N N
N
N
NHBoc
1:1 TFA/CH2Cl2
25 °C
19 20
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20: LC/MS: (ESI, m/z) calcd [M+H]+ for C24H30N6: 403.20, found 403.1. 
 
A.4.4.5 Preparation of (E)-3-(3-((4-(4-(((4-benzylpiperazin-1-yl)imino)methyl)-3,5-
dimethyl-1H-pyrazol-1-yl)benzyl)amino)-3-oxopropyl)-5,5-difluoro-7,9-dimethyl-
5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (SANT-1-BODIPY) 
(21) 
 
Triethylamine (9.1 µL, 65.0 µmol) and BODIPY-FL N-hydroxysuccinimide ester (5.0 
mg, 13.0 µmol) were added to a solution of amine 20 (6.0 mg, 15.0 µmol) in dichloromethane 
(800 µL). The reaction mixture was stirred at room temperature for 18 h and then evaporated to 
dryness under a stream of nitrogen gas. Purification by flash chromatography on silica gel (step-
wise gradient from 100:1 to 85:15 CH2Cl2/MeOH) yielded the fluorescent amide 21 as a dark red 
solid (7.8 mg, 89 %).  
 
21: 1H NMR (400 MHz, CDCl3): δ 7.55 (s, 1H), 7.13-7.35 (m, 9H), 7.02 (s, 1H), 6.79 (d, 
J = 4.0 Hz, 1H), 6.22 (d, J = 4.0 Hz, 1H), 6.12 (t, J = 5.2 Hz, 1H), 6.03 (s, 1H), 4.36 (d, J = 6.0 
Hz, 2H), 3.56 (d, J = 7.6 Hz, 1H), 3.52 (d, J = 7.2 Hz, 1H), 3.23 (t, J = 7.2 Hz, 2H), 3.04-3.16 
(m, 4H), 2.59-2.71 (m, 6H), 2.47 (s, 3H), 2.31 (s, 6H), 2.17 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 171.6, 160.4, 156.9, 148.1, 144.1, 138.4, 137.9, 135.2, 133.4, 129.3, 128.4, 128.2, 
127.3, 125.1, 123.9, 120.5, 117.5, 63.5, 62.5, 53.0, 52.1, 51.4, 45.8, 42.9, 35.9, 24.8, 19.0, 14.9, 
13.0, 11.9, 11.3, 8.1; LC/MS: (ESI, m/z) calcd  [M+H]+ for C38H43BF2N8O: 677.4, found 677.1. 
N
N N
N
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A.4.5 Synthesis of 27-nor-5-cholesten-20,3β-diol methyl ether 
 
 
To a dry 250 mL flask equipped with a magnetic stir bar was added pregnenolone methyl 
ether (960 mg, 2.9 mmol, from Steraloids) and 5 mL anhydrous tetrahydrofuran. The solution 
was stirred under argon while 14.5 mL (29 mmol, 10 eq) of 2M pentyl magnesium bromide was 
added dropwise to the flask. The reaction was left stirring overnight under argon. The reaction 
was diluted with 100 mL diethyl ether and quenched by the addition of 1% aqueous acetic acid. 
The organic phase was washed with water and brine, dried over sodium sulfate, filtered and 
concentrated under reduced pressure. The crude product (TLC: 30% ethyl acetate/hexanes, 
starting material Rf = 0.33, product Rf = 0.38) was dissolved in a small amount of 
dichloromethane and purified by column chromatography using a gradient of 5-20% ethyl 
acetate in hexanes, yielding the product as a colorless oil (806 mg, 69%).  
 
1H NMR (400 MHz) δ  5.35 (m, 1H), 3.35 (s, 3H), 3.06 (m, 1H), 2.37 (m, 1H), 1.27 (s, 
3H), 1.00 (s, 3H), 0.87 (s, 3H).  13C NMR (400 MHz) 140.84, 121.46, 80.28, 75.09, 57.64, 56.90, 
55.54, 50.10, 43.97, 42.61, 40.11, 38.65, 37.15, 36.85, 32.50, 31.79, 31.29, 27.96, 26.39, 23.93, 
23.76, 22.65, 22.32, 20.91, 19.33, 14.07, 13.57. 
O
OH
O
O
THF
O/N, RT
MgBr
Chemical Formula: C22H34O2
Molecular Weight: 330.50
Chemical Formula: C27H46O2
Molecular Weight: 402.65
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A.5 Lentiviral expression 
 
Supplementary Figure S8 Map of lentiviral packaging vector 
 
In order to express the various constructs in Smo-/- MEFs, we designed a lentiviral 
backbone based on the pHAGE-CMV-MCS backbone (Mostoslavsky et al., 2006) to which a 
selectable Blasticidin resistance marker was added under the control of an internal ribosome 
entry site (IRES). The constructs of interest were inserted immediately downstream of the CMV 
promoter using the PacI and XbaI sites in a modified multiple cloning site. The resulting 
pHAGE2 DN constructs were cotransfected with Mirrus Trans-IT 293 into 293T cells along with 
packaging plasmids containing Gag-Pol, REV, TAT and VSV-G according to manufacturer’s 
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protocol. 24 hours post-transfection, the medium was replaced and virus-containing supernatant 
was collected after another 48 hours. The supernatant was diluted 1:2 with regular medium, 
supplemented with hexadimethrine bromide (Polybrene) at a final concentration of 1µg/mL and 
used to infect MEFs. 24 hours post-infection, the transduction medium was replaced with 
medium containing 50µg/mL Blasticidin, and selection was considered complete 3 days later 
when no uninfected cells remained attached. 
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